Professional practice-standards-v4

Professional
Practice Standards
VERSION 4
2010
ProfessionalPracticeStandards | VERSION4 | 2010
PSA2524

The Professional Practice Standards version 4 has been endorsed by the following organisations at the time of publication.
A A C P
AUSTRALIAN ASSOCIATION
OF CONSULTANT PHARMACY
© Pharmaceutical Society of Australia 2010
The material in this publication has been provided by the
Pharmaceutical Society of Australia (PSA). The PSA retains copyright
in the publication as a whole and in all material in the publication that
is authored by or on behalf of the PSA.
Apart from any use permitted under the Copyright Act 1968, you
must not make any other use of this material unless you have written
permission to do so. Requests and enquiries regarding permission to
use PSA material should be addressed to:
Publications Manager
Pharmaceutical Society of Australia
PO Box 42
Deakin West ACT 2600
The review of the Professional Practice Standards is funded by
the Australian Government Department of Health and Ageing and
developed by the PSA with support from the Pharmacy Guild of
Australia as part of the Fourth Community Pharmacy Agreement.
Disclaimer
These standards have been designed for use by individual
pharmacists to assess their own professional practice. They are
intended to serve as guidance for desired standards of practice.
However, it is the sole responsibility of the individual pharmacist
to determine, in all circumstances, whether a higher standard is
required. It is equally their responsibility to meet that standard.
The PSA has made every effort to ensure that, at the date of
publication, the document is free from errors and that the advice
and information drawn upon have been provided in good faith.
However, the information contained in this publication is dynamic
in nature due to ongoing research and change in government
regulation and pharmacy practice. Neither the PSA nor any other
person associated with the preparation of this document accepts
liability for any loss that a user of this document may suffer as
a result of reliance on the document and, in particular, for:
• use of the document for a purpose for which it was not intended
• any errors or omissions in the document
• any inaccuracy in the information or data on which the document
is based or which are contained in the document OR
• any interpretations or opinions stated in, or which may be inferred
from, the document.
Notification of any inaccuracy or ambiguity found in this document
should be made without delay in order that the issue may be
investigated and appropriate action taken. Please forward your
notification to:
Policy and Practice Group
PO Box 42
ISBN: 978-0-646-53402-2
Title: Professional Practice Standards – Version 4 – June 2010
Edition: 4th
Date of Publication: June 2010
Publisher: Pharmaceutical Society of Australia

3Professional Practice Standards | Version 4 | 2010 | © Pharmaceutical Society of Australia
Foreword
Contents
Foreword........................................................................................................................................................................................................................... 4
Introduction
The Professional Practice Standards and the practice of pharmacy............................................................................................. 5
Background to the Professional Practice Standards.......................................................................................................................... 5
The broader context of guidance supporting pharmacy practice................................................................................................... 5
General resources for pharmacists............................................................................................................................................................ 6
How to use the Professional Practice Standards................................................................................................................................. 6
Significant updates in the Professional Practice Standards, version 4......................................................................................... 6
A guide to reading the standards............................................................................................................................................................... 9
Professional Practice Standards
Standard 1: Fundamental Pharmacy Practice................................................................................................................................ 11
Standard 2: Managing Pharmacy Practice....................................................................................................................................... 15
Standard 3: Counselling.......................................................................................................................................................................... 20
Standard 4: Medication Review........................................................................................................................................................... 24
Standard 5: Dispensing........................................................................................................................................................................... 28
Standard 6: Indirect Pharmacy Services........................................................................................................................................... 33
Standard 7: Dose Administration Aids Service............................................................................................................................... 36
Standard 8: Services to Residential Care Facilities....................................................................................................................... 40
Standard 9: Continuity of Care through Medication Liaison Services..................................................................................... 44
Standard 10: Compounding (also known as Extemporaneous Dispensing)........................................................................... 47
Standard 11: Compounding Sterile Preparations............................................................................................................................. 53
Standard 12: Provision of Non-prescription Medicines and Therapeutic Devices................................................................ 57
Standard 13: Health Promotion.............................................................................................................................................................. 60
Standard 14: Medicines Information Centres..................................................................................................................................... 62
Standard 15: Pharmacy Services to Aboriginal and Torres Strait Islander Health Services............................................... 65
Standard 16: Screening and Risk Assessment................................................................................................................................. 68
Standard 17: Disease State Management.......................................................................................................................................... 72
Standard 18: Harm Minimisation............................................................................................................................................................ 76
Appendices
Appendix 1: The Medicines Management Pathway....................................................................................................................... 81
Appendix 2: Quality Use of Medicines and Practice Improvement........................................................................................... 84
Appendix 3: The Health Promotion Planning Cycle....................................................................................................................... 86
Appendix 4: Adherence Assessment Tool......................................................................................................................................... 87
Appendix 5: Details of Local Health Care Providers...................................................................................................................... 88
Appendix 6: Documenting Counselling Events and Interventions............................................................................................. 89
Appendix 7: Indirect Supply Services: New Consumer Details/Change of Consumer Details Form............................ 90
Appendix 8: Medicines that may be Considered Unsuitable for Indirect Supply................................................................. 91
Appendix 9: Template Procedure for Consumer Admissions and Readmissions
to Residential Care Facilities......................................................................................................................................... 92
Appendix 10: Screening Record and Referral Form......................................................................................................................... 93
Appendix 11: Template Consumer Care Plan.................................................................................................................................... 95
Appendix 12: The History of the Professional Practice Standards............................................................................................. 97
Appendix 13: Project Participants.......................................................................................................................................................... 98
Glossary.......................................................................................................................................................................................................................... 99
Contents

Professional Practice Standards | Version 4 | 2010 | © Pharmaceutical Society of Australia4 Professional Practice Standards | Version 4 | 2010 | © Pharmaceutical Society of Australia
Foreword
The Professional Practice Standards, version 4 is the
result of many months of consultation with more than
10 organisations and more than 70 experts across various
areas of practice in Australia. Involved in the process were
consumers, hospital pharmacists, accredited pharmacists,
pharmacists from the pharmaceutical industry, community
pharmacists, and pharmacists from large metropolitan
areas right through to those in small isolated practices.
The result is a testament to the commitment of those
involved in enhancing the quality of pharmacy practice for
our communities.
Although the Professional Practice Standards are used by
pharmacy practice accreditation and registration bodies,
the principal aim of these standards remains as a tool
for us to assess and continuously evaluate the services
we deliver through any role in which we use our skills as
pharmacists.
We sincerely thank and acknowledge the contributions,
submissions, feedback and advice of so many of our
colleagues along the way. Their remit was to help ensure
the standards are realistic and as easy as possible to use
and adopt in daily practice.
What supported this endeavour was a pilot field testing
process. This step was introduced in the development of
this edition to further test, refine and enhance the quality
of the assessment system. More than 20 pharmacists
took part in the field testing process that provided an
additional layer of consultation and assurance that the
PSA Professional Practice Standards in this edition are a
progression from those in previous editions.
To all involved in the standards, the PSA owes a debt of
gratitude to you. We thank you for your time, advice and
counsel, and we trust that you will be available to support
us again in the future.
To all pharmacists, I recommend these standards to you.
I encourage pharmacists from across the country and
from all areas of practice to use these standards to their
full intent—to assess your practice against that expected
by your peers.
Warwick Plunkett
National President

Professional Practice Standards | Version 4 | 2010 | © Pharmaceutical Society of AustraliaProfessional Practice Standards | Version 4 | 2010 | © Pharmaceutical Society of Australia 5
Introduction
Introduction
The Professional Practice Standards
and the practice of pharmacy
As health professionals with a wide-ranging body of
knowledge and skills with regard to medicines and related
health products, pharmacists are in a unique position to
optimise health outcomes for the community they serve.
The primary responsibility of a pharmacist is to ensure
safe and effective use of medicines and best possible
health outcomes for consumers through the provision of
pharmaceutical care. According to the Pharmacy Board of
Australia, pharmacy practice can involve direct clinical care
or non-clinical relationships with consumers; working in
management, administration, education, and research; or
being in advisory, regulatory, or policy development roles.1
Pharmacists have an ethical and legal commitment to
the community to ensure safe and effective delivery of
pharmacy services, irrespective of the setting in which
they practice. Professional standards allow the pharmacy
profession to qualitatively and quantitatively measure this
commitment to providing high quality, reliable health care
services and products.
The Professional Practice Standards is intended to be an
educative resource for the self-regulation of pharmacists
and the pharmacy profession. The standards in this
document encourage pharmacists to be involved in a
range of pharmacy services and promote recognition of
professional service delivery. They also help consumers
recognise and build confidence in the pharmacy
profession by ensuring professional activities are
performed to a desired level.
The Professional Practice Standards, version 4 has been
produced with guidance from a Standards Steering
Committee composed of representatives from key
pharmacy organisations as well as experts from across
the profession. The content and relevance of each
standard has been reviewed and updated by Expert
Review Groups consisting of expert pharmacists and
consumer representatives. Please refer to Appendix 13 for
a list of project participants. The project team considered
and incorporated all feedback before the resulting
document was reviewed and endorsed by the Boards
of the organisations represented on the Standards
Steering Committee.
Background to the Professional
Practice Standards
These standards originate from international guidelines
for ‘Good Pharmacy Practice’2
that were endorsed by the
International Pharmaceutical Federation (FIP) in the Tokyo
Declaration of 19933
and by the World Health Organisation
(WHO) in 1997.4
They advocate good pharmacy practice in
the promotion of good health through the achievement of
health objectives, the supply of medicines and medication
delivery devices, the provision of medicines for self care,
and activities to influence the quality of prescribing or the
use of medicines.
The Professional Practice Standards was first published
in 1999; the standards in the document covered core
pharmacy services and selected specialty services.
They were developed through extensive consultation with
pharmacy organisations and practitioners in Australia, as
well as collaboration with consumers and the Australian
Government. This is the third revision of the Professional
Practice Standards; the standards were previously
revised in 2002 and 2006. The regular updates ensure
that the standards reflect current pharmacy practice as
pharmacists in Australia face a professional climate of
rapid and cumulative change.
The Professional Practice Standards, version 4 is available
on the PSA website at www.psa.org.au.
The broader context of guidance
supporting pharmacy practice
The PSA standards in the Professional Practice Standards
apply to all practising pharmacists irrespective of the
setting in which they practice. There are a number of
documents that govern how pharmacists in Australia
practice (see Figure 1).
Figure 1. Pyramid of guidance supporting
pharmacy practice.
Federal, state and territory legislation then forms
a foundation on which our practice is based. It is
mandatory that pharmacists comply with all federal, state
and territory legislation. If conflict arises between the
legislation and these standards, legislative requirements
should be adhered to. The Pharmacy Board of Australia
Introduction
Practice
guidelines
Professional
Practice Standards
Competency Standards
for Pharmacists in Australia
PSA Code of Conduct
SHPA Code of Ethics
Medicines Australia Code of Conduct
Pharmacy Board of Australia
standards, guidelines and codes
Legislation (state/territory and federal)

is the registering authority of pharmacists in Australia.
The standards, guidelines and codes developed by the
Pharmacy Board of Australia outline specific requirements
for pharmacists to maintain their registration.1,5
Further to our legal responsibilities, pharmacists are
required to practice under the PSA Code of Professional
Conduct,6
the Society of Hospital Pharmacists of Australia
(SHPA) Code of Ethics,7
and the Medicines Australia Code
of Conduct.8
These codes publicly state the principles
by which pharmacists interact with consumers, other
health care providers, and the community when delivering
pharmacy services.
Moreover the Competency Standards for Pharmacists in
Australia9
outlines the skills, attitudes, and other attributes
considered sufficient to enable an individual to practice
as a pharmacist. These skills, attitudes and attributes
are attained through professional qualifications as well as
subsequent experience. The PSA’s continuing professional
development and practice improvement (CPD&PI)
program allows pharmacists to identify areas where
improvement in their competency is needed. Workshops
are then offered as a means of professional development.
In addition to competency, pharmacists must also focus
on delivering services that are both consistent and of a
high quality. The standards in the Professional Practice
Standards are aimed specifically at pharmacists and outline
a level of service that is acceptable to both consumers and
professional peers. Pharmacists are encouraged to reflect
on these standards to ensure consumers are receiving safe
and effective pharmacy services.
Finally, practice guidelines outline systems and processes
that pharmacists and their staff can use to implement
quality services that meet the standards. These practice
guidelines are service specific and provide detailed
information about how best to deliver these services.
Each of these documents provides pharmacists with the
guidance and framework required to practice pharmacy in
a professional and ethical manner. This ensures pharmacy
services are delivered to benefit the health and wellbeing
of all consumers.
General resources for pharmacists
• Australian Government Department of Health and
Ageing. National Medicines Policy. www.health.gov.au
• Pharmaceutical Society of Australia. Code of
professional conduct. www.psa.org.au
• Medicines Australia. Code of conduct.
www.medicinesaustralia.com.au
• Society of Hospital Pharmacists of Australia.
Code of ethics. www.shpa.org.au
• Pharmacy Board of Australia. Codes and Guidelines.
www.pharmacyboard.gov.au
• Association of Professional Engineers, Scientists and
Managers, Australia. www.apesma.asn.au
• Australian Association of Consultant Pharmacy.
www.aacp.com.au
• Australian College of Pharmacy. www.acp.edu.au
• Australian Pharmacy Council.
www.pharmacycouncil.org.au
• Pharmaceutical Defence Limited. www.pdl.org.au
• Pharmaceutical Society of Australia. www.psa.org.au
• Pharmacy Guild of Australia. www.guild.org.au
www.shpa.org.au
How to use the Professional Practice
Standards
The standards in the Professional Practice Standards,
version 4 provide a framework that defines and describes
the qualities required by pharmacists to deliver a range of
pharmacy services effectively and to an acceptable level.
The standards are designed for individual pharmacists
to self-assess their professional practice, identify areas
where improvement is needed, and re-assess their
performance after the appropriate changes have
been implemented.
Table 1 is designed to aid pharmacists’ use of the
Professional Practice Standards. It shows which standards
are either directly related to each other or those that are
only applicable depending on the scope of their practice.
The first standard, Fundamental Pharmacy Practice, is the
overarching ‘universal’ standard and is directly related to all
other standards regardless of the scope of practice and is
to be applied in conjunction with all others.
The second standard, Managing Pharmacy Practice,
addresses the responsibilities of pharmacist managers.
This standard is directly related to standard 1 but is only
applicable to other standards depending on the scope
of your practice.
For all other standards, each pharmacist should reflect
on their own practice and identify which standards are
applicable. The pharmacist can then assess themselves
against the relevant standards in addition to the
Fundamental Pharmacy Practice standard.
In order to facilitate self-assessment, a box is provided
next to each indicator for the pharmacist to mark ‘yes’
I meet this indicator, ‘no’ I don’t meet this indicator, or
this indicator is ‘not applicable (NA)’ to my practice. If an
indicator is considered not applicable to the pharmacist’s
practice, the reason behind this decision should be
documented. Pharmacists should regularly self-assess;
for example, once yearly, or when a change occurs in
their professional practice.
Significant updates in the Professional
Practice Standards, version 4
One of the aims of the review of the Professional Practice
Standards, version 3 (PPSv3) was to broaden the
standards to encompass functional areas of pharmacy
practice rather than specific services. With this in mind,
Table 2 outlines the major changes you will notice in the
new Professional Practice Standards, version 4.

Introduction
New Professional
Practice Standard
Old standard(s) Notes
1: Fundamental
Pharmacy
Practice
• Fundamental Pharmacy Practice
(PPSv3)
• Comprehensive Pharmacy Care
(PPSv3)
These two standards have been combined into the
new Fundamental Pharmacy Practice standard.
Historically, Comprehensive Pharmacy Care described
a service provided by pharmacists. As pharmacy
practice has evolved, the principles of this service have
become fundamental to our roles as pharmacists.
For this reason, its principles have been incorporated
into Fundamental Pharmacy Practice and/or other
relevant standards.
4: Medication
Review
• Comprehensive Medication
Review (PPSv3)
• Home Medicines Review (also
known as Domiciliary Medication
Management Review) (PPS v3)
• Medication Profiling Service
(developed under the Fourth
Community Pharmacy
Agreement; not included in
PPSv3)
The new Medication Review standard outlines the
common principles of all proactive forms of medication
review including medication profiling services, Home
Medicines Reviews, and Residential Medication
Management Reviews. Medication reviews that
are part of the dispensing process are covered in
Professional Practice Standard 5: Dispensing.
6: Indirect Pharmacy
Services
• Distance Supply (PPSv3) The old title of this standard, Distance Supply, implied
a service delivered only in rural and remote areas. In
fact, the updated Indirect Pharmacy Services standard
is relevant to any supply of medicines, both urban and
rural, where face-to-face contact is not possible.
Introduction
Table 1. How the individual Professional Practice Standards inter-relate
Professional Practice Standards Directly Related
Standard
Other applicable standards
based on scope of practice
1: Fundamental Pharmacy Practice 2–18
2: Managing Pharmacy Practice 1 3–18
3: Counselling 1 2, 5, 6, 12, 13, 17, 18
4: Medication Review 1, 3 2
5: Dispensing 1, 3 2, 6, 7, 10, 11, 17, 18
6: Indirect Pharmacy Services 1, 3, 5 2, 10, 12
7: Dose Administration Aids 1, 3, 5 2, 4, 6, 8, 9, 15
8: Services to Residential Care Facilities 1 2-5, 7, 9-13
9: Continuity of Care through Medication Liaison Services 1 2-5, 13, 17
10: Compounding (also known as Extemporaneous Dispensing) 1, 3, 5 2, 6, 8, 11
11: Compounding Sterile Preparations 1, 3, 5, 10 2, 8
12: Provision of Non-prescription Medicines and
Therapeutic Devices
1, 3 2,13
13: Health Promotion 1 2, 3, 16-18
14: Medicines Information Centres 1 2
15: Provision of Pharmacy Services to Aboriginal and Torres
Strait Islander Health Services
1 2-7, 9, 10, 12, 13, 16, 17
16: Screening and Risk Assessment 1 2, 3, 13, 17
17: Disease State Management 1 2-4, 13, 16
18: Harm Minimisation 1, 3, 5 2, 13
Table 2. Overview of significant updates and changes in Professional Practice Standards, version 4

New Professional
Practice Standard
Old standard(s) Notes
9: Continuity of
Care through
Medication
Liaison Services
• Liaison Pharmacy (Professional
Practice Standards, version 2
but not included in PPSv3)
The pharmacist’s role in providing continuity of care is
significant, and this standard has been reinstated with
a new title in version 4.
10: Compounding
(also known as
Extemporaneous
Dispensing)
• Compounding (also known as
Extemporaneous Dispensing)
(PPSv3)
• Preparation of Cytotoxic Drug
Products (PPSv3)
The scope of this standard has been broadened to
encompass all principles of non-sterile compounding.
The previous criteria from the Preparation of
Cytotoxic Drug Products (PPSv3) standard have been
incorporated into the new Compounding (also known
as Extemporaneous Dispensing) and Compounding
Sterile Preparations standards.
11: Compounding
Sterile
Preparations
• Compounding (also known as
(PPSv3)
• Preparation of Cytotoxic Drug
Products (PPSv3)
This new standard illustrates the additional
requirements for those pharmacists preparing
sterile products.
The previous criteria from the Preparation of
Cytotoxic Drug Products (PPSv3) standard have been
incorporated into the new Compounding (also known
as Extemporaneous Dispensing) and Compounding
Sterile Preparations standards.
12: Provision of
Non-prescription
Medicines and
Therapeutic
Devices
This new standard outlines the pharmacist’s role
in the provision of non-prescription medicines and
therapeutic devices. While the Standards for the
Provision of Pharmacy Medicines and Pharmacist
Only Medicines in Community Pharmacy10
highlights
the responsibilities of the pharmacy as a whole, this
new standard focuses solely on the pharmacist’s
obligations in relation to the provision of all non-
prescription products (scheduled and unscheduled).
14: Medicines
Information
Centres
• Drug Information Service
(PPSv3)
This standard has been renamed in line with current
terminology and the content of the updated standard.
15: Provision of
Pharmacy
Services to
Aboriginal and
Torres Strait
Islander Health
Services
• The Provision of Pharmacy
Services to Aboriginal and
Islander Health Services
[guidelines and standards]
(developed by the PSA in 2005,
but not published in PPSv3)
This standard has been included in the new version of
the Professional Practice Standards so that it could be
published together with the other standards.
16: Screening and
Risk Assessment
• Monitoring and Case Detection
(PPSv3)
This new standard illustrates the services aimed
at identifying consumers at risk of chronic disease
through screening and assessment processes.
17: Disease State
Management
• Monitoring and Case Detection
(PPSv3)
This new standard outlines the principles underpinning
all disease state management (DSM) services,
regardless of the consumer’s particular disease state.
DSM services involve the monitoring of consumers
with a chronic disease to maximise their treatment and
quality of life.
18: Harm
Minimisation
• Opioid Substitution Program
(PPSv3)
• Needle and Syringe Program
(PPSv3)
The new Harm Minimisation standard combines the
principles of both of the previous standards.

Introduction
A guide to reading the standards
4
MedicationReview
Standard 4: Medication Review
Standard
The pharmacist works with the consumer, and other
health care providers, to systematically review the
consumer’s medication regimen, identify potential areas
for improvement, and provide information and advice to
optimise health outcomes.
Scope of this standard
A ‘medication review’ is a systematic assessment of a consumer’s medications and the management of those•
medications, with the aim of optimising consumer health outcomes and identifying potential medication-related issues
within the framework of the quality use of medicines.
The term ‘medication review’ encompasses a continuum of processes in various formats and complexities, ranging•
from an opportunistic discussion to a more comprehensive and proactive approach to reviewing the consumer’s
medication regimen (see figure 1).
This standard covers the key principles underpinning all types of systematic medication review services under any•
service arrangement including, but not limited to: hospital inpatient medication reviews, medication profiling services,
Home Medicines Reviews (HMRs), Residential Medication Management Reviews (RMMRs), and Medicines Use
Reviews (MURs). Opportunistic medication history reviews that are conducted during the dispensing process are
covered in Standard 5: Dispensing.
Pharmacists are reminded that this standard is to be applied in conjunction with the Fundamental Pharmacy Practice•
and Counselling standards. Refer also to the Health Promotion standard where appropriate.
Pharmacists providing medication reviews should also be familiar with the relevant professional guidelines and•
business rules relating to these services, where available. For specific service-related information, refer to the relevant
Professional Practice Guidelines for each individual service.
Opportunistic
informal process
Systematic
(HMR or RMMR)
(with consumer)
Reactive 
Medication
chart review 
Treatment
review  Proactive
Figure 1. Medication review services fall along a continuum of increasing complexity. More complex services
require additional training and skills from a pharmacist.
Note: Home Medicines Reviews were formerly known as Domiciliary Medication Management Reviews (DMMRs).
Professional Practice Standards | Version 4 | 2010 | © Pharmaceutical Society of Australia Professional Practice Standards | Version 4 | 2010 | © Pharmaceutical Society of Australia
16
ScreeningandRiskAssessment
Professional Practice Standards | Version 4 | 2010 | © Pharmaceutical Society of Australia Professional Practice Standards | Version 4 | 2010 | © Pharmaceutical Society of Australia 71
Criteria/Indicators
Self check:
Yes/No/NA
Resources
Criterion 7: The pharmacist ensures the result and referral forms, and follow-up letters (where required) are completed
in a manner that facilitates further consumer contact should the need arise
1. Documents recommendations, follow-up, and
outcomes for consumers who are referred to
other health care providers, where possible
Appendix 10: Screening Record and Referral•
Form, p. xx
2. Provides the pharmacist’s name and signature
as well as the contact details for the pharmacy
providing the clinical testing on all results, referral
forms, and follow-up letters
Criterion 8: The pharmacist implements an appropriate risk management strategy for the screening services provided
1. Follows a documented procedure to manage
spillages and contamination
Pharmaceutical Society of Australia.•
www.psa.org.au
Infection control template procedure
Incident report form template
Pharmacy Guild of Australia. Quality Care•
Pharmacy Program. www.guild.org.au/qcpp
Incident register (T7C)
Incident report (T7D)
2. Uses appropriate containers for storage and
disposal of contaminated clinical waste and
sharps
3. Segregates clinical waste prior to its disposal in
an approved manner and time interval
4. Diligently follows a documented infection control
procedure
5. Ensures pharmacy staff adhere to the infection
control requirements
6. Ensures that all necessary protective clothing,
equipment, and containers for storage and
sharps are available and used
7. Documents spillages, contamination, needle-
stick injuries, and other incidents
8. Regularly assesses the suitability of the
designated area, equipment, and facilities
allocated to the provision of screening services
Additional references
Chen LH, Emmerton L. Pharmacists’ experiences in the provision of
screening and monitoring services. Aust Pharm 2007;26:250–7.
Available at: www.psa.org.au/site.php?id=1652
Jackson S, Peterson G. Health screening in community pharmacy.
Aust Pharm 2004;23:760–4.
Jackson S, Peterson G. Health screening in community pharmacy:
an update. Aust Pharm 2006;25:846–51.
Royal Pharmaceutical Society of Great Britain. Long-term conditions:
integrating community pharmacy. Executive summary. London: RPSGB,
2006. Available at: www.rpsgb.org/pdfs/ltcondintegcommphsumm.pdf
Taylor SJ, Crockett JA, McLeod LJ. An integrated service initiated by
community pharmacists, for the prevention of osteoporosis. Final report.
November 2004. Available at: www.guild.org.au/uploadedfiles/Research_
and_Development_Grants_Program/Projects/2002-026_fr.pdf
Standard: A statement that describes the
qualities required for a service to be provided
at the desired level of performance or results.
Scope: The scope provides definitions of,
and the context for, the professional service
provided, as well as supplying appropriate
cross-references if and when other
standards apply.
Notes: The notes provide additional
background information relevant to the
standard.
Criteria: The standard is broken down into
indicative criteria that broadly express what
a competent professional would achieve in
terms of observable results or behaviours.
Indicators: Each criterion is broken down into
elements that describe a range of activities or
tasks that practicably demonstrate or provide
measurable evidence that the pharmacist is
adherent with the relevant criterion.
Resources: References and links to relevant
publications and other resources have been
provided to help pharmacists adhere with each
criterion.
Self check: A box is provided for the
pharmacist to mark ‘yes’, ‘no’ or ‘not
applicable’ to self-assess their adherence with
each indicator. Pharmacists should regularly
self-assess; for example, once yearly, or when
a change occurs in their professional practice.
Additional references: Additional resources
and references relevant to the standard are
provided.
Introduction

References
1. Pharmacy Board of Australia. Proposals to the Australian Health
Workforce Ministerial Council on registration standards and related
matters. Melbourne, 31 March 2010. Available at:
2. International Pharmaceutical Federation. Standard for quality
of pharmacy services: good pharmacy practice. The Hague:
FIP, September 1997. Available at: www.fip.org/www/index.
php?page=good_pharmacy_practice
3. Tokyo declaration on good pharmacy practice. International
Pharmaceutical Federation Congress, Tokyo, 5 September 1993.
4. WHO Expert Committee on Specifications for Pharmaceutical
Preparations. Thirty-fifth report. WHO Technical Report Series, No.
885. Geneva: World Health Organization, 1999.
5. Pharmacy Board of Australia. Consultation on Codes and Guidelines.
Melbourne, 7 April 2010. Available at: www.pharmacyboard.gov.au
6. Pharmaceutical Society of Australia. Code of professional conduct.
Canberra: PSA, 1998. Available at: www.psa.org.au/site.php?id=628
7. Society of Hospital Pharmacists of Australia. Code of ethics.
Melbourne: SHPA, 2006. Available at: www.shpa.org.au/lib/pdf/about/
SHPA_code_of_ethics.pdf
8. Medicines Australia. Code of conduct. 16th edn. Canberra: Medicines
Australia, December 2009. Available at: www.medicinesaustralia.com.
au/pages/page251.asp
9. Pharmaceutical Society of Australia. Competency standards for
pharmacists in Australia 2003. Canberra: PSA, 2003 [under review at
June 2010]. Available at: www.psa.org.au
10. Pharmaceutical Society of Australia. Standards for the provision of
pharmacy medicines and pharmacist only medicines in community
pharmacy. Revised edn. Canberra: PSA, November 2005.

Professional Practice Standards | Version 4 | 2010 | © Pharmaceutical Society of Australia
1
FundamentalPharmacyPractice
Professional Practice Standards | Version 4 | 2010 | © Pharmaceutical Society of Australia 11
Standard 1: Fundamental Pharmacy Practice
Standard
The pharmacist displays accepted professional and ethical
behaviour, maintains the consumer’s right to privacy and
confidentiality, and aims to achieve the quality use of
medicines, health and wellbeing.
• Pharmacists practise in hospitals, clinics, community pharmacies, academia, the pharmaceutical industry, government,
and the military, and this standard applies to all pharmacists regardless of the setting in which they practise.
• Pharmacists must comply with all legislation relevant to the provision of pharmacy services.
• This standard is to be applied in conjunction with each of the remaining standards in this publication.
Criteria/Indicators
Self check:
Yes/No/NA
Resources
Criterion 1: The pharmacist promotes and delivers all services in an ethical and professional manner
1. Applies the relevant code(s) of professional
conduct to everyday practice
• Pharmaceutical Society of Australia. Code of
professional conduct. www.psa.org.au
Code of ethics. www.shpa.org.au
• Therapeutic Goods Administration.www.tga.gov.au
Therapeutics goods advertising code
Price information code of practice
• Medicines Australia. Code of conduct.
www.medicinesaustralia.com.au
• Pharmacy Guild of Australia. Quality Care
Pharmacy Program. Customer service charter
(P11B). www.guild.org.au/qcpp
• Pharmacy Board of Australia.
Code of conduct for registered health
professionals
Guidelines on advertising
2. Provides access to accurate information about
the pharmacy services available and how to
access these services
3. Applies a documented procedure to ensure all
advertising and promotional material:
• is accurate
• is ethical
• contains a statement encouraging consumers
to seek advice from a pharmacist or another
health care provider on the safe use of
therapeutic products
• complies with the relevant advertising codes
Criterion 2: The pharmacist communicates with the consumer and other health care providers in a professional manner
1. Establishes and maintains professional
partnerships with the consumer and their other
health care providers
• Professional Practice Standard 3:
Counselling, p. 20
2. Actively listens to the needs of the consumer
3. Recognises and addresses any barriers to
communication
4. Adopts a communication style appropriate
for the individual consumer, accounting for
language, culture, hearing, visual or speech
requirements, or other special needs
5. Verifies that the information provided to the
consumer has been received and understood

1
Criteria/Indicators
Self check:
Yes/No/NA
Resources
Criterion 3: The pharmacist observes the consumer’s right to privacy and confidentiality at all times
1. Provides all pharmacy services in a setting that
ensures the privacy of the consumer and the
confidentiality of the information exchanged
• Pharmaceutical Society of Australia.
www.psa.org.au
Professional practice and the Privacy Act
Summary of obligations for pharmacists
Privacy policy example statement
Pharmacy Program. Confidentiality policy
(P1A). www.guild.org.au/qcpp
2. Provides information and advice in a manner that
ensures the consumer’s need for privacy and
confidentiality
3. Communicates the workplace privacy policy
to consumers
4. Stores and handles all consumer records
securely and restricts access to authorised
personnel
5. Applies a documented procedure to destroy
and/or dispose of consumer records in a manner
that ensures no breach of privacy occurs
6. Obtains consent from the consumer for the
delivery of specific pharmacy services and to
share related information with their other health
care providers
7. Documents any situations where, for the
consumer’s wellbeing, a breach of their right to
privacy and confidentiality occurs
Criterion 4: The pharmacist promotes the judicious, appropriate, safe, and effective use of medicines at all times
1. Uses a systematic process for gathering
necessary medication history and other relevant
consumer information
• Australian Government Department of Health
and Ageing. www.health.gov.au
The National Strategy for Quality Use of
Medicines
National Medicines Policy
Medication Profiling Service [guidelines and
standards]. www.psa.org.au
Pharmacy Program. Medical and other health
professionals advice referral policy. (P2I)
www.guild.org.au/qcpp
• Appendix 1: The Medicines Management
Pathway, p. 81
• Appendix 4: Adherence Assessment Tool,
p. 87
2. Reviews all relevant medicine and consumer
information to identify existing or potential issues
and to ensure safe outcomes and minimise harm
3. Provides the consumer with treatment options,
including non-pharmacological and lifestyle
interventions, and respects their right to choose
their preferred option
4. Assesses the consumer’s adherence to their
treatment regimen where necessary
5. Develops a plan to improve adherence
where necessary
6. Sets goals in agreement with the consumer for
any recommended changes to their medication
regimen and lifestyle
Criterion 5: The pharmacist’s primary concern in all services provided is the health and wellbeing of the
consumer and/or the community
1. Identifies and addresses the specific needs of
the consumer and/or the community
www.psa.org.au
Ethical issues in declining to supply
2. Applies a documented procedure for the refusal
of service where the consumer’s request is
unreasonable or unsafe
3. Responds to the consumer in a timely manner
with a referral to an appropriate service provider
when unable or unwilling to provide a service

1
Criteria/Indicators
Self check:
Yes/No/NA
Resources
4. Ensures that the consumer adequately
understands the recommendations and the
choices they have made
5. Applies a documented procedure for identifying
and resolving issues arising from procedural
errors and consumer complaints
6. Documents issues, resolution, and follow-up as
required
Criterion 6: The pharmacist provides the consumer with current, relevant evidence-based information
1. Maintains access to current evidence-based
resources about medicines, therapeutic devices,
general health topics, self-medication, and self-
care issues
www.psa.org.au
Guidelines for Pharmacists on Providing
Medicines Information to Patients
Consumer Medicine Information and the
Pharmacist
Self care fact cards
Evidence-based medicine: the basics. In:
Australian Pharmaceutical Formulary and
Handbook, 21st edn, pp. 424–8
SHPA standards of practice for the provision
of consumer medicines information by
pharmacists in hospitals. J Pharm Pract Res
2007;37:56–8
• National Prescribing Service. Patient leaflets
and action plans. www.nps.org.au
• Consumer Medicine Information.
www.medicines.org.au
• Australian Government National Health
and Medical Research Council. NHMRC
additional levels of evidence and grades for
recommendations for developers of guidelines.
www.nhmrc.gov.au
• Professional Practice Standard 3: Counselling,
p. 20
2. Evaluates information based on quality use of
medicines principles and current evidence-based
clinical guidelines
3. Reviews the consumer’s information needs and
provides written and/or verbal evidence-based
information and reinforcement as needed
Criterion 7: The pharmacist refers the consumer to other health care providers or support services when
appropriate, and/or when requested by the consumer
1. Maintains a current list of details of other health
care providers and support organisations in the
local community
professionals advice referral policy (P2I).
• Appendix 5: Details of Local Health Care
Providers, p. 88
2. Provides the consumer with the relevant details
of support services and/or other health care
providers as required
3. Refers the consumer to other health care
providers and/or support services when their
needs cannot be met by pharmacy services
Criterion 8: The pharmacist documents consumer information in a manner appropriate to the pharmacy
service provided
1. Maintains consumer-specific information that is
current and accurate
2. Uses a standard form of documentation for
recording consumer information

1
Criteria/Indicators
Self check:
Yes/No/NA
Resources
Criterion 9: The pharmacist adopts a systematic approach to monitoring and follow-up
1. Uses a documented procedure when follow-up
is required or requested by the consumer or
another health care provider
2. Records the date and details of any significant
intervention and communication with the
consumer or other health care providers
3. Regularly reviews and monitors the consumer’s
use of medicines, including adherence, where
necessary
Criterion 10: The pharmacist systematically evaluates their ability to provide pharmacy services
1. Regularly self-assesses the knowledge and skills
required to provide pharmacy services
www.psa.org.au
Education and professional development
Guidelines for Managing Pharmacy Systems
for Quality and Safety
Competency Standards for Pharmacists in
Australia 2003 [Under review at June 2010]
• Pharmacy Board of Australia. Guidelines:
Continuing Professional Development.
• National Prescribing Service. NPS Pharmacy
practice reviews. www.nps.org.au
Continuing professional development program.
www.shpa.org.au
• Australian College of Pharmacy. CPD activities.
www.acp.edu.au
Training plan (T15A)
Training record (T15B)
2. Addresses those areas identified as in need of
continuing professional development
3. Documents participation in a continuing
professional development program
4. Regularly seeks feedback to assess that services
meet consumer expectations
5. Systematically enhances the delivery of services
based on consumer feedback
Australian Government Department of Health and Ageing. National
Medicines Policy. Available at: www.health.gov.au/internet/main/
publishing.nsf/Content/nmp-objectives-index.htm
Australian Government Department of Health and Ageing. The national
strategy for quality use of medicines. Executive summary. Available at:
www.health.gov.au/internet/main/publishing.nsf/Content/4CCAC8550BA
36A52CA256F1800468A6E/$File/execsumbro.pdf
Pharmacy Board of Australia. Code of conduct for registered health
practitioners. Available at: www.pharmacyboard.gov.au
Sansom LN, ed. Australian pharmaceutical formulary and handbook.
21st edn. Canberra: Pharmaceutical Society of Australia, 2009.
Society of Hospital Pharmacists of Australia. SHPA standards of practice
for clinical pharmacy. J Pharm Pract Res 2005;35:122–46.

2
ManagingPharmacyPractice
Standard 2: Managing Pharmacy Practice
Standard
The pharmacist with management responsibilities
adequately addresses all management and organisational
needs in order to facilitate the safe, effective, and efficient
delivery of pharmacy services.
• The ‘pharmacist’ in this standard refers to a pharmacist with management responsibilities such as, but not limited to,
directors of pharmacy, pharmacists in charge, proprietors, pharmacy managers, and accredited pharmacists.
• Pharmacists with management responsibilities should self-assess themselves against the appropriate sections
in this standard.
• It is assumed that pharmacists in a management role will also apply the necessary interpersonal and management
skills, and experience to their practice.
• Operating procedures developed to meet the Quality Care Pharmacy Program (QCPP) specifications may be used to
meet this standard where appropriate.
• This standard is to be applied in conjunction with the Fundamental Pharmacy Practice standard.
Criteria/Indicators
Self check:
Yes/No/NA
Resources
Criterion 1: The pharmacist ensures the pharmacy environment, the number of individuals, and the skills of the
individuals working in the pharmacy are appropriate and adequate for the range of services provided
1. Provides and maintains areas within the
pharmacy that are suited to the privacy and
security needs of each service provided
www.psa.org.au
Competency Standards for Pharmacists in
Australia 2003
The role of non-pharmacist dispensary
assistants/technicians
• Therapeutic Goods Administration. Australian
code of good wholesaling practice for
therapeutic goods for human use.
www.tga.gov.au
Staff roster (T14A)
Confidentiality policy (P1A)
Conducting a performance review (P14C)
2. Provides storage areas for therapeutic goods
that comply with the relevant legislation, quality
assurance programs, and manufacturers’
recommended storage conditions
3. Employs adequate numbers of staff with suitable
qualifications, competence, and training to
deliver the pharmacy services offered by the
pharmacy
4. Ensures only suitably trained individuals work in
particular areas of the pharmacy where specific
skills are required (such as the dispensary)
5. Obtains a signed confidentiality form from staff
involved in providing services to consumers
6. Facilitates regular training for all individuals
working in the pharmacy with regard to their
roles and responsibilities, and general pharmacy
procedures
7. Regularly validates and reviews the skills of all
individuals working in the pharmacy to ensure
competence is maintained

2
Criteria/Indicators
Self check:
Yes/No/NA
Resources
8. Regularly monitors the resourcing requirements
of the pharmacy, and makes adjustments
accordingly to ensure quality of the services
is maintained
Criterion 2: The pharmacist provides the necessary resources and equipment for the range of services provided
1. Provides access to all current, relevant, and
essential evidence-based guidelines, business
rules, and therapeutic information resources
• Australian Government. Business. Getting
started with OH&S in your state or territory.
www.business.gov.au
2. Maintains and ensures access to an up-to-date
list of local health care providers, community
groups, and support organisations
3. Supplies and maintains protective equipment to
ensure staff safety
4. Ensures the disposal of all clinical waste and
sharps complies with Australian safety standards
Criterion 3: The pharmacist develops, documents and maintains standard operating procedures for all
services provided
1. Establishes, maintains, and routinely updates
standard operating procedures for all services
provided by the pharmacy
Pharmacy Program. Procedures.
• Royal Pharmaceutical Society of Great Britain.
Developing and implementing standard
operating procedures for dispensing.
www.rpsgb.org.uk
2. Ensures all individuals working in the pharmacy
have access to the procedures and follow them
3. Develops, documents, and maintains
occupational health and safety procedures
Criterion 4: The pharmacist documents all the necessary information required for the services provided
1. Stores all documentation in a systematic and
secure manner to allow timely retrieval when
required
2. Stores documentation in a manner that protects
consumer privacy
3. Prepares forms and tools to be used by all
pharmacy staff when delivering services
to consumers
4. Ensures all individuals working in the pharmacy
maintain relevant documentation
Criterion 5: The pharmacist ensures the range of pharmacy services are systematically evaluated and improved
1. Maintains a documented quality assurance
process appropriate to the services provided
www.psa.org.au
Guidelines for Managing Pharmacy
Systems for Quality and Safety
Policy/procedure review form
Maintaining the operations manual (P7A)
Reviewing procedures and templates (P7C)
• Appendix 2: Quality Use of Medicines and
Practice Improvement, p. 84
2. Documents the features of each pharmacy
service, and how its effectiveness is to
be measured
3. Evaluates the quality of the pharmacy service at
regular intervals
4. Uses a quality improvement tool to aid in the
review process
5. Seeks feedback from the users of services to
assess that services have been provided in a
timely and satisfactory manner

2
Criteria/Indicators
Self check:
Yes/No/NA
Resources
6. Analyses and records the results of service reviews
7. Uses the findings of the service review to take
appropriate action when designing system
improvements
Additional requirements for managing pharmacists providing online pharmacy services
Criteria/Indicators
Self check:
Yes/No/NA
Resources
Criterion 1: The pharmacist ensures that consumers can readily identify the online pharmacy and the services
it provides
1. Clearly displays all details of the pharmacy, including:
• name of the practice
• street address
• approval number
• contact details
• name(s) of the proprietor(s) and pharmacist
managers(s)
• service details, terms and conditions, and costs
• delivery timelines
• privacy and security declaration
• date of most recent update of the website
2. Maintains a document outlining the online
services the pharmacy provides, in both
electronic and hardcopy format
3. Provides the details of the online services
available each time a product is dispatched or
information about the services is requested.
Criterion 2: The pharmacist adheres to all the ethical and professional requirements of the profession when
establishing an internet pharmacy service
1. Ensures that there are no hyperlinks to promotional
material on web pages containing clinical
information on Pharmacist Only Medicines (with
the exception of those listed in Appendix H of the
Standard for the Uniform Scheduling of Drugs
and Poisons), Prescription Only Medicines, and
Controlled Drugs
• Therapeutic Goods Administration.
www.tga.gov.au
Appendix H. In: Standard for the Uniform
Scheduling of Drugs and Poisons (SUSDP)
Advertising therapeutic products
in Australia
• Medicines Australia. Code of Conduct
Edition 16. www.medicinesaustralia.com.au
• Pharmacy Board of Australia.
Guidelines on Dispensing Medicines
Guidelines on Advertising
2. Ensures that no claims and testimonials are
posted on the website that are promotional or
comparative in nature
Criterion 3: The pharmacist ensures that a reliable and secure online pharmacy service is provided
1. Provides adequate electronic security to prevent
access to consumers’ electronic records by
unauthorised personnel
2. Provides a privacy and security declaration
on the website
3. Ensures that information transferred to and from
consumers via the internet is protected by:
• encryption technology
• user name and password access
• Written, legally binding agreement with
third parties, such as webmasters, internet
providers, and contracted computer specialists

2
Additional requirements for managing pharmacists providing non-sterile compounding services
Criteria/Indicators
Self check:
Yes/No/NA
Resources
Criterion 1: The pharmacist provides a safe working environment for all staff involved in the preparation of
high-risk products
1. Establishes and maintains a documented
procedure for monitoring the necessary
biological parameters (such as liver function) of
staff involved in the preparation of cytotoxic and
hazardous products
SHPA standards of practice for the safe
handling of cytotoxic drugs in pharmacy
departments. J Pharm Pract Res 2005;35:
44–52
2. Applies a documented procedure to exclude
certain staff members from the preparation of
cytotoxic and hazardous products (such as
pregnant women)
3. Provides appropriate protective clothing to all
staff preparing cytotoxic and hazardous products
4. Informs all personnel involved in handling
cytotoxic products of the potential hazards
and precautions required in their handling of
such products
Criterion 2: The pharmacist implements a documented procedure in the event of a needlestick injury or
contamination from a cytotoxic spill
1. Develops a documented procedure to be
used in the event of a needlestick injury or an
unexpected exposure to a cytotoxic spill
44–52
• Pharmaceutical Society of Australia. Clinical
resource centre. www.psa.org.au
2. Trains staff on the actions to be taken in the
event of contamination and/or a needlestick
injury in accordance with documented
procedures
3. Provides the materials required for cleaning up
cytotoxic spills
4. Ensures adherence to the developed
procedures in the event of a needlestick injury
or contamination in the area where cytotoxic
products are prepared
5. Establishes a register of any accidents or
cytotoxic spills that includes the date, time and
place of spill, drug name, approximate drug
volume, form of the drug (i.e. liquid or powder),
the names of the staff involved and the actions
taken to remedy the incident
Additional requirements for managing pharmacists providing sterile compounding services
Criteria/Indicators
Self check:
Yes/No/NA
Resources
Criterion 1: The pharmacist ensures that pharmacy staff preparing sterile products are specifically trained and
assessed in compounding techniques
1. Develops and applies a documented procedure
for training and assessing staff in techniques for
the preparation of sterile products
Staff training (P15A)
2. Maintains a current list of trained staff and the
date of training/assessment, in accordance with
the documented training procedure

2
Criteria/Indicators
Self check:
Yes/No/NA
Resources
3. Regularly assesses the aseptic technique and
skill of staff members
SHPA Practice guidelines for aseptic
dispensing services. Aust J Hosp Pharm
1994;24:509–12
Criterion 2: The pharmacist develops and maintains policies and procedures that are relevant to
sterile compounding
1. Develops policies and procedures customised
to the sterile compounding working environment
and facilities
Extemporaneous dispensing. In: Australian
Pharmaceutical Formulary and Handbook,
21st edn, pp. 31–4
www.shpa.org.au
departments. J Pharm Pract Res
2005;35:44–52
SHPA Practice guidelines for aseptic
dispensing services. Aust J Hosp Pharm
1994;24:509–12
2. Develops and maintains a procedure for cleaning
and sanitising the controlled areas
3. Provides all staff with access to the policies and
procedures at all times
4. Regularly reviews the policies and procedures
for sterile compounding to reflect current
best practice
5. Regularly monitors adherence to Australian
standards, policies, and procedures, and takes
appropriate action to ensure these are upheld
6. Maintains certification of isolators and laminar
flow units
7. Reviews and implements corrective quality
assurance checks for all stages of compounding
8. Establishes a daily operator log of staff involved
in preparing cytotoxic products and cleaning the
anteroom and clean room
medicines policy 2000. Canberra: Commonwealth of Australia, 1999.
Available at: www.health.gov.au/internet/main/publishing.nsf/Content/
nmp-objectives-policy.htm
Australian Government Department of Health and Ageing. The national
strategy for quality use of medicines. Plain English edition. Canberra:
Commonwealth of Australia, 2002. Available at: www.health.gov.au/
internet/main/publishing.nsf/Content/nmp-pdf-natstrateng-cnt.htm
Wilson RM, Runciman WB, Gibberd RW et al. The Quality in Australian
Health Care Study. Med J Aust 1995;163:458–71.

3
Counselling
Standard 3: Counselling
Standard
The pharmacist works with the consumer to provide tailored
verbal and written information to ensure the consumer has
sufficient knowledge and understanding of their medicines
and therapeutic devices to facilitate safe and effective use.
• This standard applies to consumer counselling associated with the supply of prescription and non-prescription
medicines and therapeutic devices.
• The term ‘counselling’ refers to a two-way communication process between the pharmacist and the consumer in
which the pharmacist ascertains the needs of the consumer and provides them with the information required to safely
and effectively use medicines and/or therapeutic devices.
• It is envisaged that counselling will be offered to all consumers each time a medicine or therapeutic device is requested
or supplied, and that where the need for counselling is identified, the pharmacist will be available in a timely manner.
• The expressed needs of the consumer, as well as the pharmacist’s professional judgement, particularly with regard to
the consumer’s level of understanding and the context in which the counselling is required, will influence the scope of
the counselling, and how and where it is conducted.
• This standard is to be applied in conjunction with the Fundamental Pharmacy Practice standard. Refer also to the
Managing Pharmacy Practice, Medication Review, Dispensing, Indirect Pharmacy Services, Dose Administration
Aids Service, Provision of Non-prescription Medicines and Therapeutic Devices, Health Promotion, Disease State
Management, and Harm Minimisation standards, where appropriate.
Criteria/Indicators
Self check:
Yes/No/NA
Resources
Criterion 1: The pharmacist is available to provide counselling to all consumers
1. Responds to all requests for consumer
counselling
2. Ensures that the most appropriately trained
person undertakes the counselling
3. Directs and educates pharmacy staff involved
in the provision of medicines and therapeutic
devices to identify and refer consumers who
may benefit from additional counselling by a
pharmacist
Criterion 2: The pharmacist provides counselling that is supported by current, evidence-based information from
relevant resources
1. Regularly accesses current therapeutic
information resources
• National Library of Medicine. PubMed.
www.ncbi.nlm.nih.gov/pubmed
• Medical Matrix. www.medmatrix.org
• National Prescribing Service. www.nps.org.au
Drugs and therapeutic topics
NPS RADAR

3
Counselling
Criteria/Indicators
Self check:
Yes/No/NA
Resources
2. Ensures the information provided is evidence-
based and current
• Evidence-based medicine: the basics. In:
• Information from the world wide web. In:
• The Cochrane Collaboration. The Cochrane
Library. www.cochrane.org
• Veterans’ MATES [Medicines Advice and
Therapeutics Education Services].
www.veteransmates.net.au
• Centre for Evidence-Based Medicine.
EBM tools. www.cebm.net
• Auspharmacist. AusPharm Research
Roundup. www.auspharmacist.net.au
Criterion 3: The pharmacist utilises a range of communication methods to ensure that counselling is effective
1. Identifies barriers to effective communication and
uses strategies to overcome them
• Translating and Interpreting Service (TIS)
National. www.immi.gov.au/living-in-australia/
help-with-english/help_with_translating
Tel: 131 450
• Vision Australia. Resources. Communicating
effectively with people who are blind or vision
impaired. www.visionaustralia.org
• Deaf Society NSW. Information. How to
communicate with a deaf person.
www.deafsocietynsw.org.au
• International Pharmaceutical Federation (FIP).
MEPS Pictogram Project. www.fip.org
• United States Pharmacopeia. USP
Pictograms. www.usp.org
• National Prescribing Service. Translated health
information about medicines. www.nps.org.au
• Health Translations Directory. Translated health
information. www.healthtranslations.vic.gov.au
• NSW Multicultural Health Communication
Service. Publications and resources.
www.mhcs.health.nsw.gov.au
• Pharmaceutical Society of Australia. Guidelines
for Pharmacists in Providing Services to
People with Impaired Vision. www.psa.org.au
• Pharmacy Guild of Australia. Medication
Management Review Program.
Communication and concordance module.
www.guild.org.au
• National Health and Medical Research Council.
Communicating with Patients: Advice for
Medical Practitioners. www.nhmrc.gov.au
• Mind Tools. Communication skills.
www.mindtools.com
2. Uses other appropriate information materials,
such as pictures and models, to effectively
convey information when comprehension
issues arise
3. Uses a translation service or appropriate
alternative where language barriers exist
4. Confirms consumer understanding
during counselling
Criterion 4: The pharmacist provides counselling according to the needs of the consumer
1. Communicates with the consumer to identify
their information needs
• Harvard School of Public Health. Health
Literacy Studies. Innovative materials.
Plain language glossaries.
www.hsph.harvard.edu/healthliteracy

3
Counselling
Criteria/Indicators
Self check:
Yes/No/NA
Resources
2. Tailors communication to the needs and
understanding of the individual consumer
• National Prescribing Service. Medicines Line.
Tel: 1300 888 763
• Poisons Information Centre. Tel: 13 11 26
3. Offers consumers the opportunity to return
and seek further clarification and information
as required
4. Provides consumers with details of other
medicine information services that can be
accessed when the pharmacy is closed
Criterion 5: The pharmacist uses written information or other suitable materials to supplement oral counselling
1. Has access to written materials that can
reinforce oral counselling
Consumer Medicine Information
(CMI) search
Patient leaflets and action plans
www.psa.org.au
Consumer Medicine Information and
the Pharmacist
2007;37:56–8
• HealthInsite. www.healthinsite.gov.au
• Better Health Channel.
www.betterhealth.vic.gov.au
2. Offers Consumer Medicine Information
(CMI) leaflets to consumers and explains
the information contained in the CMI and its
relevance to the medicine supplied
3. Provides the consumer with CMI, or other written
information, when requested or where necessary
Criterion 6: The pharmacist adequately explains and/or demonstrates the use of therapeutic devices to the
consumer
1. Has access to common therapeutic devices
and demonstrates their use to the consumer
during counselling
• Professional Practice Standard 7: Dose
Administration Aids Service, p. 36
• National Prescribing Service. Common inhaler
devices chart. www.nps.org.au
• National Asthma Council. Inhaler technique in
adults with asthma or COPD.
www.nationalasthma.org.au
2. Confirms by observing that the consumer
can demonstrate correct use of the
therapeutic device
Criterion 7: The pharmacist systematically records counselling events that are considered clinically important
1. Documents significant counselling issues or
events in the consumer’s profile
• Appendix 6: Documenting Counselling Events
and Interventions, p. 89
2. Records recommended actions and timelines for
follow-up in the consumer’s medication profile,
where appropriate
3. Documents reasons why counselling and/or
written information, including CMI, were not
provided, where considered important

3
Counselling
Adams RJ, Stocks NP, Wilson DH et al. Health literacy – a new concept
for general practice? Aust Fam Physician 2009;38:144–7.
HRH Global Resource Center. Counselling, Concordance and
Communication: Innovative Education for Pharmacists. Available at:
www.hrhresourcecenter.org/node/1938.
Pharmaceutical Society of Australia. Section E: OTC counselling guides.
In: Sansom LN, ed. Australian pharmaceutical formulary and handbook.
21st edn. Canberra: PSA, 2009: 373–414.
Pharmacy Board of Australia. Guidelines on dispensing medicines.
Available at: www.pharmacyboard.gov.au

4
MedicationReview
Standard 4: Medication Review
Standard
The pharmacist works with the consumer, and other
health care providers, to systematically review the
consumer’s medication regimen, identify potential areas
for improvement, and provide information and advice to
optimise health outcomes.
• A ‘medication review’ is a systematic assessment of a consumer’s medications and the management of those
medications, with the aim of optimising consumer health outcomes and identifying potential medication-related issues
within the framework of the quality use of medicines.
• The term ‘medication review’ encompasses a continuum of processes in various formats and complexities, ranging
from an opportunistic discussion to a more comprehensive and proactive approach to reviewing the consumer’s
medication regimen (see Figure 1).
• This standard covers the key principles underpinning all types of systematic medication review services under any
service arrangement including, but not limited to: hospital inpatient medication reviews, medication profiling services,
Home Medicines Reviews (HMRs), Residential Medication Management Reviews (RMMRs), and Medicines Use
Reviews (MURs). Opportunistic medication history reviews that are conducted during the dispensing process are
covered in Standard 5: Dispensing.
• This standard is to be applied in conjunction with the Fundamental Pharmacy Practice and Counselling standards.
Refer also to the Health Promotion standard, where appropriate.
• Pharmacists providing medication reviews should also be familiar with the relevant professional guidelines and
business rules relating to these services, where available. For specific service-related information, refer to the
relevant Professional Practice Guidelines for each individual service.
Opportunistic Systematic
Reactive
review
e.g. medication history
review at the time of
dispensing

Medication chart
review
e.g. hospital or residential
care facility inpatient
medication chart review

Treatment
review
e.g. MUR, medication
profiling service

Proactive
review
e.g. HMR and RMMR
with consumer
involvement
Figure 1. Medication review services fall along a continuum of increasing complexity. More complex services
require additional training and skills from a pharmacist.
Note: Home Medicines Reviews were formerly known as Domiciliary Medication Management Reviews (DMMRs).

4
MedicationReview
Criteria/Indicators
Self check:
Yes/No/NA
Resources
Criterion 1: The pharmacist maintains the relevant level of competency necessary to undertake the specific
medication review service
1. Has completed the appropriate level of training
and credentialing for the medication review
service being delivered
• Australian Association of Consultant
Pharmacy. www.aacp.com.au
AACP Competency Map: Medication
Management Reviews
Accreditation diagram
HMR Mentoring Service
Fact sheet 5. Reaccreditation for MMRs
MMR [Medication Management Review]
accreditation. www.shpa.org.au
2. Maintains currency of the knowledge and skills
required to deliver the medication review service
3. Accesses appropriate resources to support
service delivery
Criterion 2: The pharmacist works collaboratively with the consumer and other health care providers
1. Determines and uses the preferred method of
communication for the consumer and other
health care providers
www.guild.org.au
2. Ensures the consumer has provided
informed consent for both the service and
for communication with their other health
care provider(s)
3. Conducts the medication review in an environment
that meets the needs of the consumer
4. Liaises with any other pharmacists involved in
the medication review service to ensure all tasks
are completed and follow-up occurs if required
Criterion 3: The pharmacist follows a systematic procedure for conducting the medication review
1. Forms an agreement with any other pharmacists
involved in different aspects of the review to
ensure all tasks are performed
Pharmacy. www.aacp.com.au
AACP Procedures and Resources Manual:
Medication Management Review
Framework Document for Domiciliary
Medication Management Reviews
SHPA standards of practice for clinical
pharmacy. Appendix A: Accurate medication
history. J Pharm Pract Res 2005;35:122–46
www.psa.org.au
Guidelines for pharmacists: Domiciliary
Medication Management Review
Guidelines and Standards for the
Collaborative and Pharmacist Residential
Medication Management Review (RMMR)
Program and Associated Quality Use of
Medicines (QUM) Services
Medication Profiling Service [guidelines
and standards]
Pharmacy Program. Home Medicines Review
checklist (T3F). www.guild.org.au/qcpp
2. Conducts a consumer interview to compile a
medication history, unless direct communication
with the consumer is not possible
3. Reviews consumer’s current medication,
utilises consumer files, pharmacy records, and
information from other health care providers to
further inform the medication review
4. Assesses adherence and provides advice on
how to improve adherence if necessary
5. Assesses the consumer’s medication regimen
and identifies potential medication-related issues
Criterion 4: The pharmacist conducts the medication review and reports findings, where relevant, in a
timely manner
1. Completes the medication review within
2–4 weeks of receiving the referral or notifies
the referring health care provider if there is
to be a delay

4
MedicationReview
Criteria/Indicators
Self check:
Yes/No/NA
Resources
2. Completes medication reviews initiated upon
hospital discharge, or those indicated as urgent,
within 7–10 days of receiving the referral
Criterion 5: The pharmacist maintains accurate documentation for the medication review service provided
1. Records all activities undertaken and strategies
developed in the course of a medication review
Pharmacy. AACP sample agreement between
HMR Service Provider and the Accredited
Pharmacist. www.aacp.com.au2. Stores all medication review documentation in a
safe, systematic and secure manner that allows
timely and accurate retrieval
3. Prepares a comprehensive report documenting
recommendations, if relevant
Criterion 6: The pharmacist addresses and follows up any issues arising from the medication review
1. Addresses any current, or potential, medication-
related issues identified in the medication review,
in conjunction with other health care providers,
where appropriate
2. Prioritises any identified issues and addresses
them in a timely manner
3. Promptly communicates to the appropriate
health care provider any findings that may
seriously affect the consumer’s health
4. Records any follow-up actions resulting from the
medication review, if known
Criterion 7: The pharmacist creates and maintains a comprehensive medication profile with involvement from
the consumer and their other health care providers
1. Uses suitable computer software to
record relevant consumer details in the
medication profile
• National Prescribing Service. Medicines list.
www.nps.org.au
and Ageing. Medi-list. www.health.gov.au
2. Maintains a medication profile for each consumer
that is current and complete at the time of review
3. Shares and discusses details of the medication
profile with the consumer, including how it can be
used as a resource to improve continuity of care
4. Obtains relevant information from the consumer’s
other health care providers as required
Criterion 8: The pharmacist provides the consumer and other health care providers with relevant information to
optimise health outcomes
1. Provides accurate and relevant written and
verbal information to the consumer’s other health
care providers as needed
Medicines Information to Consumers
Program
When to Provide Consumer Medication
Information
www.psa.org.au
Pharmacist
2. Maintains access to current sources of evidence-
based information about medicines, therapeutic
devices, and lifestyle issues

4
MedicationReview
Criteria/Indicators
Self check:
Yes/No/NA
Resources
3. Provides the consumer with written and oral
information and advice appropriate to their needs
• Consumer Medication Information.
Consumer Medicine Information
(CMI) search
NPS patient resources for
health professionals
Counselling, p. 20
4. Demonstrates and observes the use of any
therapeutic devices, aids, and systems designed
to assist in medication use and adherence
5. Provides any other pharmacists involved with the
medication review with relevant information to
ensure continuity of care
Medicines Policy: Quality Use of Medicines (QUM). Available at: www.
health.gov.au/internet/main/Publishing.nsf/Content/nmp-quality.htm
Australian Pharmaceutical Advisory Council. Guiding principles to achieve
continuity in medication management. Canberra: Commonwealth of
Australia, 2005.
Chen T, Moles R, Nishtala P, Basger B. Medication review: a process
guide for pharmacists. 2nd edn. Canberra: Pharmaceutical Society of
Australia, 2010.
Cipolle R, Strand L, Morley P. Pharmaceutical care practice: the
clinician’s guide. 2nd edn. New York: McGraw-Hill, 2004.
Clyne W, Blenkinsopp A, Seal R; National Prescribing Centre. A guide
to medication review, 2008. Liverpool: National Prescribing Centre,
2008. Available at: www.npci.org.uk/medicines_management/review/
medireview/library/library_good_practice_guide1.php
Gowan J, Roller L. Practical disease state management for pharmacists.
Sydney: Australian Pharmaceutical Publishing Company Ptd Ltd, 2004.
Hughes J, Tenni P, Peterson G. The Australian pharmacist aged care
primer. Canberra: Pharmaceutical Society of Australia, 2007.
Medicare Australia. Home Medicines Review (HMR). Available at:
www.medicareaustralia.gov.au/provider/pbs/fourth-agreement/hmr.jsp
Medicare Australia. Residential Medication Management Review (RMMR).
Available at: www.medicareaustralia.gov.au/provider/pbs/fourth-
agreement/rmmr.jsp
Pharmaceutical Society of Australia. Medication review. In: Sansom
LN, ed. Australian pharmaceutical formulary and handbook. 21st edn.
Canberra: PSA, 2009: 276–9.
Pharmacy Guild of Australia. About Home Medicines Review. Available
at: www.guild.org.au/mmr/content.asp?id=53
Pharmacy Guild of Australia. RMMR. Available at: www.guild.org.au/
mmr/content.asp?id=62

5
Dispensing
Standard 5: Dispensing
Standard
The pharmacist ensures that dispensing occurs accurately,
reflects the prescriber’s intentions, and is consistent with
the needs and safety of the consumer.
• This standard applies to the dispensing of prescription medicines and to products prepared extemporaneously from
the point of receiving the prescription (by hand or electronic means), assessing it against the consumer’s needs and
any safety concerns, and accurately supplying the medicine.
• It is assumed that the pharmacist has adequate knowledge of the dispensing software and systems he or she uses to
meet the requirements of this standard.
• A pharmacy technician may carry out the functions of assembling medicines and data entry (where legally allowed).
However, the pharmacist is responsible for assessing the appropriateness of the medicines in relation to the full
medication history (or medication profile if available), the final check of dispensed medicines, and the counselling
of the consumer.
Refer also to the Managing Pharmacy Practice, Indirect Pharmacy Services, Dose Administration Aids Service,
Compounding, Compounding Sterile Preparations, Disease State Management, and Harm Minimisation standards for
additional information, where appropriate.
Criteria/Indicators
Self check:
Yes/No/NA
Resources
Criterion 1: The pharmacist implements systems of good dispensing practice
1. Applies and supervises a documented dispensing
procedure that covers receipt of prescriptions,
preparation, and supply of medicines
Dispensing Practice Guidelines.
www.psa.org.au
• Pharmaceutical Defence Limited. Guide to
good dispensing chart. www.pdl.org.au
2. Checks details of repeat prescriptions against
the original prescription
3. Uses barcode scanners to verify the selection of
correct medicines just prior to attaching the label
4. Applies a documented procedure to detect
and appropriately address excessive supply,
fraudulent prescriptions, and insufficient or
apparent non-adherence
5. Processes non-prescription items written on
prescriptions in the same manner as prescription
only items
Criterion 2: The pharmacist obtains personal details and a complete medication history from the consumer
1. Collects and accurately records sufficient personal
details and a complete medication history to
establish a consumer profile when dispensing

2. Collects and documents any special needs of
the consumer in the consumer profile so that
verbal counselling or written information can be
tailored accordingly

5
Dispensing
Criteria/Indicators
Self check:
Yes/No/NA
Resources
3. Considers all the information collected in order to
make an informed professional judgement about
the supply of the requested medicine
Criterion 3: The pharmacist reviews and updates the consumer’s medication history during the dispensing process
1. Reviews and considers the multiple sources of
medicines (prescription, non-prescription, and
complementary) and the influence of relevant
disease states on the action and/or effect of
prescribed medicines
2. Confirms that the consumer’s information
downloaded from e-prescriptions or e-health
records is current and accurate
3. Records all dispensed medicines in the
consumer’s medication history
Criterion 4: The pharmacist identifies, records, and considers the consumer’s suspected and known adverse
drug reactions (ADRs), precautions, and contraindications when dispensing
1. Gathers information and records details of any
ADRs, including allergies, precautions, and
contraindications known to the consumer
• Therapeutic Goods Administration.
Report of suspected adverse reactions to
medicines/vaccines.
www.tga.gov.au/adr/bluecard.htm
Safety alerts and advisory statements.
www.tga.gov.au/alerts/
Advisory Committee on the Safety
of Medicines.
www.tga.gov.au/committee/acsom.htm
2. Uses alerts to remind pharmacy staff of the
consumer’s known or suspected ADRs,
including allergies
3. Considers potential drug interactions each time
a medicine is dispensed
4. Accesses current information on clinically
significant interactions, contraindications,
precautions, and disease states
5. Provides advice to consumers about potential
ADRs that is consistent with, and complementary
to, the advice given by the prescriber or other
relevant health care providers
6. Discusses potential or existing ADRs with
the consumer’s other health care providers
when required
7. Reports clinically significant ADRs to the
Advisory Committee on the Safety of Medicines
where appropriate
Criterion 5: The pharmacist contacts the prescriber about a prescription or a consumer’s therapy when necessary
1. Documents on the prescription and in the
dispensing history, all communication with the
prescriber about prescriptions, medicines, and/
or consumer issues
2. Documents on the prescription, and in the
consumer profile, where possible, all changes to
treatment regimen authorised by the prescriber
3. Confirms and documents the outcome
of any conversation with the prescriber
about off-label use
Criterion 6: The pharmacist uses appropriate care when dispensing cytotoxic medicines
1. Ensures all cytotoxic medicines stored in the
dispensary are clearly identified as such using
supplementary labelling
www.shpa.org.au

5
Dispensing
Criteria/Indicators
Self check:
Yes/No/NA
Resources
2. Counts and handles cytotoxic medicines where
necessary using equipment that is specifically for
cytotoxic use only
SHPA standards of practice for the
transportation of cytotoxic drugs from
pharmacy departments. J Pharm Pract Res
2007;37:234–5
2005;35:44–52
provision of oral chemotherapy for the
treatment of cancer. J Pharm Pract Res
2007;37:149–52
Criterion 7: The pharmacist dispenses medicines with legible and unambiguous labels, and with adequate
dosing instructions
1. Uses labels with clearly marked dark print,
ensuring manufacturer’s batch number and expiry
date are clearly visible, and includes both brand
and generic names for prescription medicines
• Counselling and cautionary advisory labels
for medicines. In: Australian Pharmaceutical
Formulary and Handbook, 21st edn,
pp. 2–20
2. Considers the need for child-resistant packaging
when a medicine that warrants such packaging
is repackaged from its original container
3. Includes manufacturer’s batch number and
expiry date on the label of the dispensed
medicine when repackaging from an
original container
4. Labels medicines with dark print and large
font size to allow easier reading for visually
impaired consumers
5. Provides labels with specific and complete
instructions for use
6. Uses cautionary advisory labels to indicate
specific usage instructions (e.g. ‘Shake well
before each use’)
Criterion 8: The pharmacist ensures the consumer has adequate dosing instructions and fully understands how
to safely use, store, and dispose of dispensed medicines
1. Provides additional written medicine dosing
instructions, such as Consumer Medicine
Information (CMI) or a Medication Profile,
where required
• Pharmaceutical Society of Australia. Consumer
Medicine Information and the Pharmacist.
www.psa.org.au
• Counselling and cautionary advisory labels
Formulary and Handbook, 21st edn, pp. 2–20
2007;37:56–8
Counselling, p. 20
2. Provides written and verbal information in a
manner that addresses communication barriers,
such as literacy level, cultural background, and
language mastery
3. Uses appropriate cautionary advisory labels on
dispensed medicines as recommended in the
current edition of the Australian Pharmaceutical
Formulary and Handbook
4. Offers counselling to ensure that the consumer
has sufficient knowledge of their medications to
facilitate their safe and effective use
5. Offers advice on how to safely store and dispose
of dispensed medicines
6. Provides counselling to a consumer so they
understand the benefits and risks associated
with any off-label use of medicines

5
Dispensing
Criteria/Indicators
Self check:
Yes/No/NA
Resources
7. Advises the consumer about the correct
handling, storage, and disposal of cytotoxic
medicines, particularly for those in tablet form
that are not film-coated
8. Advises the consumer to contact the
prescriber when the last repeat of a
prescription is dispensed
9. Provides appropriate advice on the safe
storage and handling of dispensed
medicines, particularly when child-resistant
packaging is used
Criterion 9: The pharmacist checks the dispensed medicine for accuracy
1. Checks the dispensed medicine against the
original prescription before the medicine is
supplied to the consumer
www.psa.org.au
2. Checks the expiry date of the dispensed
medicine is valid for the expected duration
of treatment
3. Ensures the dispensing record shows which
pharmacist dispensed the medicine(s)
4. Initials the dispensing label when the pharmacist
who physically issues the medicine is not the
dispensing pharmacist
5. Uses barcode scanners to verify the correct
medicine has been dispensed
Criterion 10: The pharmacist accurately identifies the consumer or agent when dispensing and supplying the medicine
1. Seeks confirmation of the consumer’s identity
prior to dispensing
2. Seeks confirmation of the consumer’s identity
to ensure the correct medicine is handed to the
correct consumer
3. Confirms an agent’s identity and their
authorisation to collect a prescribed item
on behalf of the consumer
Criterion 11: The pharmacist completes all dispensing in a timely manner
1. Routinely assesses current workload and the
number of prescriptions received to determine
the likely amount of time the consumer will
need to wait
2. Informs pharmacy staff and the consumer of the
anticipated waiting time for the prescription and
discourages the expectation of fast service.
Criterion 12: The pharmacist ensures the consumer fully understands the nature of brand substitution when it occurs
1. Checks whether the ‘not for substitution’ box
has been ticked on the prescription before
offering brand substitution to the consumer
for Pharmacists on PBS Brand Substitution.
www.psa.org.au
2. Checks whether the ‘not for substitution’ box
has been ticked on the original prescription
before dispensing a repeat prescription

5
Dispensing
Criteria/Indicators
Self check:
Yes/No/NA
Resources
3. Follows a process to inform consumers of
generic brand substitutes where they are
available and consistent with the prescriber’s
intent and desired health outcomes
4. Records in the dispensing history and on
the medicine label when initial brand
substitution occurs
5. Issues the same generic brand as previously
given wherever possible to minimise medication
misadventure and consumer confusion
6. Substitutes brands only where bioequivalence
has been established and the consumer
has consented
7. Informs the consumer of the risks and/or benefits
associated with brand substitution
8. Counsels the consumer when brand substitution
is inappropriate or cannot occur

Pharmaceutical Defence Limited. Guide to good dispensing chart.
Available at: www.pdl.org.au/publications/gtgd

6
IndirectPharmacyServices
Standard 6: Indirect Pharmacy Services
Standard
In circumstances where face-to-face contact is not
possible, the pharmacist provides an ethical indirect supply
service that maintains the principles of quality use of
medicines and consumer privacy.
• This standard applies to the provision of medicines and therapeutic devices by a pharmacist to a consumer living at
an Australian address where supply occurs without face-to-face contact. Where possible, face-to-face contact with
consumers should be encouraged.
• This standard covers the supply of medicines and therapeutic devices via mail, courier, taxi, remote dispensing units,
telepharmacy, and depots, as well as the ordering of these via email, internet, teleconference, or facsimile.
• This standard is to be applied in conjunction with the Fundamental Pharmacy Practice, Counselling, and Dispensing
standards. Refer also to the Managing Pharmacy Practice, Compounding, and Provision of Non-prescription Medicines
and Therapeutic Devices standards, where appropriate.
Criteria/Indicators
Self check:
Yes/No/NA
Resources
Criterion 1: The pharmacist provides the consumer with information about the indirect pharmacy service
1. Gives the consumer the full contact details
of the pharmacy
Pharmacy Program. Distance supply checklist
(T2A). www.guild.org.au/qcpp
• Appendix 7: Indirect Pharmacy Services:
New Consumer Details/Change of Consumer
Details Form, p. 90
2. Explains the service to the consumer
3. Advises the consumer when a pharmacist will be
available to provide information and counselling
4. Advises the consumer of the usual
delivery timeframe
5. Advises the consumer of the costs associated
with the service provided
Criterion 2: The pharmacist follows a documented procedure when setting up consumer profiles
1. Records the contact details of consumers
accessing the service, including telephone
number and residential street address
2. Establishes and records a medication history,
including all prescription, non-prescription, and
complementary medicines
3. Collects and documents any special needs
of the consumer so that oral counselling and
the provision of written information can be
tailored accordingly
4. Uses mandatory fields in online application
forms to gather all relevant information before
dispensing can proceed

6
Criteria/Indicators
Self check:
Yes/No/NA
Resources
Criterion 3: The pharmacist follows a documented procedure for the indirect supply of medicines and
therapeutic devices
1. Documents the date and details of both the
request and dispatch in a manner that links this
information to the consumer’s profile
www.psa.org.au
• Pharmaceutical Defence Limited. Guide to
good dispensing chart. www.pdl.org.au
Deliveries by pharmacy staff (excluding
contractors) (P11F)
Distance supply checklist (T2A)
• Appendix 7: Indirect Pharmacy Services:
New Consumer Details/Change of Consumer
Details Form, p. 90
2. Exercises due care to ensure all details
gathered and supplied are accurate in relation
to the consumer, prescriber, prescription, and
therapeutic need
3. Documents in the consumer’s profile the
medicines supplied, including complementary,
prescription, and non-prescription medicines
4. Applies, and supervises, the pharmacy’s
documented procedure for the indirect supply
of non-prescription medicines and devices, with
particular attention paid to relevant state/territory
legislation for Pharmacist Only Medicines
5. Applies the pharmacy’s documented procedure
to detect and appropriately deal with excessive
or fraudulent orders for medicines
6. Documents the time, date, name of the
pharmacist supplying the order, and details of
any information provided to the consumer
Criterion 4: The pharmacist ensures the consumer’s profile is current at the time of dispensing and prior to dispatch
1. Verifies contact details of all consumers at the
time of dispensing
2. Records the date of verification and/or
amendments to the consumer profile
3. Ensures the most recently amended information
and its date of entry are easily accessible
Criterion 5: The pharmacist supplies medicines and therapeutic devices to the consumer in a secure and
timely manner
1. Ensures the privacy and confidentiality of the
consumer are maintained throughout all stages
of the indirect supply process
Distance supply checklist (T2A)
Deliveries register (T11A)
• Appendix 8: Medicines that may be
Considered Unsuitable for Indirect
Supply, p. 91
2. Records the consumer’s preferred mode and
time of delivery
3. Maintains a list of medicines that are not suitable
for delivery by indirect supply
4. Ensures the package contains the pharmacy’s
contact details and instructions to indicate that
professional advice is available
5. Ensures all items are packaged adequately for
delivery to meet the manufacturer’s specified
storage requirements
6. Ensures all items are packaged securely to
protect from damage during transit
7. Ensures packages containing medicines are
labelled in a way that minimises potential loss,
diversion, or intentional tampering

6
Criteria/Indicators
Self check:
Yes/No/NA
Resources
8. Ensures cytotoxic medicines are packaged
and labelled adequately, and that specific
instructions for disposal and management
of spills are included
9. Uses a reliable and efficient courier with an
audit trail or delivery tracking system, a delivery
confirmation receipt, and a mechanism to return
the package to the sender if undelivered
10. Instructs all individuals to carry identification
when they are involved in the delivery of
medicines and therapeutic devices from
the pharmacy
11. Notifies the consumer promptly if the medicines
cannot be delivered
Criterion 6: The pharmacist provides appropriate information to the consumer to enable safe and effective use
of the medicines and therapeutic devices supplied
1. Accesses a range of information resources that
can be provided to consumers
www.psa.org.au
Pharmacist
Counselling, p. 20
2. Provides a Consumer Medicine Information (CMI)
leaflet and/or other written information with all
therapeutic goods
3. Establishes contact with all consumers when a
medicine or therapeutic device is supplied for the
first time to check they understand how to take
or use the medicine or therapeutic device, and to
inform them of potential adverse effects and how
these might best be managed
Australian Pharmacy Council. Remote Rural Pharmacists Project.
Canberra: APC, June 2009. Available at: www.pharmacycouncil.org.au/
APC_publications.htm
Pharmaceutical Society of Australia. Position statement. Distance
dispensing. November 1997. Available at: www.psa.org.au/site.
php?id=3672

7
DoseAdministrationAidsService
Standard 7: Dose Administration Aids Service
Standard
The pharmacist identifies consumers who would benefit
from a Dose Administration Aids Service, and works with
them to provide an accurate and tailored service with
regular monitoring and advice.
• This standard applies to the provision of a Dose Administration Aids Service to assist in the safe and effective
administration of a consumer’s medication and improve adherence. It is a holistic service that covers the packing of
dose administration aids (DAAs) and the professional support services provided to ensure the optimal use of DAAs.
• DAAs are well-sealed, tamper-evident devices that allow individual medicine doses to be organised according to the
prescribed dose schedule. Note if the pharmacist provides a non-tamper-evident DAA at a consumer’s request, the
service provided must still meet the criteria in this standard.
standards. Refer also to the Managing Pharmacy Practice, Medication Review, Indirect Pharmacy Services, Services to
Residential Care Facilities, Continuity of Care through Medication Liaison Services, and Provision of Pharmacy Services
to Aboriginal and Torres Strait Islander Services standards, where appropriate.
• Pharmacists providing a Dose Administration Aids Service should also be familiar with the relevant professional
guidelines and business rules relating to these services. For specific service-related information, refer to the PSA’s
Dose Administration Aids Service guidelines.
Criteria/Indicators
Self check:
Yes/No/NA
Resources
Criterion 1: The pharmacist provides a Dose Administration Aids Service that meets the consumer’s needs
1. Systematically and routinely assesses and
documents the consumer’s needs
www.psa.org.au
Dose Administration Aids Service
Dose Administration Aids Service. Guidance
and checklists for service delivery
Appendix 3: Discussion guide and sample
agreement for a DAA service. In: Dose
Administration Aids Service, pp. 17–18
• Australian Government Department of
Veterans’ Affairs. www.dva.gov.au
Dose Administration Aid Service: The Right
Dose [information brief for pharmacists]
Dose Administration Aid Service: The Right
Dose [brochure for veterans]
Counselling, p. 20
Continuity of Care through Medication
Liaison Services, p. 44
2. Ensures the consumer understands the nature
and benefits of the service provided
3. Provides comprehensive instructions to the
consumer relating to the use of the DAA
4. Follows a process to ensure the provided
instructions are clearly understood
5. Provides ongoing support, such as counselling
or Consumer Medical Information (CMI) leaflets,
to consumers using DAAs for the duration
of the service
6. Ensures continuity of care when a consumer
transfers between different care settings
7. Ensures that all DAAs are provided to the
consumer in a timely manner

7
Criteria/Indicators
Self check:
Yes/No/NA
Resources
Criterion 2: The pharmacist implements systems to ensure accuracy of packing
1. Generates and maintains a current
medication profile
SHPA standards of practice for the provision of
medication reconciliation. J Pharm Pract Res
2007;33:231–3
www.psa.org.au
Dose Administration Aids Service. Checklist
C: Packing the consumer’s DAA. Guidance
Appendix 4: Record of packing dispensed
medicines into DAA. In: Dose Administration
Aids Service, p. 19
Clinical resource centre. Incident report
form template
Dose Administration Aids source
checklist (T3B)
Storing and re-packaging cytotoxic drug
products (P2D)
Incident reporting (P7D)
2. Implements a documented procedure for the
packing of DAAs
3. Ensures staff involved in packing DAAs have the
appropriate skills to perform the task
4. Checks the contents and packing records of all
DAAs packed under the pharmacist’s supervision
prior to issue
5. Follows a process to manage medicine recalls
6. Uses a quality assurance system to record,
actively review, and regularly monitor
discrepancies to minimise any systematic errors
7. Maintains documentation that tracks all DAAs
packed to ensure the accuracy of DAA packing
and distribution processes
Criterion 3: The pharmacist packs the DAA with reference to the consumer’s current medication regimen
1. Maintains and documents a current and complete
medication profile that includes medicines packed
and not packed in the DAA, and documents
decisions to not pack a medicine
www.psa.org.au
Dose Administration Aids Service. Guidance
• National Prescribing Service. Generic
medicines training kit: safe and appropriate
use of generic medicines. www.nps.org.au
2. Provides medicines packed in a DAA that match
the consumer’s current medication regimen
3. Supports the consumer in managing any
medications not packed in the DAA
4. Follows a process to incorporate any regimen
changes into an existing DAA
5. Promotes effective communication with the
prescriber, consumer, carer, and family members
to ensure accurate and well-timed updates of
the DAA and the consumer’s medication profile
Criterion 4: The pharmacist maximises the stability of medicines throughout the process of DAA packing and
distribution, and considers end-use conditions
1. Accesses current information on medicines
that should not be removed from their original
packaging and therefore not repackaged
into a DAA
• Pharmaceutical Society of Australia. Appendix
5: Examples of medicines which should not be
packed into DAA. In: Dose Administration Aids
Service, p. 20. www.psa.org.au
• Church C, Smith J. How stable are medicines
moved from original packs into compliance
aids? Pharm J 2006;276:75–81
• Glass BD, Haywood A, Llewelyn V, Mangan M.
Compliance aids and medicine stability: new
evidence of quality assurance. Current Drug
Safety 2009;4:74–8
2. Assesses the risks and benefits of including
medicines in a DAA, and considers alternative
methods of administration where appropriate
3. Adheres to specific manufacturers’ instructions
that relate to medicine stability

7
Criteria/Indicators
Self check:
Yes/No/NA
Resources
4. Makes individualised decisions about whether
to pack, or not pack, particular medicines into a
DAA and documents these decisions
5. Minimises the duration of time that medicines
are exposed to the atmosphere by promptly
transferring them from their original packaging
into the DAA
6. Seals the DAA immediately after it is packed
7. Stores packed DAAs in an area that is cool, dry,
and protected from light to protect the stability of
the medicines
8. Minimises the time taken for the packing process
Criterion 5: The pharmacist ensures that the DAA label contains complete consumer, medicine, and pharmacy details
1. Clearly displays the consumer’s name, and
the pharmacy’s name, address, and telephone
number on the DAA label
www.psa.org.au
Counselling and cautionary advisory labels
pp. 2–20
2. Ensures the DAA labelling identifies the active
ingredient, brand name, and strength of the
medicines it contains, and the directions for use
(in simple English)
3. Displays the shape, colour, size, and
manufacturer’s markings for each medicine on
the DAA label if possible
4. Uses appropriate cautionary and advisory labels,
and ensures the words ‘Keep out of reach of
children’ are placed on the DAA label
5. Ensures packing date, date of commencement,
and expiry date are included on the DAA label
Criterion 6: The pharmacist follows a procedure for deciding how to dispose of or re-use returned medicines
and the consumer’s own medications when packing DAAs
1. Ensures that no medicines returned to the
pharmacy are re-used by other consumers
• Pharmaceutical Society of Australia. Dose
Administration Aids Service [guidelines and
standards] www.psa.org.au
Pharmacy Program. Return of unwanted
medicines (P2J). www.guild.org.au/qcpp
2. Establishes the source and storage conditions of
the medicines before deciding whether to re-use
or dispose of medicines
3. Disposes of medicines in a responsible manner,
such as via the Return Unwanted Medicines
(RUM) bins
4. Disposes of DAA materials in a manner that
protects the privacy of the consumer
Criterion 7: The pharmacist monitors all consumers who use DAAs
1. Collaborates with the consumer and other
health care providers to address any medication
management issues that arise
Appendix 2: Assessment of consumer
non-adherence when considering a DAA.
In: Dose Administration Aids Service, p. 16.
www.psa.org.au
• National Prescribing Service. Medicines list.
www.nps.org.au
3. Follows a procedure to ensure that the
prescriptions required for medicines packed in
DAAs are regularly provided
5. Ensures that the consumer has a current list of all
their medications, and encourages them to share
this list with their other health care providers

7
Criteria/Indicators
Self check:
Yes/No/NA
Resources
7. Monitors the consumer’s adherence with the
DAA, and addresses any concerns with the
consumer’s other health care providers
9. Regularly reviews the consumer’s medication
regimen in line with their needs
Pharmaceutical Society of Australia. Dose administration aids service.
Guidelines and standards for pharmacists. Canberra: PSA, July 2007.
Pharmacy Board of Australia. Guidelines on specialised supply
arrangements. Available at: www.pharmacyboard.gov.au
Roberts M, Lentile C, Lewis G et al. Effectiveness and cost effectiveness
of dose administration aids (DAAs): final report. Brisbane: University of
Queensland, 2004.

8
ServicestoResidentialCareFacilities
Standard 8: Services to Residential Care Facilities
Standard
The pharmacist provides timely advice, access to
medicines, and other required services to support the
residential care facility and its residents in achieving safe
and effective medicines management.
• This standard describes the systems used to support access to, and the management and use of, medicines and
therapeutic devices in residential care facilities.
• It is expected that the individual elements of the services provided, and the roles and responsibilities of both parties
are clearly defined in a contractual agreement between the relevant pharmacists and the facility.
• For the purpose of this standard, the following definitions apply:
the ‘facility’ refers to the ‘residential care facility’, which includes, but is not limited to, aged care homes (low care,
high care and respite facilities), retirement facilities, supported residential services (previously known as special
accommodation homes), and correctional facilities
‘resident notes’ refers to the facility’s progress notes for a particular resident, where available
a ‘medication chart’ refers to the official document used to order, supply, and administer medicines
‘pharmacist’ may refer to more than one pharmacist providing more than one service; that is, a supply pharmacist
or the Residential Medication Management Review (RMMR) pharmacist. In some instances, the same individual
pharmacist may provide more than one service.
• This standard is to be applied in conjunction with the Fundamental Pharmacy Practice. Refer also to the Managing
Pharmacy Practice, Counselling, Medication Review, Dispensing, Dose Administration Aids Service, Continuity of
Care through Medication Liaison Services, Compounding, Compounding Sterile Preparations, Provision of Non-
prescription Medicines and Therapeutic Devices and Health Promotion standards, where appropriate. See Figure 1
for further clarification on the relationship between this standard and the Medication Review and Dose Administration
Aids Service standards.
Supply of medicines/devices
(See Standard 7: Dose
Administration Aids Service)

Residential Medication
Management Reviews
(See Standard 4:
Medication Review)

Quality use of medicines
services
(This standard)
Figure 1. Continuum of services provided to residential care facilities.

8
Criteria/Indicators
Self check:
Yes/No/NA
Resources
Criterion 1: The pharmacist follows a documented process when a resident is admitted into the facility to allow
timely access to medicines
1. Requests routine notification when a resident is
admitted, or re-admitted
• Appendix 9: Template Procedure for
Consumer Admissions and Readmissions to
Residential Care Facilities, p. 92
SHPA standards of practice for the provision of
medication reconciliation. J Pharm Pract Res
2007;37: 231–3
2. Reviews the charted medication chart when a
resident has been admitted, or re-admitted after
extended leave or hospitalisation
3. Maintains a copy of the current medication
regimen for all residents
Criterion 2: The pharmacist ensures that medicines are provided to the facility in a timely manner that makes
certain the treatment of residents is not compromised
1. Maintains a regular schedule for delivering
medicines, as agreed with the facility,
and in consultation with the relevant health
care providers
A: Sample pharmaceutical services contract.
In: The Provision of Pharmacy Services to
Residential Aged Care Facilities, pp. 7–10.
www.psa.org.au
2. Prioritises orders for medicines based on
their urgency
3. Has a contingency plan for the provision of
emergency/after-hours services to the facility
4. Ensures that medicines are delivered to an
authorised person and a documented procedure
for receipt of medicines is used
Criterion 3: The pharmacist maintains appropriate systems for the supply of medicines to the facility
1. Dispenses medications for the resident in
response to a prescription order in accordance
with the contractual arrangements with the facility
A: Sample pharmaceutical services contract.
In: The Provision of Pharmacy Services to
Residential Aged Care Facilities, pp. 7–10.
www.psa.org.au2. Has a process in place for supplying
medicines for stock in response to a
requisition from the facility in accordance
with contractual arrangements
3. Has a process in place to be notified of changes
to medication regimens
Criterion 4: The pharmacist liaises with appropriate nursing staff/carers to address issues relating to
medicine administration
1. Has systems in place for monitoring patterns of
medicine use in the facility
• National Prescribing Service. DUE (Drug Use
Evaluation) for aged care facilities.
www.nps.org.au
SHPA standards of practice for drug usage
evaluation in Australian hospitals. J Pharm
Pract Res 2004;34:220–3
• Victorian Government Health Information.
Resource kit to enable implementation of the
APAC Guidelines for Medication Management
in Residential Aged Care Facilities.
www.health.vic.gov.au
2. Documents interactions with health care
providers with whom medicine-related issues
are discussed
3. Has a process in place to follow up on any
medicine administration issues identified
Criterion 5: The pharmacist supports the facility in maintaining medicines safety systems
1. Facilitates a system for reporting adverse drug
events (ADEs)
• Therapeutic Goods Administration. Report
of suspected adverse reaction to medicines/
vaccines. [Blue card] www.tga.gov.au
2. Facilitates a system to prevent ADEs reoccurring
3. Facilitates a system to identify potential
medicines safety issues

8
Criteria/Indicators
Self check:
Yes/No/NA
Resources
Criterion 6: The pharmacist provides information and education on medicines and the quality use of medicines
that meets the needs of residents and the facility
1. Liaises with the director of nursing and/or
relevant committees to identify the needs
of the facility
www.psa.org.au
Guidelines and Standards for the
Collaborative and Pharmacist Residential
Medication Management Review (RMMR)
Program and Associated Quality Use of
Medicines (QUM) Services
Quality Use of Medicines kits
Counselling, p. 20
2. Has access to current relevant resources
to support the provision of information
on medicines
3. Responds to medicine information queries
promptly and efficiently
4. Delivers information on medicines according to
the needs and arrangements of the resident,
facility, and other health care providers
5. Recommends appropriate sources of drug
information for use by facility staff
6. Delivers an education program according to
agreed arrangements
Criterion 7: The pharmacist liaises with the facility to ensure that all medicines are stored according to
legislative and manufacturers’ requirements
1. Advises the facility of the need to have a
documented procedure for the safe and secure
storage of medicines
2. Provides and documents any advice given to the
facility on how to comply with relevant legislation
3. Liaises with the facility to ensure that
medicines held at the facility are regularly
checked to ensure they are stored and
discarded appropriately
Criterion 8: The pharmacist supports and advises the facility on stock control systems where appropriate
1. Facilitates a system to determine the range
of commonly used medicines that would be
required as stock, where appropriate
2. Facilitates the regular review of medicine usage
to ascertain the appropriateness of medicines
held at the facility
3. Conducts regular checks that sufficient
medicines are available and excess stock is
not accumulating
4. Provides education for facility staff on the correct
procedure for medicine storage and rotation
5. Liaises with the facility to assist in the
development of systems to monitor expired
medicines and other medicines considered
unsuitable for use, and, where necessary,
to remove those medicines
Criterion 9: The pharmacist advises the facility on a systematic approach to improving medicine-related
systems within the facility
1. Assists in the evaluation of the medicine-related
systems within the facility
• Aged Care Standards and Accreditation
Agency Ltd. Assessment modules. Medication
administration and management.
www.accreditation.org.au

8
Criteria/Indicators
Self check:
Yes/No/NA
Resources
2. Provides regular advice to the facility, or
appropriate committees, on the relevant
quality and safety aspects of medicines
within the facility
Resource kit to enable implementation of the
APAC Guidelines for Medication Management
in Residential Aged Care Facilities.
www.health.vic.gov.au
• Australian Pharmaceutical Advisory Council.
Guidelines for Medication Management in
Residential Aged Care Facilities.
www.health.gov.au
• Australian Commission on Safety and Quality
in Health Care. Medication Safety.
www.safetyandquality.gov.au
3. Contributes to the development and review of
relevant medicine policy and procedures
4. Documents any recommendations provided to
the facility and subsequent outcomes
Criterion 10: The pharmacist supports the continuity of care for residents transferring between health care
settings or providers
1. Liaises with local hospitals and other temporary
care facilities to ensure a smooth transition for
residents transferring between settings
• Society of Hospital Pharmacists of Australia
provision of medication reconciliation.
J Pharm Pract Res 2007;37: 231–3
community liaison pharmacist. Aust J Hosp
Pharm 1996;26:570–2
Continuity of Care through Medication
Liaison Services, p. 44
2. Communicates with a transferring resident’s
other health care providers to gather and
provide information that will assist in maintaining
continuity of care
3. On termination of a contract with the facility,
the departing pharmacist provides relevant
information about consenting residents to the
incoming pharmacist who will next provide
contract pharmacy services to the facility
Australian Government Department of Health and Ageing.
Documentation and accountability manual. Last amended December
1999. Available at: www.health.gov.au/internet/main/publishing.nsf/
Content/ageing-manuals-dam-index.htm
Australian Government Department of Health and Ageing. Residential
care manual. 2009. Available at: www.health.gov.au/internet/main/
publishing.nsf/Content/ageing-manuals-rcm-rcmindx1.htm
Australian Government Department of Health and Ageing. Residential
Medication Management Reviews (RMMR) information for aged care
homes. Available at: www.health.gov.au/internet/main/publishing.nsf/
Content/health-epc-dmmrqa-pdf-agedcarefact
Australian Government Department of Health and Ageing. Standards and
accreditation. Available at: www.health.gov.au/internet/main/publishing.
nsf/Content/ageing-rescare-rescprov-standard.htm
Australian Government Department of Health and Ageing. Standards and
guidelines for residential aged care service manual. Last amended 2001.
Available at: www.health.gov.au/internet/main/publishing.nsf/Content/
ageing-manuals-sgr-sgrindex.htm
Australian Pharmaceutical Advisory Council. Guidelines for medication
management in residential aged care facilities. 3rd edn. Canberra:
internet/main/publishing.nsf/Content/nmp-pdf-resguide-cnt.htm
NSW Department of Health. Best practice model for the use of
psychotropic medication in residential aged care facilities and guidelines
on the management of challenging behaviour in residential aged care
facilities in New South Wales. Sydney: NSW Department of Health, 2000.
for drug information services. Aust J Hosp Pharm 1999;29:171–6.

9
ContinuityofCarethroughMedicationLiaisonServices
Standard 9: Continuity of Care through
Medication Liaison Services
Standard
The pharmacist provides timely and tailored medication
liaison services to consumers transferring between health
care settings and providers to facilitate quality use of
medicines and continuity of care.
• The medication liaison pharmacist provides medication management services, including medication review and
medicines information, to targeted consumers who are transferring between health care settings and providers.
Examples of such transfers may include transfer between the home and hospital or residential care facility settings,
and transfer from a GP to a specialist.
• The pharmacist targets medication liaison services to consumers who are most at risk of medication misadventure.
These may include consumers who:
are on multiple medications
have chronic conditions
have had their medication regimen changed recently
have a history of hospitalisation from medication misadventure or misuse
are living alone and/or are housebound
are elderly
are preparing to enter hospital
recently commenced use of a dose administration aid
do not have the capacity or support needed to manage their medications
have a physical or intellectual disability.
• Medication liaison services are provided by all pharmacists, including community pharmacists, hospital pharmacists,
and consultant pharmacists. In some circumstances, there may be a dedicated medication liaison pharmacist as part
of a pharmacy team.
Managing Pharmacy Practice, Counselling, Medicines Review, Dose Administration Aids Service, Health Promotion,
and Disease State Management standards, where appropriate.
Criteria/Indicators
Self check:
Yes/No/NA
Resources
Criterion 1: The pharmacist understands the importance of medication liaison services in ensuring continuity of care
1. Understands the principles of continuity of care
and quality use of medicines
National Medicines Policy: Quality Use of
Medicines (QUM)
The National Strategy for Quality Use
of Medicines
Guiding Principles to Achieve Continuity in
Medication Management
2. Understands pharmacy practice in a range
of different health care settings such as the
community, hospitals, and residential
care facilities
3. Ensures effective communication of accurate,
complete and comprehensive information across
the health care system

9
Criteria/Indicators
Self check:
Yes/No/NA
Resources
4. Identifies the potential risk to the consumer of
medication misadventure when transferring
between health care settings and providers
Criterion 2: The pharmacist adopts a collaborative approach to providing medication liaison services to the consumer
1. Informs appropriate health care providers in the
community of the medication liaison service
and Ageing. Guiding Principles to Achieve
Continuity in Medication Management.
www.health.gov.au2. Establishes professional relationships with other
health care providers and communicates with
them to ensure continuity of care
3. Consults the consumer’s other health care
providers for the information needed to establish
the consumer’s medication liaison service,
where appropriate
4. Informs the consumer’s other health care
provider(s) of the extent of the medication liaison
service provided to the consumer
5. Actively participates in health care educational
activities in the community to promote quality
use of medicines
6. Provides health and medicines information to
individuals, other health care providers, and
support groups to promote quality use
of medicines in the community
7. Refers to a dedicated medication liaison
pharmacist, where appropriate
Criterion 3: The pharmacist systematically identifies consumers at risk of medication misadventure who could
benefit from medication liaison services
1. Uses a system to prioritise consumers in most
need of medication liaison services
2. Communicates with other health care providers
to assist in the identification of consumers in
need of medication liaison services
3. Has a system for receiving referrals for at-risk
consumers from local hospitals and other health
care providers in the community
Criterion 4: The pharmacist tailors medication liaison services to the needs of the consumer
1. Follows a systematic procedure for identifying
the consumer’s individual pharmaceutical needs
• Professional Practice Standard 3: Counselling,
p. 20
pharmacy. J Pharm Pract Res 2005;35:
122–46
2. Where necessary, formulates a medication action
plan (MAP) in collaboration with the consumer
3. Counsels the consumer on safe and effective
use of their medications
4. Facilitates access to other services from which
the consumer may benefit
5. Makes prior arrangements with the consumer
when making home visits
6. Assists the consumer with dose
administration aids

9
Criteria/Indicators
Self check:
Yes/No/NA
Resources
Criterion 5: The pharmacist keeps accurate records of the medication liaison services undertaken for each
consumer
1. Systematically documents the medication liaison
service provided to the consumer
2. Documents problems identified, actions taken,
date and details of contact with other health care
providers, and the outcomes of the actions for
each consumer
3. Stores consumer records safely and securely
Criterion 6: The pharmacist regularly evaluates the medication liaison service provided
1. Implements a system to evaluate the medication
liaison service at regular intervals
2. Seeks feedback from consumers and other
health care providers to evaluate the medication
liaison service
3. Implements appropriate changes to medication
liaison services according to feedback
Australian Pharmaceutical Advisory Council. Guiding principles for
medication management in the community. 2006. Available at:
www.health.gov.au/internet/main/publishing.nsf/Content/
apac-publications-guiding
Australian Pharmaceutical Advisory Council. Guiding principles to achieve
continuity in medication management. Canberra: Commonwealth of
Australia, 2005. Available at: www.health.gov.au/internet/main/publishing.
nsf/Content/nmp-guiding
Blennerhassett JD, Cusack BM, Smith CD et al. A novel medicines
management pathway. J Pharm Pract Res 2006;36:175–9.
for the community liaison pharmacist. Aust J Hosp Pharm 1996;26:
570–2.
Stowasser DA, Allinson YM, O’Leary KM. Understanding the medicines
management pathway. J Pharm Pract Res 2004;34:293–6.

10
Compounding(alsoknownasExtemporaneousDispensing)
Standard 10: Compounding (also known as
Standard
The pharmacist prepares and dispenses compounded
products in a manner that ensures product quality, safety,
and efficacy.
• This standard applies to the preparation and supply of a single unit of a non-sterile product intended for immediate
use by a specific consumer. It includes the preparation of products whose formulations may be drawn from recognised
pharmaceutical formularies, such as the Australian Pharmaceutical Formulary and Handbook and other sources.
• Batch manufacturing (also known as extemporaneous manufacturing) and additional requirements for the preparation
of sterile products by aseptic technique or sterilisation are not covered in this standard; please refer to the Guide for
Good Manufacturing Practice for Medicinal Products produced by the Pharmaceutical Inspection Convention and
Pharmaceutical Inspection Co-operation Scheme for guidance on these requirements. Refer to the Compounding
Sterile Preparations standard for additional requirements for sterile compounding.
• The preparation of cytotoxic products requires specialised equipment and should be undertaken only by trained staff at
premises that are adequately designed and equipped, and approved by relevant authorities. The storage, removal and
transportation of cytotoxic drug products and contaminated waste beyond the pharmacy are outside the scope of this
standard; please refer to the standards for the handling and transportation of cytotoxic drugs produced by the Society
of Hospital Pharmacists of Australia for this information.
• Consistent with usual professional practice and competence, quality standards should be applied to starting
ingredients and finished products. Medicines supplied under the Pharmaceutical Benefits Scheme are required to
conform to standards of composition or purity prescribed in the Therapeutic Goods Act 1989. In practice, this means
that ingredients (including water) and dosage forms must comply with the standards of the British Pharmacopoeia.
Requirements applicable under other Commonwealth, state or territory legislation, such as those concerning weights
and measures, may also apply.
• Pharmacists are advised to familiarise themselves with the relevant state or territory occupational health and safety
legislation for guidance on handling toxic products.
standards. Refer also to the Managing Pharmacy Practice, Indirect Pharmacy Services, Services to Residential Care
Facilities and Compounding Sterile Preparations standards, where appropriate.
Criteria/Indicators
Self check:
Yes/No/NA
Resources
Criterion 1: The pharmacist reviews the ingredients, preparation process, and the intended use of the product,
and conducts a risk assessment
1. Assesses the use, safety, efficacy, and risks
associated with the preparation of compounded
products according to professional judgement
• Material Safety Data Sheet database.
www.msds.com.au
2. Assesses the risks to staff and the consumer
from the preparation, and follows procedures to
manage such risks

10
Criteria/Indicators
Self check:
Yes/No/NA
Resources
3. Uses protective clothing (such as a laboratory
coat, disposable gloves, and a hair cover)
and takes additional precautions (such as
eye protection, a dust mask, and powder-
contamination systems) when compounding
high-risk substances
4. Maintains a register listing each hazardous
substance used and a material safety data sheet
(available from wholesalers) for each ingredient
Criterion 2: The pharmacist carries out all compounding, or directly supervises appropriately trained staff in doing so
1. Ensures all staff authorised to carry out
compounding under the pharmacist’s supervision
are trained and experienced in compounding
Extemporaneous dispensing form. In:
Handbook, 21st edn, p. 34
2. Checks all measurements, packaging, and
labelling of compounded products made by
supervised staff
3. Ensures that staff handling cytotoxic drug
products are trained and assessed in the
preparation and safe handling of cytotoxic drug
products and waste
4. Maintains the knowledge and skills necessary to
deliver the level of compounding required
Criterion 3: The pharmacist ensures compounding occurs in a dedicated area that is clean and appropriate to
the preparation processes to be undertaken
1. Prepares all compounded products in an area
dedicated for the purpose away from routine
dispensing activities, counselling, and
high-traffic areas
2. Prepares all compounded products using
equipment specifically dedicated for the purpose
3. Ensures all working surfaces are in good
condition, hygienic, and covered with impervious
washable materials
Criterion 4: The pharmacist ensures the equipment used in compounding is in good working order, in
accordance with the manufacturers’ instructions and other requirements
1. Uses equipment that is suitable for the task
to be performed
21st edn, pp. 31–3
Pharmacy Program. Equipment calibration
schedule and record (T5B).
2. Cleans all equipment and work surfaces before
and after product preparation
3. Ensures the equipment is maintained and
calibrated regularly, according to a
documented procedure
4. Maintains a record of equipment calibration or
maintenance
5. Ensures all equipment is stored in a manner that
protects it from damage and contamination
6. Clearly labels equipment that is to be used only
for the preparation of cytotoxic drug products
7. Stores equipment used for the preparation
of cytotoxic drug products separately from
other equipment

10
Criteria/Indicators
Self check:
Yes/No/NA
Resources
Criterion 5: The pharmacist uses pharmaceutical grade ingredients that are stored in accordance with the
manufacturers’ recommendations
1. Uses pharmaceutical grade ingredients,
when available, that are suitable for
administration to humans and comply with
pharmacopoeial standards
21st edn, pp. 31–3
Pharmacy Program. Temperature record (T5C).
2. Uses pharmacopoeial grade
ingredients that have been stored
under recommended conditions
3. Ensures any cytotoxic drug products and other
hazardous ingredients are clearly identified
as such and are stored according to the
manufacturers’ recommendations
4. Stores ingredients that require storage at
room temperature in a cool place away from
direct sunlight
5. Stores ingredients that require refrigeration or
freezing in a refrigerator or freezer dedicated to
pharmaceuticals
6. Regularly maintains and records details of
temperature-monitoring systems, such as
cool rooms, air conditioners, refrigerators,
and freezers, to ensure appropriate storage
temperatures
Criterion 6: The pharmacist prepares compounded products in accordance with pharmacopoeial formulations
when available, and in a manner that ensures product quality and efficacy
1. Follows pharmacopoeial or other reputable
formulations when compounding
• See Additional Information box, p. 52
2. Accurately measures all ingredients using
appropriate measuring equipment
3. Uses appropriate techniques when compounding
to ensure the quality of the final product
4. Establishes an expiry date for the product based
on recommendations in reliable literature
Criterion 7: The pharmacist documents the details of the compounding procedure
1. Uses an extemporaneous dispensing form to
record the approved pharmacopoeial name
(where applicable), the formula and its source
(including edition), the procedure, and the
strength/amount of any preservatives used
Extemporaneous dispensing form. In:
Handbook, 21st edn, p. 34
Simple compounding (P2C)
Compounding worksheet (T2B)
2. Uses the dispensing form to record the
source, batch number, and expiry date of
ingredients used
3. Uses the extemporaneous dispensing form to
record any considerations about the stability
of the product, methodologies, notes, and
calculations, with references where appropriate

10
Criteria/Indicators
Self check:
Yes/No/NA
Resources
4. Uses the duplicate label attached to the
extemporaneous dispensing form to record the:
• approved pharmacopoeial name (if not a
pharmacopoeial formulation, the name and
amount of all ingredients must be listed)
• strength/amount of any preservative used
• instructions for use
• date of preparation
• expiry date of the product
5. Records on the extemporaneous dispensing form
any ancillary labels or additional instructions used
6. Signs and dates the extemporaneous dispensing
form, noting any supervisory involvement prior to
dispensing the product
7. Stores the extemporaneous dispensing form
on the premises for 2 years from the date of
dispensing or according to state legislation
Criterion 8: The pharmacist uses Purified Water BP or Water for Irrigation when water is required as an
ingredient in non-sterile preparations
1. Indicates on the extemporaneous dispensing
form the type of water used, its date of
preparation or opening, and the manufacturer’s
batch number (where applicable)
Criterion 9: The pharmacist uses suitable containers and packaging to maintain the quality and stability of
prepared products
1. Uses light-resistant (amber glass or high-density
plastic) containers for the storage of light-
sensitive products
• Pharmaceutical Society of Australia. General
formulary. In: Australian Pharmaceutical
pp. 35–56
2. Uses air-tight packaging for protection from
exposure to air if necessary
3. Uses moisture-proof packaging for moisture-
sensitive products
4. Uses secure packaging such as child-resistant
packaging where appropriate
5. Dispenses liquid cytotoxic drug products (such
as ophthalmic preparations and products for
instillation into body cavities) in a suitable,
ready-to-use unit-dosage form (e.g. a Luer Lock
syringe) in a sealed container
6. Heat-seals the immediate container of a
cytotoxic drug product into suitable impervious
outer packaging
Criterion 10: The pharmacist follows a procedure for the disposal of waste (including contaminated waste and
sharps) that ensures the safety of staff and the environment
1. Separates and clearly labels cytotoxic and other
hazardous waste from general waste
2005;35: 44–52
2. Ensures waste products are collected for
disposal regularly
3. Ensures any sharps used in the
compounding process are disposed
of safely in specified containers

10
Criteria/Indicators
Self check:
Yes/No/NA
Resources
Criterion 11: The pharmacist labels all compounded products to provide adequate identification of all
ingredients and clear directions for administration and use
1. Labels the compounded products with the
following information:
• the approved pharmacopoeial name
(where applicable)
• the name and edition of the
pharmaceutical formulary
• all active ingredients and their amounts/
proportions if the preparation is not a
pharmacopoeial formulation
• the names and strength/amount of any
preservatives used
• expiry date
• complete and unambiguous directions for use
www.psa.org.au
General formulary. In: Australian
21st edn, pp. 35–56
pp. 2–20
• Society of Hospital Pharmacists of
Australia. SHPA standards of practice for
the transportation of cytotoxic drugs from
pharmacy departments. J Pharm Pract Res
2007;37:234–5
2. Labels products intended for external use
with clear instructions indicating they are for
external use only
3. Uses ancillary labels to indicate specific usage
instructions (e.g. ‘Shake well before each use’)
4. Applies the necessary cytotoxic warning labels
on the outer packaging of cytotoxic drug
products that are to be delivered
5. Places cytotoxic drug products into well-marked,
rigid containers for transportation
Criterion 12: The pharmacist provides the consumer with information about the compounded product, including
stability, storage, and expiry date
1. Provides the consumer with instructions on
how to use the compounded product and the
duration of treatment
www.psa.org.au
pp. 2–20
General formulary. In: Australian
21st edn, pp. 35–56
Counselling, p. 20
2. Communicates any specific storage
requirements that may be indicated on ancillary
labels (such as ‘Refrigerate – Do Not Freeze’ and
‘Protect from light’)
3. Highlights the expiry date of the compounded
product to the consumer and provides
information on appropriate disposal
4. Provides the consumer with information on the
correct handling and storage of cytotoxic or
other hazardous preparations
Criterion 13: The pharmacist uses a documented procedure for complaints and recalls of dispensed
compounded products
1. Documents all complaints and recalls • Pharmaceutical Society of Australia.
21st edn, pp. 31–3
2. Investigates all errors, defects, and complaints
about compounded products
3. Takes the necessary steps to remedy
the problems associated with the
compounded products
4. Uses a documented procedure for tracking and
retrieving any dispensed compounded products

10
Additional information
• When a non-pharmacopoeial formulation is prescribed, the pharmacist should first consider using a
pharmacopoeial formulation that most closely resembles the prescribed item, and liaise with the prescriber
where appropriate.
• If any minor change is made to the pharmacopoeial formulation, the pharmacist must ensure that it does not
affect the product’s therapeutic efficacy or stability. The exact formula used should be documented on the
prescription and on the extemporaneous dispensing form.
• In the absence of a pharmacopoeial formula that closely resembles the prescribed non-pharmacopoeial
formulation, the pharmacist should contact the prescriber to find out the indication the prescription is for and
the length of treatment required to establish whether there is a reasonable alternative treatment available. If
the product must be prepared, the pharmacist should confirm the source of the formula, the stability of the
product, the procedure to be used, and the appropriateness of the ingredients and their concentrations. In
these situations, formulations may also be sourced from some health care institutions and pharmaceutical
manufacturers that have products that are not registered but that have undergone stability tests. The source
of such formulations should always be noted on the worksheet. During this process, the pharmacist should
liaise with the prescriber as necessary. The pharmacist is responsible for ensuring that the prepared product is
physically and chemically stable.
British Medical Association; Royal Pharmaceutical Society of Great
Britain. British national formulary. London: British Medical Journal
Publishing Group and Pharmaceutical Press. Available at:
http://bnf.org/bnf
British Pharmacopoeia Commission. The British Pharmacopoeia 2010.
London: British Pharmacopoeia Commission, 2010. Available at:
www.pharmacopoeia.co.uk
European Pharmacopoeia Commission. European Pharmacopoeia.
6th edn. Strasbourg: European Directorate for the Quality of Medicines
and Healthcare, July 2007.
National Coordinating Committee on Therapeutic Goods. A discussion
paper on regulation of extemporaneously prepared medicines in
non-hospital pharmacies. April 2008. Available at: www.tga.gov.au/
meds/extempcomp2.pdf
Pharmaceutical Inspection Convention; Pharmaceutical Inspection
Co-operation Scheme. Guide to good manufacturing practice for
medicinal products. PE 009-9. Geneva: PIC/S, 2009. Available at:
www.picscheme.org/publication.php?id=4
Co-operation Scheme. PIC/S guide to good practices for the preparation
of medicinal products in healthcare establishments. PE 010-3. Geneva:
PIC/S, October 2008. Available at: www.picscheme.org/publication.
php?id=8
for the safe handling of cytotoxic drugs in pharmacy departments.
J Pharm Pract Res 2005;35:44–52.
for the transportation of cytotoxic drugs from pharmacy departments.
Sweetman SC, ed. Martindale: the complete drug reference. 36th edn.
London: Pharmaceutical Press, 2009.
US Pharmacopeia. The United States Pharmacopeia–national formulary.
USP 33-NF 28. Rockville, Maryland: United States Pharmacopeial
Convention, 2010. Available at: www.usp.org/USPNF
Workplace Safety Australia. Available at: www.worksafe.com.au
Worksafe Victoria. Handling cytotoxic drugs in the workplace. Melbourne:
Worksafe Victoria, 2003. Available at: www.worksafe.vic.gov.au/wps/
wcm/connect/wsinternet/WorkSafe/Home/Forms+and+Publications/
Publications/import_Handling+Cytotoxic+Drugs+In+The+Workplace
World Health Organization. The International Pharmacopoeia. 4th edn.
Geneva: WHO, 2008.

11
CompoundingSterilePreparations
Standard 11: Compounding sterile preparations
Standard
The pharmacist prepares and dispenses sterile products in
such a way that ensures the sterility of the end product, and
maximises product quality, safety, and efficacy.
• This standard applies to the preparation and supply of a single unit of a sterile product (by aseptic technique or end
sterilisation) that is intended for immediate use by a specific consumer. It covers the preparation of products whose
formulations may be drawn from recognised pharmaceutical formularies, such as the Australian Pharmaceutical
Formulary and Handbook and other sources.
• This standard outlines the additional requirements for pharmacists in preparing or supervising the preparation of sterile
products. Pharmacists preparing sterile products must also comply with the Compounding standard.
• The quality of compounded sterile products, including cytotoxic and biological agents, cannot be tested once
prepared, and therefore, quality assurance processes must be built into the sterile compounding procedure.
Compounding sterile products requires specialised equipment and facilities, and should only be undertaken by trained
and experienced pharmacists and staff under their supervision.
• Batch manufacturing (also known as extemporaneous manufacturing) is not covered in this standard; please refer
to the Guide for Good Manufacturing Practice for Medicinal Products produced by the Pharmaceutical Inspection
Convention and Pharmaceutical Inspection Co-operation Scheme for guidance on these requirements.
• This standard is to be applied in conjunction with the Fundamental Pharmacy Practice, Counselling, Dispensing, and
Compounding standards. Refer also to the Managing Pharmacy Practice and Services to Residential Care Facilities
standards, where appropriate.
• Pharmacists are also advised to familiarise themselves with the relevant state or territory occupational health and safety
legislation for guidance on handling toxic products.
Criteria/Indicators
Self check:
Yes/No/NA
Resources
Criterion 1: The pharmacist ensures that the sterile compounding environment complies with the relevant
Australian standards
1. Uses clean rooms and anterooms that meet
Australian standards for the preparation of all
sterile products
• Standards Association of Australia.
www.standards.org.au
Australian Standard AS 2567–2002.
Laminar flow cytotoxic drug safety cabinets
Australian/New Zealand Standard AS/
NZS ISO 14644.4:2002. Cleanrooms and
associated controlled environments Part 4:
Design, construction and start-up
2. Uses cabinets and storage facilities that meet
Australian Standards for storing all ingredients
required for the preparation of sterile products
3. Uses isolators, laminar flow cabinets, and
laminar flow work benches appropriate to the
risk levels associated with the preparation of
sterile products
4. Uses Water for Injection BP when water is
required as an ingredient in a sterile preparation

11
Criteria/Indicators
Self check:
Yes/No/NA
Resources
Criterion 2: The pharmacist uses equipment that is appropriate for the preparation of sterile products
1. Uses equipment specifically designed for and
dedicated to the preparation of sterile products
2. Clearly labels equipment used for the preparation
of sterile cytotoxic drug products
3. Stores equipment used for the preparation of
sterile cytotoxic drug products separately from
other equipment
4. Uses appropriately sterilised measuring
equipment to assist in sterile compounding
Criterion 3: The pharmacist and all staff working under the pharmacist’s supervision receive and maintain the
knowledge and skills required for sterile compounding
1. Maintains training and awareness of sterile
compounding techniques
• Standards Association of Australia. Australian
Standard AS 2639–1994. Laminar flow
cytotoxic drug safety cabinets – Installation
and use. www.standards.org.au2. Maintains knowledge of the different levels of risk
associated with sterile compounding
3. Maintains training and knowledge of the
principles and manipulation techniques used
when operating isolators, laminar flow cabinets,
and laminar flow work benches
4. Provides relevant ongoing training and
education to staff
5. Regularly validates the aseptic technique of
staff under the pharmacist’s supervision
Criterion 4: The pharmacist prepares sterile products in a manner that ensures the quality and sterility of the
final product
1. Cleans and disinfects all controlled areas
and equipment regularly, in accordance with
workplace procedures
2. Incorporates quality control measures into the
compounding process
3. Compounds products that are terminally
sterilised separate from those that are
prepared aseptically
4. Follows guidelines and instructions on the
correct use of laminar flow cabinets and laminar
flow work benches
5. Conducts a risk assessment to classify
the compounded preparation as low,
medium, or high risk, and prepares the
preparation appropriately
6. Ensures all ingredients are correct, stable,
compatible, within expiry date, and appropriately
stored prior to compounding
7. Inspects the containers of ingredients for defects
and product integrity, and reports any defect to
the manufacturer
8. Compounds sterile cytotoxic products in a
separate cabinet to non-cytotoxic products

11
Criteria/Indicators
Self check:
Yes/No/NA
Resources
9. Checks all preparations prepared by staff under
the pharmacist’s supervision
Criterion 5: The pharmacist takes particular care when labelling and packaging high-risk sterile cytotoxic drug
products to ensure safe administration
1. Applies a documented procedure for labelling
and packaging cytotoxic drug products for
intrathecal use
44–522. Labels all cytotoxic drug products prepared for
intrathecal use with the words ‘For Intrathecal
Use’ in large, bold print
3. Labels all vincristine products, including outer
wraps, with a prominent warning label stating
‘FOR INTRAVENOUS USE ONLY – Fatal if given
by other routes’
Criterion 6: The pharmacist follows documented procedures for monitoring the sterility of compounded products
and controlled areas
1. Regularly monitors and documents the
microbiological and particulate cleanliness
of the air and surfaces within the controlled
area using settle plates, and volumetric air
or surface sampling
2. Applies validated sterilisation processes that
have been verified and documented
3. Conducts sterility tests in accordance with
Criterion 7: The pharmacist and all staff working under the pharmacist’s supervision follow hygiene procedures
to reduce the risk of product contamination
1. Adheres to the workplace standard code of
hygiene and cleanliness
44–52
2. Wears protective clothing, including gowns,
a face mask, safety glasses, gloves, a hair
cover and shoe covers in accordance with
3. Follows procedures for the changing of clothes,
removal of jewellery and make-up, and scrubbing
of hands before entering the controlled area
4. Reports and records any personal health
conditions, or those of supervised staff, that may
increase the risk of product contamination to the
pharmacist in charge
Criterion 8: The pharmacist records details of sanitisation and temperature controls relating to sterile
compounding
1. Records the temperatures of air conditioned
rooms, refrigerators, and freezers within the
sterile compounding facility on a daily basis
2. Records sanitisation levels of the anteroom
and clean room
3. Records the ongoing sanitisation levels of
isolators, laminar flow cabinets, and laminar
flow workbenches

11
British Medical Association; Royal Pharmaceutical Society of Great
Britain. British national formulary. London: British Medical Journal
Publishing Group and Pharmaceutical Press. Available at:
http://bnf.org/bnf
British Pharmacopoeia Commission. The British Pharmacopoeia 2010.
London: British Pharmacopoeia Commission, 2010. Available at:
www.pharmacopoeia.co.uk
European Pharmacopoeia Commission. European Pharmacopoeia.
6th edn. Strasbourg: European Directorate for the Quality of Medicines
and Healthcare, July 2007.
National Coordinating Committee on Therapeutic Goods. A discussion
paper on regulation of extemporaneously prepared medicines in non-
hospital pharmacies. April 2008. Available at: www.tga.gov.au/meds/
extempcomp2.pdf
Co-operation Scheme. Guide to good manufacturing practice for
medicinal products. PE 009-9. Geneva: PIC/S, 2009. Available at:
Co-operation Scheme. PIC/S guide to good practices for the preparation
of medicinal products in healthcare establishments. PE 010-3. Geneva:
PIC/S, October 2008. Available at: www.picscheme.org/publication.
php?id=8
for the safe handling of cytotoxic drugs in pharmacy departments.
for the transportation of cytotoxic drugs from pharmacy departments.
Standards Australia. Available at: www.standards.org.au
Sweetman SC, ed. Martindale: the complete drug reference. 36th edn.
London: Pharmaceutical Press, 2009.
US Pharmacopeia. The United States Pharmacopeia–national formulary.
USP 33-NF 28. Rockville, Maryland: United States Pharmacopeial
Convention, 2010. Available at: www.usp.org/USPNF
Workplace Safety Australia. Available at: www.worksafe.com.au
Worksafe Victoria. Handling cytotoxic drugs in the workplace. Melbourne:
Worksafe Victoria, 2003. Available at: www.worksafe.vic.gov.au/wps/
wcm/connect/wsinternet/WorkSafe/Home/Forms+and+Publications/
Publications/import_Handling+Cytotoxic+Drugs+In+The+Workplace
World Health Organization. The International Pharmacopoeia. 4th edn.
Geneva: WHO, 2008.

12
ProvisionofNon-prescriptionMedicinesandTherapeuticDevices
Standard 12: Provision of Non-prescription
Medicines and Therapeutic Devices
Standard
The pharmacist is responsible for the safe and judicious
provision of non-prescription medicines and therapeutic
devices appropriate to the needs of the consumer.
• This standard applies to the provision of non-prescription medicines and therapeutic devices by the pharmacist,
or by other pharmacy staff under the pharmacist’s supervision.
• To achieve this standard, the pharmacist must ensure that pharmacy staff are adequately resourced and supported
to enable them to provide consumers with non-prescription medicines and therapeutic devices.
• The pharmacist and their pharmacy staff should also refer to the Standards for the Provision of Pharmacy
Medicines and Pharmacist Only Medicines in Community Pharmacy. These standards contain protocols and
procedures to ensure the pharmacy as a whole supports the safe and effective provision of Pharmacy and
Pharmacist Only Medicines.
Refer also to the Managing Pharmacy Practice and Health Promotion standards, where appropriate.
Criteria/Indicators
Self check:
Yes/No/NA
Resources
Criterion 1: The pharmacist is directly involved in the provision of Pharmacist Only Medicines (S3)
1. Follows a systematic procedure when a
Pharmacist Only Medicine is requested and
supports other pharmacy staff in following
the procedure
www.psa.org.au
Standard 4 and 5. In: Standard for
the Provision of Pharmacy Medicines
and Pharmacist Only Medicines in
Community Pharmacy
CARER protocol for providing Pharmacy
Medicines and Pharmacist Only Medicines.
In: Standards for the Provision of Pharmacy
Medicines and Pharmacist Only Medicines
in Community Pharmacy, p. 56
WHAT-STOP-GO protocol for providing
Pharmacy Medicines and Pharmacist Only
Medicines. In: Standards for the Provision
of Pharmacy Medicines and Pharmacist
Only Medicines in Community Pharmacy,
p. 57
Pharmacy Program. Clinical interventions and
adverse drug reactions policy (P2H).
2. Assesses the consumer’s therapeutic need
for, and the risks involved with, the use of a
requested Pharmacist Only Medicine, before
deciding whether or not to supply the medicine
3. Monitors for potential inappropriate use of
Pharmacist Only Medicines by the consumer and
responds appropriately
4. Records the supply of Pharmacist Only Medicines
in accordance with relevant state or territory
legislation and professional responsibilities
5. Provides advice and information on the use of
Pharmacist Only Medicines that is relevant to
the consumer’s needs and in accordance with
principles in the quality use of medicines
6. Stores Pharmacist Only Medicines in an area
of the pharmacy, under supervision of the
pharmacist, and out of reach of consumers in
accordance with state or territory legislation

12
Criteria/Indicators
Self check:
Yes/No/NA
Resources
Criterion 2: The pharmacist provides assistance in the provision of non-prescription medicines and therapeutic
devices, when required
1. Provides primary health care to consumers • Pharmaceutical Society of Australia. Standard
2. In: Standard for the Provision of Pharmacy
Medicines and Pharmacist Only Medicines in
Community Pharmacy. www.psa.org.au
Medical and other health professionals
advice referral policy (P2I)
Training and QCPP
Refresher Training Guidelines
2. Actively engages with consumers upon
request for a non-prescription medicine or
therapeutic device
3. Assists pharmacy staff in the provision of
non-prescription medicines and therapeutic
devices when requested
4. Directs and educates pharmacy staff involved
in the provision of non-prescription medicines
and therapeutic devices to refer to a pharmacist
when necessary
Criterion 3: The pharmacist ensures that appropriate information is gathered when responding to consumer
requests for non-prescription medicines and therapeutic devices
1. Is aware of, and follows, a systematic
procedure for obtaining all relevant information
from the consumer
www.psa.org.au
Standard 4. In: Standard for the Provision
Only Medicines in Community Pharmacy
CARER protocol for providing Pharmacy
Medicines and Pharmacist Only Medicines.
In: Standards for the Provision of Pharmacy
Medicines and Pharmacist Only Medicines
in Community Pharmacy, p. 56
WHAT-STOP-GO protocol for providing
Pharmacy Medicines and Pharmacist Only
Medicines. In: Standards for the Provision
Only Medicines in Community Pharmacy,
p. 57
2. Supports and educates pharmacy staff in
following the procedure for gathering the relevant
information from the consumer
Criterion 4: The pharmacist provides consumers with appropriate care and advice tailored to their needs,
when required
1. Makes an assessment of the risks and benefits
to the consumer before supplying a non-
prescription medicine or therapeutic device
www.psa.org.au
Standard 4. In: Standard for the Provision
Only Medicines in Community Pharmacy
OTC counselling guides. In: Australian
21st edn, pp. 373–414
Counselling, p. 20
2. Provides advice on the treatment of symptoms
and the appropriate selection and use of non-
prescription medicines and therapeutic devices
3. Demonstrates the correct and effective use of
therapeutic devices to consumers as needed
4. Provides information and advice on alternative
options for consumers if the provision of
medicines or therapeutic devices is inappropriate
or unnecessary
5. Refers consumers to other health care providers
when necessary
Criterion 5: The pharmacist displays and stores non-prescription medicines and therapeutic devices safely
and appropriately
1. Displays non-prescription medicines and
therapeutic devices in a professionally
responsible manner
• Pharmaceutical Society of Australia. Standard
3. In: Standard for the Provision of Pharmacy
Medicines and Pharmacist Only Medicines in
Community Pharmacy. www.psa.org.au

12
Criteria/Indicators
Self check:
Yes/No/NA
Resources
2. Stores non-prescription medicines and
therapeutic devices in accordance with
scheduling classifications and the relevant state
or territory legislation
3. Identifies non-prescription medicines and
therapeutic devices subject to misuse or abuse,
and stores them in an area of the pharmacy
under the direct supervision of a pharmacist
Criterion 6: The pharmacist has timely access to sources of evidence-based information relating to non-
prescription medicines and therapeutic devices
1. Provides evidence-based information to
consumers as appropriate
www.psa.org.au
Evidence-based medicine: the basics.
In: Australian Pharmaceutical Formulary
and Handbook, 21st edn, pp. 424–8
Information from the world wide web.
NPS RADAR
Patient leaflets and action plans
Common inhaler devices chart
• HealthInsite. Medicines.
www.healthinsite.gov.au
• National Asthma Council. Inhaler technique in
adults with asthma or COPD.
www.nationalasthma.org.au
• Monash Institute of Health Services Research.
Evidence-Based Answers to Clinical Questions
for Busy Clinicians. www.mihsr.monash.org
2. Assists pharmacy staff in accessing relevant
information as required
Pharmaceutical Society of Australia. Standards for the provision of
pharmacy medicines and pharmacist only medicines in community
pharmacy. Revised. Canberra: PSA, 2005.
Pharmacy Board of Australia. Guidelines on practice specific issues.
Reeve J, Polack M. Counselling guide for non-prescription medicines:
including pharmacist only medicines, pharmacy medicines, unscheduled
medicines, complementary medicines, vitamins: a companion guide
for the counselling shelf talkers. Canberra: Pharmaceutical Society of
Australia, 2005.

13
HealthPromotion
Standard 13: Health Promotion
Standard
The pharmacist actively engages the individual consumer
and the community to promote health and wellbeing.
• This standard encompasses any action of the pharmacist in the practice of health promotion to individual consumers
and the community. This includes opportunistic engagement with consumers while providing everyday pharmacy
services. It may also include the systematic identification of consumer and community needs; for example, through
interaction with other health care providers or community groups, or through utilisation of established health
promotion programs.
• The pharmacist plays an important role in supporting pharmacy staff to deliver health promotion activities by providing
them with information and appropriate resources.
• This standard is to be applied in conjunction with the Fundamental Pharmacy Practice standard. Refer also
to the Managing Pharmacy Practice, Counselling, Screening and Risk Assessment, Disease State Management,
and Harm Minimisation standards, where appropriate.
Criteria/Indicators
Self check:
Yes/No/NA
Resources
Criterion 1: The pharmacist provides information and resources to enable consumers to take the necessary
steps to achieve better health outcomes
1. Provides health information that is relevant
to the consumer
www.psa.org.au
Self care fact cards.
Health promotion articles in Australian
Pharmacist
2. Maintains access to and knowledge of
evidence-based health promotion resources
3. Highlights to consumers that health promotion
information is available
4. Is available to act as an information resource for
individuals and community groups
5. Is aware of health organisations and resources
(local, national and international) that can
provide additional support to consumers or
community groups
6. Reviews information resources to ensure
currency and credibility
Criterion 2: The pharmacist adopts a collaborative approach to health promotion
1. Establishes partnerships with other health care
providers, consumers, or community groups to
promote health
www.guild.org.au
2. Facilitates the provision of health promotion
information to and from community groups and
other organisations

13
HealthPromotion
Criteria/Indicators
Self check:
Yes/No/NA
Resources
3. Educates and supports pharmacy staff in the
provision of health promotion activities
Criterion 3: The pharmacist systematically evaluates and refines the health promotion activities undertaken
1. Selects appropriate measures for evaluation that
reflect the structure, process, and outcomes of
the health promotion activity undertaken
• ACT Health Promotion. Evaluation basics.
www.healthpromotion.act.gov.au
Health Promotion.
www.health.vic.gov.au/healthpromotion
• Appendix 2: Quality Use of Medicines and
Practice Improvement, p. 84
• Appendix 3: The Health Promotion Planning
Cycle, p. 86
2. Follows a process for obtaining feedback about
the health promotion activities provided
3. Implements appropriate changes to
health promotion activities according to
evaluation feedback
Anderson C, Blenkinsopp A, Armstrong M. The contribution of
community pharmacy to improving the public’s health. Report
7: Summary report of the literature review 1990–2007. London:
PharmacyHealthLink, 2009.
Blenkinsopp A, Anderson C, Armstrong M. The contribution of
community pharmacy to improving the public’s health. Report 2:
Evidence from the non peer-reviewed literature 1990–2002. London:
PharmacyHealthLink and the Royal Pharmaceutical Society of Great
Britain, 2003.
Blenkinsopp A, Panton R, Anderson C. Health promotion for
pharmacists. 2nd edn. Oxford: Oxford University Press, 2000.
Catford J. Health promotion’s record card: how principled are we
20 years on? Health Promot Int 2004;19(1):1–4.
Centre for Evidence-Based Medicine. Available at: http://www.cebm.net
Egger G, Spark R, Donovan R. health promotion strategies and methods.
2nd edn. Sydney: McGraw-Hill, 2004.
Kotecki J, Elanjian S, Torabi M. Health promotion beliefs and practices
among pharmacists. J Am Pharm Assoc 2000;40:773–9.
Ludwig Boltzman-Institute for the Sociology of Health and Medicine.
Health promotion in general practice and community pharmacy –
conclusions and proposals from a European project. Vienna: Ludwig
Boltzman-Institute for the Sociology of Health and Medicine, 2001.
Available at: http://www.univie.ac.at/phc/e/tx_1040_87.htm
Maguire T. Helping community pharmacists in their emerging public
health roles. Pharmaceutical Journal 2002;269(7227):808.
Nutbeam D, Harris E, Wise M. Theory in a nutshell: a practical guide to
health promotion theories. 3rd edn. Sydney: McGraw-Hill, 2010.
Pharmaceutical Services Negotiating Committee, National
Pharmaceutical Association; Royal Pharmaceutical Society of Great
Britain; PharmacyHealthLink. Public Health: a practical guide for
community pharmacists. London: Royal Pharmaceutical Society of Great
Britain, 2003.
World Health Organization. Jakarta declaration on health promotion into
the 21st century. Geneva: WHO, 1997.
World Health Organization. Ottawa charter for health promotion. WHO/
HPR/HEP/95.1. Geneva: WHO, 1986.

14
MedicinesInformationCentres
Standard 14: Medicines Information Centres
Standard
The pharmacist working in a medicines information centre
provides accurate, relevant, and timely information on
medicines and pharmacotherapy most commonly to assist
centre users in optimising health outcomes.
• This standard applies to the provision of medicines information by a medicines information pharmacist in a medicines
information centre. It excludes the provision of counselling associated with the supply of a medicine or therapeutic
device, and excludes the financial and administrative issues of operating a medicines information centre.
Managing Pharmacy Practice standard where appropriate.
Criteria/Indicators
Self check:
Yes/No/NA
Resources
Criterion 1: The pharmacist maintains the current knowledge and skills needed to provide a reliable medicines
information service
1. Maintains a current knowledge of
applied therapeutics and how to critically
analyse information
• Evidence-based medicine: the basics.
• Centre for Evidence-Based Medicine.
EBM tools. www.cebm.net
2. Maintains a current knowledge of relevant
databases, publications, reference materials,
guidelines, regulations, and information
retrieval systems
3. Develops and maintains literature research
and evaluation skills
4. Develops and maintains good communication
skills to establish the needs of centre users and
deliver appropriate information
Criterion 2: The pharmacist has access to relevant and current medicines information resources to support
service delivery
1. Maintains access to databases and information
retrieval systems, including web-based resources
• National Library of Medicine. PubMed.
www.ncbi.nlm.nih.gov/pubmed
• Medical Matrix. www.medmatrix.org
NPS RADAR
Medicines Line. Tel: 1300 888 763
• Information from the world wide web. In:
2. Maintains access to current publications and
reference materials, including journals,
reference books, and other materials relevant
to medicines information
3. Maintains access to and knowledge of current
Australian guidelines and regulations, and is able
to distinguish these from international guidelines
and regulations

14
Criteria/Indicators
Self check:
Yes/No/NA
Resources
4. Maintains access to specialists with expertise
in various medical specialties who can provide
authoritative advice, when necessary
• Cochrane Collaboration. The Cochrane Library.
www.cochrane.org
• Auspharmacist. AusPharm Research
Roundup. www.auspharmacist.net.au
• National Health and Medical Research Council.
National Institute of Clinical Studies. Clinical
Practice Guidelines Portal.
www.clinicalguidelines.gov.au
• National Electronic Library for Medicines.
www.nelm.nhs.uk/en/
• National Prescribing Centre. www.npc.co.uk
5. Maintains a list of other relevant information
providers to whom enquiries may be referred,
when necessary
Criterion 3: The pharmacist defines the scope, nature, and availability of the medicines information service
1. Maintains a policy document that specifies who
may use the service
SHPA standards of practice for drug
information services. Aust J Hosp Pharm
1999;29:171–6.2. Communicates details about the service,
including who operates the service, the days and
hours of operation, how to access the service,
response times, and costs involved in accessing
the service as required
3. Provides a means for centre users to either
leave a message or be referred for immediate
service elsewhere if the medicines information
service is unavailable
Criterion 4: The pharmacist establishes the nature of the centre user’s enquiry
1. Uses good communication and interview skills
to gather all necessary information pertinent
to the enquiry, including what the centre user
already knows and understands, and the
context of the enquiry
2. Establishes the urgency of the enquiry
3. Works with the centre user to establish the most
practical format for providing the information
Criterion 5: The pharmacist prioritises medicines information enquiries
1. Prioritises enquiries based on the urgency of the
request and their impact on consumer safety
2. Refers the centre user to other appropriate
sources of information should the enquiry be
outside the pharmacist’s scope of practice
Criterion 6: The pharmacist provides appropriate medicines information and advice
1. Provides medicines information tailored to the
needs of the centre user
for Pharmacists on Providing Medicines
Information to Patients. www.psa.org.au
• UK Medicines Information. Guidelines for
ensuring quality in enquiry answering.
www.ukmi.nhs.uk
2. Communicates the information in a clear and
concise manner
3. Provides the information in a format established
in consultation with the centre user, and in a
timely manner
Criterion 7: The pharmacist documents the details of enquiries and consultations
1. Maintains a system for recording enquiries

14
Criteria/Indicators
Self check:
Yes/No/NA
Resources
2. Documents the date, time, details of the enquiry,
details of the centre user, the pharmacist’s name,
the response given, and, where possible, the
outcome of the enquiry
3. Documents the resources and references used
in formulating the response and includes the
date of access when databases and web-based
resources are accessed
4. Stores medicines information service records
in a manner that allows timely retrieval of
individual enquiries
Criterion 8: The pharmacist systematically reviews the quality of the medicines information service
1. Evaluates the service at regular intervals • UK Medicines Information. www.ukmi.nhs.uk
User satisfaction questionnaire
User survey guidance
2. Uses records of the services provided to assess
workloads and quality assurance activities
3. Seeks feedback from centre users to confirm
that the service has been provided in a timely
and satisfactory manner
4. Takes appropriate action after each evaluation
Foran S, ed. Australian drug information procedure manual. Melbourne:
Society of Hospital Pharmacists of Australia, 1996.
for drug information services. Aust J Hosp Pharm 1999;29:171–6.
Spencer Tindale R. Drug information: a source book for health
professionals, including a section on medical writing. 2nd edn. Sydney:
Drugsearch, Medifacts Pty Ltd, 2007.

15
PharmacyServicestoAboriginalandTorresStraitIslanderHealthServices
Standard 15: Pharmacy Services to Aboriginal
and Torres Strait Islander Health Services
Standard
The pharmacist provides pharmacy services to Aboriginal
and Torres Strait Islander health services in a timely
and culturally sensitive manner, with the primary aim of
promoting the quality use of medicines.
• In this standard, Aboriginal and Torres Strait Islander health services are referred to as Aboriginal Health
Services (AHS).
• This standard outlines the general principles applicable to the range of pharmacy services that may be provided
to remote and urban AHS, and is to be read in conjunction with the PSA’s The Provision of Pharmacy Services
to Aboriginal and Islander Health Services guidelines.
to the Managing Pharmacy Practice, Counselling, Medicines Review, Dispensing, Indirect Pharmacy Services,
Dose Administration Aids Service, Continuity of Care through Medication Liaison Services, Compounding,
Compounding Sterile Preparations, Health Promotion, Screening and Risk Assessment, and Disease State
Management standards, where appropriate.
Criteria/Indicators
Self check:
Yes/No/NA
Resources
Criterion 1: The pharmacist is aware of the relevant health and cultural issues facing Aboriginal and Torres
Strait Islander communities
1. Maintains an awareness of local and regional
issues that may affect the delivery of a pharmacy
service to the AHS
• Pharmaceutical Society of Australia. QUMAX:
An Introduction to Cultural Orientation for
Participating Pharmacists. www.psa.org.au
• Pharmacy Guild of Australia. Pharmacy
Information Kit: Section 100 Pharmacy
Support Allowance Program.
www.guild.org.au
2. Undertakes appropriate professional
development and cultural awareness training
3. Utilises available programs to assist in providing
a high quality, cost-effective service to the AHS
Criterion 2: The pharmacist has systems in place to receive requests and to enable the timely delivery of
medicines and therapeutic devices to the AHS
1. Establishes and maintains a system for the timely
ordering of a standard medicines list
Pharmacy Information Kit: Section 100
Pharmacy Support Allowance Program
Section 100 work plan [template form]
2. Maintains a system for the professional
supervision of orders for medicines outside the
standard medicines list
3. Maintains a regular schedule for delivering
therapeutic goods, as agreed with the AHS
4. Uses a system for the transportation of medicines
to the AHS that meets manufacturers’ storage
requirements, including cold chain requirements

15
Criteria/Indicators
Self check:
Yes/No/NA
Resources
5. Establishes and uses a system for the
provision of medicines when immediate or
urgent supply is required
Criterion 3: The pharmacist maintains a documented system for the delivery of all pharmacy services to the AHS
1. Establishes policies and procedures appropriate
for the provision of pharmacy services to
the AHS
• Pharmaceutical Society of Australia. The
Provision of Pharmacy Services to Aboriginal
and Islander Health Services [guidelines and
Sample work plan. In: Pharmacy
Support Allowance Program
Medication Review, p. 24
Dose Administration Aids Service, p. 36
Disease State Management, p. 72
2. Informs the AHS of the types of pharmacy
services that the pharmacist can provide and
how the AHS can access these services
3. Documents the details of the services
provided to AHS
4. Maintains a system for providing Dose
Administration Aids Services to the AHS
5. Maintains a system, in collaboration with the
AHS, for providing medication review services
6. Maintains systems for monitoring and notification
related to patterns of medicine use in the AHS
7. Facilitates a system to identify potential
medicines safety issues
8. Maintains a system for delivering disease state
management services
9. Negotiates with the AHS a feasible and
cost-effective structure for delivering
pharmacy services
Criterion 4: The pharmacist provides advice and information to the AHS on the safe and effective storage and
supply of all medicines
1. Provides information to AHS staff on the
appropriate and safe storage and disposal
of medicines
2. Provides AHS staff with information on stock
control procedures, stock rotation, and the
management of expired or recalled stock
3. Assists AHS staff in complying with the legislative
requirements of storing and supplying medicines
4. Monitors AHS staff to ensure that storage,
stock control, and supply procedures are being
followed in the AHS
Criterion 5: The pharmacist provides education, training, and supervision to AHS staff on quality use of
medicines (QUM)
1. Maintains a system, in collaboration with the
AHS, for identifying the training needs of AHS
staff and delivering appropriate training
for Pharmacists on Providing Medicines
Information to Patients. www.psa.org.au
• Australian Indigenous HealthInfoNet.
www.healthinfonet.ecu.edu.au
2. Provides current information on medicines and
therapeutic devices to AHS staff in a manner
that enables them to select, monitor, and adjust
drug therapies, taking into account their clients’
characteristics and co-morbidities
3. Collaborates with indigenous AHS staff and/or
community members to deliver current medicines
information in a manner that enables staff to easily
forward the information on to their clients

15
Criteria/Indicators
Self check:
Yes/No/NA
Resources
Criterion 6: The pharmacist maintains the communication channels needed to support continuity of care
1. Establishes networks, or utilises existing
networks, of health care providers and
community members in the local and regional
area, where possible
2. Communicates in a manner that is
culturally sensitive
Criterion 7: The pharmacist maintains a system to monitor and evaluate the pharmacy services provided to
ensure continuous quality improvement
1. Identifies the most immediate needs
of the AHS and its clients, and prioritises
services accordingly
Section 100 needs assessment
[template form]
Sample work plan. In: Pharmacy
Support Allowance Program
Section 100 evaluation feedback
[template form]
2. Provides proactive reporting and feedback to
the AHS on its management of medicines and
pharmacy services
3. Maintains a system by which the AHS can
provide feedback about the pharmacy services
being provided
4. Regularly evaluates the supply of medicines and
pharmacy services provided through internal
review and feedback from the AHS
5. Implements the actions required to improve the
current service provision systems, based on the
feedback provided
6. Adjusts the existing contract, in collaboration
with the AHS, in accordance with any additional
service needs that have been identified
Board of Studies NSW. Working with Aboriginal communities: a guide to
community consultation and protocols. Revised edn. Sydney: Board of
Studies NSW, 2008. Available at: http://ab-ed.boardofstudies.nsw.edu.
au/go/partnerships
Chaseling M, Mentha R, Davey C. CARPA standard treatment manual 4th
edition evaluation report. Alice Springs: Centre for Remote Health, 2008.
Available at: http://crh.flinders.edu.au/research/CARPA_4th_Ed.pdf
Couzos S, Murray R. Aboriginal primary health care: an evidence-based
approach. 3rd edn. Melbourne: Oxford University Press, 2007.
Farthing A, Jensen H, Urban M. Allied health: A good life for old and
disabled people living in remote communities. Alice Springs: Centre for
Remote Health, 2004.
McRae M, Taylor SJ. Medicines education for Aboriginal health workers:
is there a role for the pharmacist? Aust Pharm 2008;27:502–507.
National Aboriginal Community Controlled Health Organisation. Medicine
management: guidelines for preparing for the Section 100 Scheme in
Aboriginal primary health care services. Available at: www.naccho.org.au/
Files/Documents/s100_guidelines.pdf
Office of Aboriginal Health, Western Australian Department of Health.
A best practice model for health promotion programs in Aboriginal
communities: based on the formative evaluation of the Kuwinyuwardu
Aboriginal Resource Unit Gascoyne Healthy Lifestyle Program written
by Royden James Howie. Fact sheet. Perth: Office of Aboriginal Health.
Available at: www.diabetes.health.wa.gov.au/services/aboriginal.cfm
Pharmacy Guild of Australia. Pharmacy information kit: section 100
pharmacy support allowance program. Canberra: Commonwealth of
Australia, 2008.
Vaughan F, Woodard S, Misan G, Thompson C. Medicines book for
Aboriginal health workers. Alice Springs: Central Australian Division of
Primary Health Care, 2005.

16
Standard 16: Screening and Risk Assessment
Standard
The pharmacist uses evidence-based screening tests to
systematically identify members of a defined population
who may be at risk of disease and complications, and
provides referral as appropriate.
• This standard applies to those pharmacists who wish to exercise their role in disease prevention by providing screening
and risk assessment services. These services can be integrated with those of other health care providers, particularly
with medical practitioners, and practice or community nurses.
• Screening and risk assessment services should be used to identify consumers who may be at risk of disease and to
refer them for further investigations. This timely intervention can increase consumer awareness on health issues, aid in
identifying undiagnosed symptoms, and potentially reduce secondary complications of already diagnosed diseases.
• Common examples of screening services conducted within pharmacies include:
blood pressure testing
diabetes risk assessment (blood glucose, cholesterol, etc)
respiratory disease risk assessment
cardiovascular disease risk assessment (body mass index [BMI], waist circumference, weight,
blood pressure, cholesterol, etc)
chlamydia screening clinics
cancer risk assessment (bowel cancer screening)
• It is important to note that screening and risk assessment services should NOT be used for any of the following:
to make a diagnosis
as the basis for pharmacists initiating medical or drug treatment
for altering therapy prescribed by the other health care providers.
to the Managing Pharmacy Practice, Counselling, Health Promotion, and Disease State Management standards,
where appropriate.
Criteria/Indicators
Self check:
Yes/No/NA
Resources
Criterion 1: The pharmacist undertakes all necessary training needed to deliver a screening and risk
assessment service
1. Regularly undertakes training on the roles,
responsibilities, and general procedures for the
range of services delivered in the pharmacy
Training record (T15B)2. Documents all training undertaken and
date of completion
3. Is trained to perform any clinical tests required as
part of the screening service

16
Criteria/Indicators
Self check:
Yes/No/NA
Resources
Criterion 2: The pharmacist ensures all pharmacy staff authorised to conduct screening services are trained
and competent
1. Ensures pharmacy staff recognise the role
screening services provide in illness prevention,
managing long-term conditions, and health
promotion, and are able to distinguish this
service from diagnosis
2. Ensures only suitably trained staff conduct
screening tests and discuss test results with
the consumer
Criterion 3: The pharmacist provides the screening and risk assessment service in an environment that is
appropriate
1. Delivers the service in a location agreed to by the
consumer that protects their privacy
2. Ensures specimen collection and the test itself
are not conducted within the dispensing area, or
in any area where food or drinks are consumed
Criterion 4: The pharmacist undertakes appropriate measures to ensure the reliability of the results
1. Uses screening tests that have been
demonstrated to be appropriate and effective
for the particular assessment
2. Performs all services and assessments in a
manner consistent with the current relevant
Australian professional and clinical guidelines
and standards
3. Applies a quality assessment process, including
testing of blind samples, to establish that results
produced are reliable and replicable
4. Uses equipment that meets relevant Australian
standards and is serviced regularly according to
the manufacturers’ recommendations
5. Uses equipment that is calibrated according to
6. Maintains adequate documentation of all
calibration and maintenance activities, which
includes the date, the activity undertaken, and
the name and signature of the person involved
7. Uses an internal quality control procedure,
where appropriate, for the screening service
equipment by using a control sample from the
manufacturers at the start and end of a session
8. Maintains records of all screening services
provided, including the batch numbers of all
ancillary testing products, and signs off each test
performed
Criterion 5: The pharmacist uses a systematic operating procedure for conducting screening services
1. Follows a procedure to identify consumers who
would benefit from screening
• Appendix 10: Screening Record and Referral
Form, p. 93
2. Provides the consumer with information to
ensure they understand the nature and purpose
of the test, and any significant risk involved in
having or not having the test

16
Criteria/Indicators
Self check:
Yes/No/NA
Resources
3. Obtains informed consent from the consumer, or
carer, before undertaking any screening tests
4. Uses an established procedure to document
all aspects of the service, including management
of consumer information, privacy of files,
and consent
5. Undertakes and documents the consumer
interview to ascertain the consumer’s risk factors
for chronic disease and to identify unhealthy life
style choices as soon as possible
6. Ensures that all measurements and data
are in accordance with the systematic
operating procedure
7. Ensures that results are recorded in accordance
with documented procedures
8. Ensures collected samples are labelled clearly
9. Communicates details of the service provided,
including any limitations, and the fee payable by
the consumer
Criterion 6: The pharmacist follows a systematic operating procedure for providing results, counselling,
and referrals
1. Ensures that the explanation of results, and their
significance and limitations, is based on current
knowledge and provided in a timely manner
• Pharmaceutical Society of Australia. Self care
fact cards. www.psa.org.au
• National Prescribing Service. Patient leaflets
and action plans. www.nps.org.au
Counselling, p. 20
2. Interprets test results while considering any
medications the consumer might be taking,
which could influence the results
3. Provides test results to the consumer, or an
authorised agent, in a sensitive manner
4. Explains the relevance of the results in the
context of the consumer’s current conditions
and/or risk factors, where applicable
5. Discusses the results in the context of the
consumer’s overall health and lifestyle
6. Has easy and immediate access to current
information resources, and provides consumers
with relevant reading materials
7. Documents the key features of the explanation
and recommended follow-up actions, including
referrals, on the service record form
8. Provides the consumer with a report outlining
the results and recommendations arising from
the screening test
9. Establishes a network of health care
professionals and primary care organisations to
refer consumers to when needed
10. Determines, in consultation with other health
care providers, the referral criteria and best
method for referral
11. Discusses the referral process and the relevance
of the referral with the consumer

16
Criteria/Indicators
Self check:
Yes/No/NA
Resources
Criterion 7: The pharmacist ensures the result and referral forms, and follow-up letters (where required) are
completed in a manner that facilitates further consumer contact should the need arise
1. Documents recommendations, follow-up, and
outcomes for consumers who are referred to
other health care providers, where possible
• Appendix 10: Screening Record and Referral
Form, p. 93
2. Provides the pharmacist’s name and signature
as well as the contact details for the pharmacy
providing the clinical testing on all results, referral
forms, and follow-up letters
Criterion 8: The pharmacist implements an appropriate risk management strategy for the screening
services provided
1. Follows a documented procedure to manage
spillages and contamination
• Pharmaceutical Society of Australia Clinical
resource centre. www.psa.org.au
2. Uses appropriate containers for storage
and disposal of contaminated clinical waste
and sharps
3. Segregates clinical waste prior to its disposal in
an approved manner and time interval
4. Diligently follows a documented infection
control procedure
5. Ensures pharmacy staff adhere to the infection
control requirements
6. Ensures that all necessary protective clothing,
equipment, and containers for storage and
sharps are available and used
7. Documents spillages, contamination, needle-
stick injuries, and other incidents
8. Regularly assesses the suitability of the
designated area, equipment, and facilities
allocated to the provision of screening services
Chen LH, Emmerton L. Pharmacists’ experiences in the provision of
screening and monitoring services. Aust Pharm 2007;26:250–7.
Jackson S, Peterson G. Health screening in community pharmacy.
Aust Pharm 2004;23:760–4.
Jackson S, Peterson G. Health screening in community pharmacy:
an update. Aust Pharm 2006;25:846–51.
Royal Pharmaceutical Society of Great Britain. Long-term conditions:
integrating community pharmacy. Executive summary. London: RPSGB,
2006. Available at: www.rpsgb.org/pdfs/ltcondintegcommphsumm.pdf
Taylor SJ, Crockett JA, McLeod LJ. An integrated service initiated by
community pharmacists, for the prevention of osteoporosis. Final report.
November 2004. Available at: www.guild.org.au/uploadedfiles/Research_
and_Development_Grants_Program/Projects/2002-026_fr.pdf

17
DiseaseStateManagement
Standard 17: Disease State Management
Standard
The pharmacist works with the consumer and other
health care providers to systematically manage the
consumer’s disease state, optimise the consumer’s health
and wellbeing, raise awareness of risk factors for chronic
disease states, and motivate and engage the consumer to
accept responsibility for their own health.
• This standard serves as an overarching standard covering the principles of all disease state management (DSM)
programs. These services may include smoking cessation, diabetes, asthma, weight management, and
cardiovascular disease.
• DSM is a consumer-centred process that focuses on enabling consumers suffering from chronic conditions to
participate in the management of their disease with the objective of reducing their disease-related risk factors.
This can be achieved through monitoring, counselling, education, enhancement of self-management, and promotion
of the quality use of medicines. The pharmacist must recognise the need for involvement in an ongoing cycle of care,
assessment, intervention, monitoring/feedback, and assessment of consumer behaviour changes when providing
DSM services.
Managing Pharmacy Practice, Counselling, Medication Review, Health Promotion, and Screening and Risk
Assessment standards, where appropriate.
• Pharmacists should also refer to the relevant practice guidelines for specific DSM programs.
Criteria/Indicators
Self check:
Yes/No/NA
Resources
Criterion 1: The pharmacist fulfils their role in providing a DSM service
1. Applies the principles of quality use of medicines
of the National Medicines Policy
National Medicines Policy
Australian Guide to Healthy Eating
• Miller WR, Rollnick S. Motivational
Interviewing: Preparing People for Change.
2nd edn. New York: Guilford Press, 2002
and Ageing. Healthy weight website. Being
active. www.healthyactive.gov.au
• Australian Government. Every cigarette is
doing you damage. The National Tobacco
Campaign. www.quitnow.info.au
• See Additional Information: Stages of Change
box, p.75
2. Provides the consumer with details of the DSM
service and the pharmacist’s role in providing
the service
3. Provides counselling and education to raise
consumer awareness of the implications
of chronic disease, the value of preventive
strategies, and the importance of appropriate
medicine use
4. Works with the consumer to address lifestyle
changes that can have a positive impact on
chronic disease, and/or improve the outcomes
of medicines use
5. Applies different motivational techniques and
understands the ‘Stages of Change Model’

17
Criteria/Indicators
Self check:
Yes/No/NA
Resources
6. Motivates and encourages consumers to accept
responsibility for their own health, medical
conditions, and appropriate use of medicines
• Prochaska JO, DiClemente CC. Transtheoretical
therapy: toward a more integrative model of
change. Psychotherapy: Theory, Research and
Practice 1982;19:276–88
Criterion 2: The pharmacist establishes and maintains the relevant knowledge and skills to undertake the
specific DSM service being provided
1 Completes the appropriate level of training and/
or credentialing required to deliver the service
2 Maintains access to appropriate resources to
support the services being provided
3 Maintains a detailed knowledge of relevant
therapeutic areas required to deliver the service
4 Maintains the skills to operate equipment and
perform the relevant clinical testing proficiently.
5 Ensures staff authorised to assist in providing the
DSM service are trained and competent
Criterion 3: The pharmacist provides the DSM service in an environment that is appropriate and acceptable to
the consumer
1. Delivers the service in a location that protects the
privacy of the consumer
2. Ensures clinical tests are not conducted within
the dispensing area, or in any area where food or
drinks are consumed
Criterion 4: The pharmacist uses appropriate equipment to deliver the service
1. Uses equipment that meets relevant Australian
standards and is serviced regularly according to
the manufacturers’ instructions
• Pharmaceutical Society of Australia. Infection
control template procedure. www.psa.org.au
2. Uses equipment that is calibrated according to
3. Uses appropriate containers for the
storage and disposal of contaminated
clinical waste and sharps
Criterion 5: The pharmacist follows a documented procedure to collect consumer information
1. Obtains informed consent from the consumer
before collecting, storing, and sharing the
consumer’s details
pharmacy. J Pharm Pract Res 2005;35:
122–46
• Rigby D. Adherence assessment tools: drugs
don’t work when they’re not taken. Aust J
Pharm 2007;88:32–3
2. Conducts consumer interviews that are
appropriate to the specific condition, including
assessing consumer knowledge of the disease
state, symptoms, and gathering a social and
family history
3. Documents the consumer’s relevant
medical history, and ensures privacy of
all consumer information
4. Conducts any relevant physical assessments
(such as weight and height measurements)
and obtains and utilises available
laboratory information
5. Collaborates with the consumer’s other health
care providers to obtain, and also provide,
additional relevant information

17
Criteria/Indicators
Self check:
Yes/No/NA
Resources
6. Assesses the consumer’s adherence to
their medications
Criterion 6: The pharmacist works with the consumer and the consumer’s other health care providers to
develop a documented consumer care plan
1. Reviews and interprets the consumer’s health
information objectively, and evaluates the
consumer’s current pharmacological,
non-pharmacological, and self-care
therapies and activities
• Appendix 11: Template Consumer Care Plan,
p. 95
professionals advice referral policy (P2J).
2. Identifies and addresses the consumer’s
information needs
3. Assists the consumer in gaining an
understanding of their condition, and encourages
the consumer to improve their health
4. Works with the consumer and the consumer’s
other health care providers to establish realistic
therapeutic and lifestyle goals
5. Provides the consumer with a copy of
their care plan
6. Recommends pharmacological, non-
pharmacological, and self-care plans that are
consistent with current guidelines and desired
health outcomes
7. Documents all relevant communications with
the consumer and the consumer’s other health
care providers
8. Liaises closely with the consumer’s other health
care providers to address any issues identified
and/or discuss suggested interventions
Criterion 7: The pharmacist develops a systematic procedure to monitor and evaluate the consumer’s progress
against their consumer care plan and therapeutic goals
1. Regularly assesses the consumer’s care
plan, motivation, adherence and progress,
and develops a regular follow-up schedule,
as necessary
• Appendix 11: Template Consumer Care Plan,
p. 95
2. Provides evidence-based information and advice
to inform the consumer care plan and to enable
the consumer to achieve their therapeutic goals
3. Conducts clinical assessment as required
4. Assesses the safety and effectiveness of the
consumer’s therapy
5. Monitors adverse reactions, interactions,
and/or contraindications
6. Recommends alternative modes of treatment
and interventions in consultation with the
consumer’s other health care providers in
situations where the desired outcomes are
not being achieved
7. Continues to collaborate with the consumer and
the consumer’s other health care providers for
the benefit of the consumer

17
Additional information: Stages of change
Consumers may find it difficult to make the necessary changes and to achieve their therapeutic goals despite the
known health risks and consequences associated with their condition. Pharmacists need to provide a supportive
environment at all times, and to adopt a sensitive and respectful attitude. Pharmacists should have a good
understanding of Prochaska and DiClemente’s Stages of Change Model, which draws on psychotherapy theories
to explain the variations in a consumer’s response to advice about changing behaviour.
Stages of Change Model
Stage Behaviour Implications for pharmacist intervention
Pre-contemplation The individual is content with current
behaviour, has no intention of changing,
and is not considering change.
Listen and respond to questions. Attempts
to persuade are unlikely to be successful.
Contemplation The individual is thinking about the
possibility of changing, but has made no
plans to change.
Listen and respond to questions.
Provide information.
Preparation The decision has been made to change,
and the person is getting ready to make
the change.
Help with planning and goal setting.
Action The change is implemented. Encourage the consumer to return to the
pharmacy to discuss progress. Aim to use
a supportive approach.
Maintenance The individual works to prevent relapse to
the previous behaviour.
Continue using a supportive approach.
Encourage discussion of possible
problems that might lead to relapse.
Give positive feedback.
Adapted from Prochaska JO, DiClemente CC. Transtheoretical therapy: toward a more integrative model of change. Psychotherapy: Theory,
Research and Practice 1982;19:276–88.
International Pharmaceutical Federation. FIP statement of policy.
The role of the pharmacist in the prevention and treatment of chronic
disease. The Hague: FIP, 2006. Available at: http://fip.org/statements
International Pharmaceutical Federation. FIP statement of professional
standards on pharmaceutical care. The Hague: FIP, 1998. Available at:
http://fip.org/statements
Miller WR, Rollnick S. Motivational interviewing: preparing people for
change. 2nd edn. New York: Guilford Press, 2002.
Pharmaceutical Society of Australia. Diabetes medication assistance
service guidelines. Guidelines and standards for pharmacists.
Canberra: PSA, 2008.
Prochaska JO, DiClemente CC. Transtheoretical therapy: toward a more
integrative model of change. Psychotherapy: Theory, Research and
Practice 1982;19:276–88.

18
HarmMinimisation
Standard 18: Harm Minimisation
Standard
The pharmacist provides opioid substitution and/or needle
and syringe services to optimise therapeutic outcomes for
drug-dependent consumers and to help reduce the harm
associated with illicit drug use.
• This standard applies to the delivery of opioid substitution and needle and syringe programs aimed at reducing the
morbidity and mortality associated with illicit drug use. This standard may also be applied to the provision of other
supervised or restricted supplies, such as benzodiazepine withdrawal regimens.
• Needle and syringe programs involve the supply of sterile needles, syringes and other injecting equipment; the
collection and disposal of used needles and syringes; and the provision of advice and information relevant to injecting
drug users.
• Opioid substitution programs involve the provision of medicines, which are intended to reduce or eliminate illicit opioid
use, along with support and advice on substance abuse.
• The principle of harm minimisation has formed the basis of successive phases of Australia’s National Drug Strategy
since its inception in 1985. The concept of harm minimisation is outlined in The National Drug Strategy: Australia’s
Integrated Framework 2004–2009 and consists of three components:
supply reduction
demand reduction
reducing drug-related harm.
• Harm minimisation does not condone drug use; it aims to improve health, social, and economic outcomes for both
the individual and the community, and encompasses a wide range of approaches, including abstinence-orientated
strategies. Australia’s harm minimisation strategy focuses on both licit and illicit drugs, and includes preventing
anticipated harm and reducing actual harm.
• Pharmacists may find it useful to publicly display a one-page policy to inform other consumers and the community
about local and national harm reduction strategies.
• Pharmacists have a duty of care to use their professional judgement when deciding whether to supply or decline
supply to an obviously drug- or alcohol-affected person.
• This standard is to be applied in conjunction with the Fundamental Pharmacy Practice standard, as well as the
Counselling and Dispensing standards. Refer also to the Health Promotion standard, where appropriate.
Criteria/Indicators
Self check:
Yes/No/NA
Resources
Criterion 1: The pharmacist has the training and experience needed to provide harm minimisation services
1. Has completed on-the-job training in providing
opioid substitution therapies and/or needle and
syringe programs
Training record (T15B)2. Undertakes regular education in the area of
substance abuse and treatment
3. Understands the objectives and principles of
harm minimisation

18
HarmMinimisation
Criteria/Indicators
Self check:
Yes/No/NA
Resources
Criterion 2: The pharmacist integrates harm minimisation services into pharmacy practice
1. Prioritises harm minimisation services within the
framework of other service demands
2. Adapts workflow to facilitate the delivery of
opioid substitution and/or needle and
syringe services
3. Ensures opioid substitution supply occurs
discreetly to maintain consumer dignity
4. Supplies and collects needles, syringes,
and injecting equipment in a manner that
acknowledges the consumer’s dignity and so
protects the safety of pharmacy staff and
other consumers
Criterion 3: The pharmacist uses appropriate equipment and resources to support and assist in the delivery of
harm minimisation services
1. Accesses the policies, guidelines, and relevant
regulations governing the delivery of harm
minimisation services
Guidelines for Pharmacists Providing Opioid
Pharmacotherapy Services. www.psa.org.au
2. Ensures current substance abuse and treatment
information resources are available to consumers
and staff to support service delivery
3. Provides consumers with drinking water and
facilities to dispose of, or adequately clean,
drinking cups
4. Maintains access to an approved
sharps container
5. Uses appropriate equipment for providing
opioid substitution pharmacotherapy doses to
consumers. Appropriate equipment will include
accurate dose dispensing and measuring
devices (such as pumps and syringes) and
containers for dosing (such as disposable or
washable drinking cups, and containers with
child-resistant closures for take-away doses)
Criterion 4: The pharmacist follows a systematic dispensing and dosing procedure for providing an opioid
substitution program
1. Maintains a documented operating procedure
for dispensing and dosing of opioid substitution
therapy (including take-away doses)
• Pharmaceutical Society of Australia. Sample
client/pharmacist agreement form.
www.psa.org.au
Dispensing p. 28
2. Ensures the dispensing and dosing procedure
document is available and displayed in the area
where opioid substitution therapy is prepared
3. Maintains a file with current photo identification
for each consumer
4. Maintains an accurate and unambiguous dosing
record system
5. Uses a pharmacist/consumer agreement form
6. Ensures that dosing only occurs for a single
consumer at a time

18
HarmMinimisation
Criteria/Indicators
Self check:
Yes/No/NA
Resources
7. Documents any event where supply of a
dose is declined
8. Stores opioid substitution therapies and
any prepared doses appropriately in an
approved safe
Criterion 5: The pharmacist liaises with the consumer’s prescriber and/or other health care providers, when
appropriate
1. Records contact details of the consumer’s
prescriber and other relevant health
care providers
professionals advice referral policy (P2I)
2. Reports to the prescriber or other relevant
health care providers any issues relating to the
consumer’s treatment, such as consecutive
missed doses, erratic attendance, unusual
behaviour by the consumer, or any other
important information
3. Documents any significant communication
with the prescriber or other relevant health
care providers
4. Communicates or documents relevant
consumer information for other pharmacists
working in the pharmacy
Criterion 6: The pharmacist assists the consumer with general health and medicines information
1. Provides written and oral information appropriate
to the consumer’s needs
• Australian Drug Information Network. Alcohol
and drug services. www.adin.com.au
• Drug Info Clearinghouse. Alcohol and drug
info. www.druginfo.adf.org.au
• Centre for Education and Information on Drugs
and Alcohol. Drugs and alcohol services.
www.ceida.net.au
• State Government of Victoria. Department of
Health. DirectLine. Ph: 1800 888 236
www.health.vic.gov.au/doh
2. Provides the consumer with access to current
sources of information about medicines and
therapeutic devices, safe injecting techniques,
and general health topics
3. Maintains a current list of details for support
services to refer consumers to as needed
4. Refers consumers to relevant local support
services and other health care providers
when necessary
5. Maintains a list of referral points for the collection
of used needles and syringes, when this service
is not provided by the pharmacy
6. Provides information on possible injuries
and complications that the consumer
could experience, including significant drug
interactions, major side effects, symptoms of
overdose, and the effects of polydrug use and
excessive alcohol intake
7. Provides counselling specific to the harm
minimisation service provided
8. Records significant advice given in the
consumer’s file
Criterion 7: The pharmacist ensures the safety of all pharmacy staff and the community when delivering harm
1. Explains the principles of harm minimisation
to all staff
• Pharmaceutical Society of Australia. Infection
control template procedure. www.psa.org.au

18
HarmMinimisation
Criteria/Indicators
Self check:
Yes/No/NA
Resources
2. Allows pharmacy staff, other than pharmacists,
the option to not participate in harm
Opioid Substitution Program checklist (T3A)
Needle and Syringe Program
checklist (T3D)
• Department of Health. Section 23. Needlestick
and other blood or body fluid incidents. In:
Infection Control Guidelines for the Prevention
of Transmission of Infectious Diseases in the
Health Care Setting. www.health.gov.au
3. Ensures all pharmacy staff follow the
documented procedures for the delivery of harm
4. Instructs all pharmacy staff on the potential risks
and precautionary measures that should be
taken when delivering the service
5. Counsels and advises all pharmacy staff and
consumers on the safe disposal of used needles
and syringes
6. Directs consumers using the harm minimisation
service to place any used equipment in the
pharmacy disposal units provided to reduce the
risk of infection and needlestick injuries
7. Maintains an appropriate system for the
disposal of full sharps containers
8. Ensures sharps containers are clearly labelled
with appropriate warning labels/symbols
and located in an area that cannot be easily
accessed by unsupervised children
9. Ensures all staff follow a systematic procedure
in the event of a needlestick injury
10. Practises general hygiene principles to limit the
spread of infection by all staff
Australian Government Department of Health and Ageing for National
Drug Strategy. The national drug strategy: Australia’s integrated
framework 2004–2009. Canberra: Commonwealth of Australia, 2004.
Available at: www.health.gov.au/internet/drugstrategy/publishing.nsf/
Content/framework0409
Drug Strategy. Clinical guidelines and procedures for the use of
methadone in the maintenance treatment of opioid dependence.
Canberra: Commonwealth of Australia, 2003. Available at:
www.health.vic.gov.au/dpu/downloads/guidelines-methadone.pdf
Drug Strategy. National clinical guidelines and procedures for the use
of buprenorphine in the maintenance treatment of opioid dependence
National Drug Strategy. Canberra: Commonwealth of Australia, 2006.
Available at: www.health.gov.au/internet/drugstrategy/publishing.nsf/
Content/9011C92D2F6E1FC5CA2575B4001353B6/$File/bupren.pdf
Australian Government Department of Health and Ageing. Infection
control guidelines for the prevention of transmission of infectious
diseases in the health care setting. Canberra: Commonwealth of
Australia, 2004. Available at: www.health.gov.au/internet/main/publishing.
nsf/Content/icg-guidelines-index.htm
Australian Government Department of Health and Ageing. Needle and
Syringe Program. Needle and syringe programs information kit. Available
at: www.health.gov.au/internet/main/publishing.nsf/Content/needle-kit
Pharmaceutical Society of Australia. Guidelines for pharmacists providing
opioid pharmacotherapy services. Canberra: PSA, 2004.
Pharmaceutical Society of Australia. Opioid substitution therapy. In:
21st edn. Canberra: PSA, 2009: 61–4.

18
HarmMinimisation
Additional information: Harm minimisation
Harm minimisation is consistent with a comprehensive approach to drug-related harm. There is a balance between
supply reduction, demand reduction, and harm reduction strategies.
• Supply reduction strategies disrupt the production and supply of illicit drugs, and the control and regulation of
licit substances (e.g. age restrictions on alcohol and tobacco sales).
• Demand reduction strategies prevent the uptake of harmful drug use, including abstinence-orientated
strategies and treatment to reduce drug use (e.g. ‘Every cigarette is doing you damage’ the National Tobacco
Campaign, and pharmacotherapy).
• Harm reduction strategies reduce drug-related harm to individuals and communities (e.g. the provision of safe,
clean injecting equipment).
This professional standard only refers to the concepts of harm and demand reduction at a basic, introductory level.
A more comprehensive treatment of the subject is beyond the scope and intention of this document. However,
pharmacists can obtain more detailed information from the information resources at the end of this standard.
Pharmacists should be aware of issues such as general health, street drugs, preparation and administration
of injections, phlebitis (‘track marks’), collapsed veins, burning pain on injection, ‘dirty hits’, abscesses, ulcers,
cellulitis, gangrene, and endocarditis.
Safer injecting practices
Pharmacists should recommend that injecting drug users take note of the following recommendations.
• Always inject with the blood flow.
• Rotate injection sites.
• Use sterile new injecting equipment with the smallest bore needle possible.
• Do not share any equipment used in the injecting process (e.g. needles, syringes, cups, water, spoons, filters,
and swabs).
• Mix powders with sterile water, and filter the solution before injecting.
• Remember tablets are not designed for injection, and the risk of problems caused by the injection of insoluble
materials is high.
• Note that gel-containing capsules are also not designed for injection, and vein damage caused by gel capsule
contents is common.
• Avoid injecting into infected areas.
• Do not inject into swollen limbs even if the veins appear to be distended.
• Avoid veins in the neck, groin, breast, feet, and hands as injection sites.
• Always dispose of equipment safely.
• Be aware that poor veins indicate a poor technique; try to see what is going wrong.
• Remember needles go blunt after one use, leading to increased risk of vein damage if used again.
• Do not inject while alone.
• Remember tolerance will be reduced after a period of abstinence (e.g. rehabilitation, detoxification, or
imprisonment), making the effects of injecting drug use more difficult to predict.
• Be aware that obtaining drugs from a different dealwer, and/or using different batches, may mean a change in
the strength or potency of the drug.
• Note that the use of multiple drugs may increase the risk of overdose and other negative effects.
• Be aware that there is an increased risk of a systemic infection caused by a dose first being ‘stored’ in the
mouth later being injected.
• Learn basic principles of first aid and cardiopulmonary resuscitation so that you can help friends at times of crisis.
Many people who inject drugs regard community pharmacies as their preferred location for obtaining needles and
syringes, and receiving advice and information on drug-related matters. The aim of a needle and syringe program is to:
• supply sterile needles and syringes
• discourage practices that lead to needles and syringes being shared or re-used
• promote the safer use of needles and syringes
• reduce the risk of transmission of blood borne viruses, in particular HIV and hepatitis B and C
• provide a mechanism to collect and dispose of used needles and syringes
• provide information and advice on aspects of harm reduction
• assist injecting drug users to achieve an improved quality of life, by improving their physical and psychological
health and social functioning.
Opioid substitution pharmacotherapy has been used in Australia since 1969. It is recognised as an effective public health
measure and a vital component of harm reduction. The main objectives of providing an opioid substitution program are to:
• assist individuals in reducing or eliminating illicit opioid drug use
• reduce the mortality and morbidity associated with illicit drug use
• reduce the risk of transmission of blood-borne viruses, in particular HIV and hepatitis B and C
• reduce the social costs of illicit drug use
• assist individuals in achieving an improved quality of life, by improving their physical and psychological health
and social functioning.

Appendices
Appendix 1: The Medicines Management Pathway
Adapted from Stowasser DA, Allinson YM, O’Leary KM. Understanding the medicines management pathway. J Pharm Pract Res 2004;34:293–6.
The medicines management pathway (Figure 1) has nine key steps and three system-wide background processes.1
The steps
are both cognitive and physical. Opportunities for error exist within each step, and as the processes are interdependent, they
influence each other. The pathway is a closed loop, or cycle, as feedback on the effect of the medicine and the transfer of
information relating to the previous steps influences future treatment decisions in the next cycle. The pathway is applicable to the
use of all medicines, independent of the setting, the health professionals involved, and the funding source. It provides a framework
to identify how steps are related, the potential for any errors, and thus, possible medication safety system improvements.
Figure 1. The medicines management pathway.1
In some circumstances, steps occur in parallel rather than in sequence; for example, an electronic prescribing system
with decision support may simultaneously ‘review the medicine order’ at the ‘record medicine order (prescribe)’ step.
On occasions, the steps may not occur in strict sequence, as when medicine information is provided as the medicine
is ordered. The same person may be responsible for consecutive steps. Generally each step will be undertaken when
medicines are used, although how the steps are undertaken may differ depending on the setting.
The consumer is the central focus of the pathway, with direct involvement in some or all of the steps (such as when self
medicating). Depending on the pharmacy practice setting, pharmacists have newly developing and/or well established
roles at all steps of the pathway.
Steps in the medicines management pathway
1. Decision on appropriate treatment and decision to prescribe medicine
The prescriber needs access to accurate, complete, and up-to-date consumer-specific information and consumer input
to assess the most appropriate treatment option, considering both the best available evidence and the consumer’s
treatment goals. If the most appropriate option is the use of a medicine, the decision becomes the choice of the most
appropriate, safe, and cost-effective medicine for that person. The decision may be influenced by treatment protocols,
cost‑effectiveness, and acceptability to the consumer, as well as the funding source. An example of a pharmacist
undertaking this step is providing a recommendation for an over-the-counter medicine.
2. Record medicine order (prescribe)
The intention of the prescriber needs to be conveyed to others involved in the medicines management pathway.
The medicine order (or prescription) needs to be clear, unambiguous and contain enough information to support the
use of the medicine as intended. Therefore communication is required with the consumer, the person issuing the medicine
(often a pharmacist), the person administering the medicine (the consumer or carer, or in the hospital setting, usually a
nurse), and finally, the person assessing the impact of the use of the medicine.
Decision on
appropriate treatment
Decision to prescribe
medicine
Record medicine
order (prescribe)
Review of
medicine order
Issue of
medicine
Provision of
medicine
information
Distribution
and storage
of medicine
Administration of
medicines
(re-assessment, preparation,
administration and recording)
Monitor for
response
Transfer of verified
information
Effective communication
of accurate, complete and
comprehensive information
Medicines procurement
and materials
management
Data collection and reporting,
audit review of quality and safety
CONSUMER

Appendices
3. Review of medicine order
The review of the order at this step provides a valuable safeguard for consumers and prescribers. Orders may be reviewed to
ensure compliance with legislative requirements or funding by a third party (e.g. the Pharmaceutical Benefits Scheme), to optimise
the use of the medicine prescribed, to verify and confirm the intention of the prescription, or to consider clinical appropriateness
prior to dispensing or administration of the medicine, according to the information available to the health care provider. If an issue
is identified, clarification is sought with the prescriber, and any proposed changes discussed and documented.
4. Issue of medicine
Issuing of medicines includes the processes of dispensing, manufacturing, or supply of medicines, and is usually
undertaken by pharmacists or other endorsed providers (e.g. rural nurses). The correct medicine should be manufactured
or selected, and it should be labelled fully and clearly. Where required, consumer-specific instructions are included to assist
the person administering the medicine to understand the prescriber’s intent, and a record of the issue is made.
5. Provision of medicine information
Appropriate consumer information about medicines, including how to store and use them correctly, improves medicine
safety and the quality use of medicines. In addition, information on the appropriate preparation and administration of the
medicine should be provided to persons involved in administering the medicine.
6. Distribution and storage of medicine
Once issued, medicines are distributed to the care delivery areas (e.g. the ward) within a residential or health care facility,
or for local storage by the consumer or carer (at home or wherever the consumer resides). The method of medicines
storage (such as using an imprest system or bedside locker) will depend on the needs of the consumer, and financial,
physical, regulatory, and safety constraints.
7. Administration of medicine
The need for a medicine may be reassessed before administration; for example, as in the need for pain relief or symptom
control. Therefore, this step encompasses reassessment of need, the selection of the correct medicine (dosage, route,
and time), appropriate preparation of the medicine, and administration of the medicine to the correct person on each
occasion. Where required, a record of the administration of the medicine is made.
8. Monitor for response
Consumers often monitor their response to medicines, particularly when self-medicating. Prescribers or other health
professionals seek the consumer’s opinion on the response or, where the response is not self evident, investigate the
person’s response to the medicine according to symptom control or investigative tests. Responses to medicines may be
both positive and negative (such as in an adverse drug reaction or event).
9. Transfer of verified information
Information on the actual use of the medicine is crucial to assess the impact of the medicine, to assist with future
decisions about care, and to enable the safe transfer of care, especially when another health care provider is involved in
ongoing care. This includes information on:
• the medicine that was issued at transfer
• current treatment regimen (a complete and accurate list of ALL medicines), including the medicine, dosage, reason for
use, and intended duration of therapy
• a description of changes to the therapy during the episode of care.
This communication step is crucial when the consumer’s care is shared between health professionals and across
the continuum of care. It is important that appropriate quality assurance steps are in place to ensure the accuracy,
completeness, and timeliness of the information provided to the next health care provider.
System-wide background processes in the medicines management pathway
These processes occur on a ‘system-wide’, rather than on an individual consumer basis. Their impact is across the whole
of the medicines pathway, with their ultimate focus being to ensure the quality use of the medicine for each consumer.
Medicines procurement and materials management
The timely access to high-quality medicines at a cost the individual and community can afford is crucial to the appropriate use of
medicines. Medicines must be procured, stored, and distributed appropriately to ensure the safety of individual consumers and
the environment (e.g. refrigerated medicines, cytotoxic medicines, etc.) and to ensure the effective use of resources.
Data collection and reporting, and audit review of quality and safety
Data on all aspects of the cycle is collected for reporting on a system-wide basis. In particular, data on the prescribing,
issuing, and administration of medicines is collected as part of audit activity to support the quality use of medicines and to
monitor medication safety. This process may also include the collection of data required for funding by third parties.

Appendices
Effective communication of accurate, complete and comprehensive information
Effective communication is fundamental to achieve optimum outcomes for consumers along the whole medicines
management pathway. For example, communication is needed to ensure that prescribers are aware of formulary
prescribing, that consumers have medicines information and knowledge of the management plan, and that verified
information is accurately communicated to the next health care provider.
The medicines management pathway in other guidelines
The medicines management pathway is also used in the Australian Pharmaceutical Advisory Council’s Guiding Principles
to Achieve Continuity in Medication Management document,2
where the pathway is referred to as the ‘medication
management cycle’. The background to this document states:
The health care continuum can be viewed as a series of cycles. Each cycle relates to an episode of care. For each
episode of care, there is a corresponding medication management cycle.
Each cycle comprises the nine steps of the medicines management pathway and the three background processes. This
document aims to achieve continuity of quality use of medicines in medication management when consumers move from
one episode of health care to another. Pharmacists may obtain copies of this document from the National Medicines Policy
Secretariat at: nmp@health.gov.au.
Application of the medicines management pathway
Identifying opportunities for error
Opportunities for consumer harm exist within the pathway and within each step. Therefore, an understanding of the
pathway and the human factors associated with each step is necessary to ensure the safe, effective, and efficient use
of medicines. The pathway can assist consumers and health professionals to understand their own role and how their
actions can improve medicine safety.
Recent innovations in pharmacy practice
A detailed understanding of the medicines management pathway is essential to support the safe, effective, and efficient
introduction of many initiatives including:
• the interpretation of the impact and applicability of medication safety projects
• the transfer of medicines information across the continuum of care
• the use of electronic prescribing systems with decision support within health services
• the use of barcode and other technologies to support safety improvements.
Relevance of the Professional Practice Standards to the medicines
management pathway
The medicines management pathway allows pharmacists to gain an overview of what happens when medicines are used. It
demonstrates the multiple opportunities for improvement in the systems and processes used in providing professional services.
Depending on the pharmacy practice setting, pharmacists may identify with newly developing and/or well established roles
at all steps of the pathway.
Some standards are directly linked to one or other step of the pathway, while others support many steps, or even the
whole of the pathway. Using the pathway can assist a better understanding of the output of the standards in terms of the
quality of the consumer service that is delivered.
The Fundamental Pharmacy Practice standard relates closely to the three background processes of the medicines
management pathway, and applies on a system-wide basis to all services provided by the pharmacist. The Managing
Pharmacy Practice standard addresses the responsibility of some individuals for providing the material and human
resources necessary to facilitate compliance by others with the Professional Practice Standards.
The Professional Practice Standards address some specialty services (including medication reviews and Dose Administration
Aids Services) that represent localised cycles of care within the medicines management pathway. These specialty services
may focus on a particular process, such as communication, reporting, or the provision of medicines, but pharmacists must
also be familiar with other inter-related professional practice standards, and any regulatory and privacy issues.
The Professional Practice Standards provides a context for the pharmacists’ contribution to the medicines management
pathway and promote uniform safety and quality in pharmacy practice.
References
1. Stowasser DA, Allinson YM, O’Leary KM. Understanding the medicines management pathway. J Pharm Pract Res 2004;34: 293–6.
2. Australian Pharmaceutical Advisory Council. Guiding principles to achieve continuity in medication management. Canberra: Commonwealth of
Australia, 2005. Available at: www.health.gov.au/internet/main/publishing.nsf/Content/nmp-guiding

Appendices
Appendix 2: Quality Use of Medicines and
Practice Improvement
Quality use of medicines (QUM) means ‘selecting management options wisely, choosing suitable medicines if a medicine is
considered necessary and using medicines safely and effectively’.1
QUM is one of the four central objectives of Australia’s
National Medicines Policy.2
This policy advocates shared responsibility between governments, health care professionals,
and consumers to achieve QUM.
‘It is estimated that over 1.5 million Australians suffer an adverse event from medicines each year resulting in at least
400,000 visits to general practitioners and 140,000 hospital admissions.’3
In 2005, the Australian Council for Safety
and Quality in Health Care noted that 90% of safety problems were based in the system, and only 10% with the
individual.4
A systems approach to improving quality involves building layers of barriers to reduce the probability of
identified risks occurring.
Maintaining a focus on continuous quality improvement is not only an effective means of improving the service provided
to consumers, but is also the key to achieving efficiency and productivity gains. The goal of all reviews is to identify
opportunities for improvement. It is important that reviews of processes are evaluated carefully, and the findings used
to improve services. For example, regular audits of service records can identify rates of compliance with required
documentation that, in turn, can indicate where documentation systems can be simplified. Surveys of consumers can
indicate the degree of satisfaction with the service, as well as elicit suggestions for changing the service so that it will meet
customer needs more effectively and so improve consumer outcomes. Further information on conducting quality reviews
may be found in the PSA’s Guidelines for Managing Pharmacy Systems for Quality and Safety.5
Investing time in improving the quality of pharmacy systems is an important task that can assist improvements in health
outcomes. Unless there are changes and improvements in the systems used, there cannot be improvements in outcomes.
While not all changes result in improvement, all improvements require change. It is important for pharmacists to
weigh the value of any improvement using objective evidence. Pharmacists routinely practise evidence-based medicine,
and the documentation recommended in these standards provides the evidence base for ‘evidence-based quality
practice improvement’.
The plan-do-study-act cycle
One model for quality improvement is the plan-do-study-act (PDSA) cycle6
adopted by the National Primary Care
Collaboratives Program. This cycle consists of the following steps:
Step 1 Plan – involves identifying the problem.
Step 2 Do – involves carrying out the plan, observing and recording data.
Step 3 Study – involves measuring or analysing the effects.
Step 4 Act – involves adjusting the activity of the next cycle based on the outcomes of this cycle.
This model adapts to pharmacy services at all levels of
practice (see Figure 1).
This same cyclic approach may be used to improve
individual cycles of care for consumers, or to improve
organisational systems.
Figure 1. The plan-do-study-act cycle in
pharmacy services.
ACT
Make
recommendations
PLAN
Identify the problem
(involves the patient,
medical practitioner
or pharmacist)
STUDY
Analyse
information
DO
Gather
information

Appendices
Quality improvement activities
Examples of activities involved in the implementation of quality improvement include the following:
a) reviewing and updating educational material provided in the pharmacy, and noting and recording the popular topics
b) drawing up a calendar of health topics and activities for pharmacy staff
c) informing consumers, through flyers and leaflets, about future health campaigns
d) encouraging feedback from consumers and health professionals by distributing surveys or feedback forms after each
health education/promotion activity, and analysing the responses
e) keeping a log of dispensing errors, analysing what factors may be attributable, and recording corrective actions already
taken and/or future strategies to prevent recurrence
f) undertaking a random self-audit regularly (e.g. once a month) to assess timeliness of supply (e.g. recording the time of
prescription receipt and the time of supply for every third prescription received)
g) maintaining a log of the extemporaneous preparations or the total number of items dispensed and analysing trends
(e.g. how busy the pharmacy usually is on pension days or before school holidays); this analysis may be used to
determine appropriate staffing levels for an anticipated workload
h) distributing standard written feedback forms to customers regularly, and recording any verbal feedback in a logbook
i) noting the types and numbers of enquiries received (including the subject involved and the enquirer), and the type
of response provided (e.g. an on-the spot response, a response after consulting references, or requiring extensive
research before answer)
j) recording the usual or average response time to a request for a professional service
k) keeping an audit trail to ensure ease in tracing the original enquiry in cases where follow-up information is required
l) providing feedback forms with written reports when reports are requested and/or supplied, and analysing any
comments received from enquirers.
m) seeking external or peer review of the service supplied.
References
1. Australian Government Department of Health and Ageing. The national strategy for quality use of medicines. Plain English edition. Canberra:
Commonwealth of Australia, 2002. Available at: www.health.gov.au/internet/main/publishing.nsf/Content/nmp-pdf-natstrateng-cnt.htm
2. Australian Government Department of Health and Ageing. National medicines policy 2000. Canberra: Commonwealth of Australia, 1999.
Available at: www.health.gov.au/internet/main/publishing.nsf/Content/nmp-objectives-policy.htm
3. Roughead L, Bedford G. Chapter 4. Medication safety: will adverse drug events be reduced? In: Windows into safety and quality in health care 2008.
Sydney: Australian Commission on Safety and Quality in Health Care, 2008: 27–37. Available at:
www.safetyandquality.gov.au/internet/safety/publishing.nsf/Content/com-pubs_MedSafety
4. Australian Council on Safety and Quality in Health Care. Achieving safety and quality improvements in health care. Sixth report to the Australian
Health Ministers’ Conference. Canberra: Commonwealth of Australia, 2005. Available at:
www.safetyandquality.gov.au/internet/safety/publishing.nsf/Content/a-zpublicationsa-e
5. Pharmaceutical Society of Australia. Guidelines for managing pharmacy systems for quality and safety. Canberra: PSA, November 2002.
Available at: http://psa.advsol.com.au/scriptcontent/Custom/MC_ShowPage.cfm?page=163
6. Australian Primary Care Collaboratives. The model for improvement. Available at: www.apcc.org.au/about_the_APCC/the_model_for_improvement

Appendices
Appendix 3: The Health Promotion Planning Cycle
Figure 1. The health promotion planning cycle.
Adapted from Egger G, Spark R, Donovan R. Health promotion strategies and methods. 2nd edn. Sydney: McGraw-Hill, 2005.
When planning a health promotion activity, a structured
approach can ensure the best outcomes. The steps
in the health promotion planning cycle (shown above)
can be used in planning a health promotion activity on
any topic. Pharmacists should start by analysing the
area they want to promote and the type of activity they
would like to implement and then move on to setting
goals and preparing the pharmacy for the delivery of
the health promotion activity (including training staff).
Further planning is then needed before implementing the
activity. Once the health promotion activity is completed,
it is important to always reflect and to identify how such
activities could be improved in the future.
Analyse the situation
• Identify the problem
• Target audience
• Promotional materials
Planning
• Determine the message
• Getting the message
across
• Setting the goals
• Seek additional support
Evaluation
• Determine what
worked well
• Work out how to do
it better next time
Implementation
• Putting the plan into
action
• Display promotional
materials
• Work to achieve goals
Set goals and objectives
• Specific
• Measurable
• Achievable
• Realistic
• Timely
Capacity building
• Increasing the capacity of
the pharmacy’s workforce
to implement a specific
health promotion activity
• Staff training

Appendices
Appendix 4: Adherence Assessment Tool
The following modification of the Morisky scale1
is a validated tool for assessing whether a consumer is unintentionally
non-adherent with their medicines. It may assist the consumer to adhere with their medication regimen through increased
awareness of their medicines.
First name Family name
Address
Date Assessed by
Pharmacy details
Ask the consumer
Question Answer (score)
Patient’s answer
and score
1. Do you ever forget to take your medicines? No (0) Yes (1)
2. Are you always careful about taking your medicines? No (1) Yes (0)
3. When you feel better do you sometimes stop taking your medicines? No (0) Yes (1)
4 Sometimes, if you feel worse when you take your medicines, do you stop taking them? No (0) Yes (1)
Explanation of scores
Total score of zero Adequate adherence
Total score of 1–4 Inadequate adherence (partial adherence or non-adherence)
Other comments/notes
1. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986;24:67–74.

Appendices
Appendix 5: Details of Local Health Care Providers
Below is a template table to be used to document the details of health care providers in the pharmacist’s local area. This
can be a quick reference tool for the pharmacist or pharmacy staff to use when referring consumers to other health care
providers. The template is not an exhaustive list but is designed to be tailored to the needs of individual pharmacies.
Provider
Name of
Provider
Contact
Person
Phone Address Email
Aboriginal and Torres Strait
Islander Health Services
Community Nursing
Services
Dentist
Diabetes Educator
Dietician
Early Childhood Clinic
Family Counselling
Family Planning Services
General Practitioner
Hospital
Hospital
Hospital – Aged Care and
Rehabilitation Services
Hospital Pharmacy
Medical Specialist
(e.g. dermatologist)
Medical Specialist
Medical Specialist
Naturopath
Occupational Therapist
Optometrist
Podiatrist
Poisons Information Centre
Psychologist
Psychologist
Speech Therapist
Youth Counselling

Appendices
Appendix 6: Documenting Counselling Events
and Interventions
Counselling involves the communication of information that will ensure the medicine used by the consumer has the desired
therapeutic effect and the incidence of preventable adverse effects is minimised.1
Documentation of counselling events
and interventions provides a record that can be used by other pharmacists in the pharmacy to tailor their communication
with the consumer when subsequently supplying medicines. Documentation can also be used as a risk management
strategy to provide a record of evidence that an intervention has occurred.
This document provides guidance on what counselling issues may be important to record and how the information should
be documented. This list is a guide only and some situations not identified in this list may also be of clinical significance
and require recording. Pharmacists are reminded to use their professional judgement when deciding which issues are
relevant to document.
Clinically important counselling issues to record What to record
Difficulties communicating with the consumer/carer
due to:
• vision impairment
• hearing impairment
• language or cultural differences
• cognitive impairment
• Reasons for the communication difficulty
• Actions taken or methods used to overcome
communication difficulty (e.g. use of a
translation service)
• Any follow up required or recommended
A consumer or carer refusing counselling • Reasons for refusal
• Any information provided
A consumer or carer possibly having difficulties with
medicine adherence
• The adherence issue identified
• The advice given to improve adherence
The identification of a drug interaction • The drug interaction identified
• The advice given or action taken to resolve the
drug interaction issue
The identification of an adverse drug reaction • The adverse drug reaction indentified
• The advice given or action taken to resolve the adverse
drug reaction
An inadequate response to a medicine • Details of the inadequate response to the medicine
• The advice given or action taken to resolve the issue
A cessation of a medicine • Details of medicine ceased
• Reasons for medicine being ceased
A change of dose • Confirmation of change of dose
• Reasons for change of dose (if known)
• Any additional advice given relating to the change in
dose and/or expected outcomes
A change of instructions for the consumer on
a medicine
• Confirmation that the instructions have changed
• Confirmation that consumer is aware of the
new instructions
1. Sansom LN, ed. Australian pharmaceutical formulary and handbook. 21st edn. Canberra: Pharmaceutical Society of Australia, 2009.

Appendices
Appendix 7: Indirect Supply Services: New Consumer
Details/Change of Consumer Details Form
This is a template for pharmacists to use to gather all necessary information from new consumers who wish to access an
indirect supply service or for consumers whose details have changed. The template is designed to be a guide and should be
adapted to best suit the needs of the individual pharmacies.
New Consumer Details/Change of Consumer Details Date
First name Family name Date of birth
Address
Email address Phone
Concession card number Expires
Repatriation health card number Expires
Please circle colour: Gold / White / Orange
Medicare number Expires
Safety net number Expires
Emergency contact details
Carer name and contact details (if applicable)
GP name Address
Phone Email
Medication regimen (Include all prescription and non-prescription items –
if more space is required, please attach on another sheet of paper)
Directions for use (If more space is required, please attach on another
sheet of paper)
1.
2.
3.
4.
5.
6.
Medical history (e.g. medical conditions, physical disabilities – if more space is required, please attach on another
sheet of paper)
Allergies
Consumer’s preferred mode and time of delivery
Relevant delivery details (e.g. security gates, pets, house, apartment, language difficulties, etc.)
Information recorded by

Appendices
Appendix 8: Medicines that may be considered
Unsuitable for Indirect Supply
There are a variety of reasons why medicines may be considered unsuitable for delivery, and pharmacists need to make a
risk assessment to determine the suitability of a medicine for indirect supply based on the individual circumstances. There
is a greater likelihood of error when the opportunity for face-to-face contact with the consumer is absent, and this should
be taken into account when determining the appropriateness of medicines for indirect supply.
This list provides guidance on those medicines that may be unsuitable for indirect supply. Pharmacists may use this as a
template to create their own list. The list should be reviewed and updated on a regular basis.
Category Examples Comments
Commonly misused
medicines
Anabolic steroids,
benzodiazepines, stimulants,
appetite suppressants,
pseudoephedrine, codeine,
laxatives, eye drops,
analgesics
• Need to prevent inappropriate supply
• Ensure all documentation and details are accurate
and authentic
Pharmacist Only
Medicines
(Schedule 3)
Analgesics, vaginal thrush
treatments, emergency
hormonal contraception
• Some jurisdictions require face-to-face contact
between pharmacist and consumer (these may be
supplied on prescription)
• Need to consider ability to assess the therapeutic need
without face-to-face contact and the risks involved with
the use of Pharmacist Only Medicines
Medicines that require
refrigeration
Eye drops, vaccines,
thyroxine
• Need to ensure delivery arrangements are able to
accommodate temperature/storage conditions of the
medicines being delivered
Substances that
are prohibited from
commercial transport
Narcotics • Confirm which medicines are prohibited from
commercial transport with delivery companies
Medicines with a low
therapeutic index
Warfarin, digoxin • There is an increased risk of toxicity with such
medicines; consider contacting the consumer via
telephone to offer direct counselling

Appendices
Appendix 9: Template Procedure for Consumer
Admissions and Readmissions to Residential
Care Facilities
This is a template procedure for pharmacists to follow upon receiving notification that a consumer has been admitted or
readmitted to a residential care facility (RCF). The template is a guide and should be adjusted to best suit the needs of the
individual pharmacies and the RCFs involved.
Procedure for consumer admission or
readmission to a residential care facility
Person responsible
for task
Tick when task
completed
Record the admission/readmission notification received from the RCF
(via fax, email, or phone), and refer on as needed
Obtain, and record, consumer details from the RCF including:
• name
• Medicare and concession details (including expiry dates)
• safety net details
• GP name and contact details
• details of previous pharmacy used by the consumer
• billing details
Obtain and review a copy of the consumer’s medication chart
Contact the consumer’s previous pharmacy to obtain:
• previous medication details
• any prescriptions or medication held by the previous pharmacy
When received, record details as necessary
Compare consumer’s RCF medication chart with previous medication
details; record details as necessary
Confirm any differences or changes in the medication chart with the
consumer’s GP
Establish an electronic consumer profile in the dispensing software
Create a billing account for the consumer
Dispense prescriptions or obtain consumer’s own medication from the
RCF or previous pharmacy as needed
Create an electronic consumer profile in the packing software
Create a hard-copy file to store:
• a copy of the consumer’s medication chart and other details
• prescriptions
• records of packing, if applicable
Print packing materials if applicable
Supply the medication, according to the needs of the RCF (e.g. by
using medication sachets, blister packs, or original packaging)
Check repacked medication or original packs against the
medication chart
Deliver medication to the facility in a timely manner

Appendices
Appendix 10: Screening Record and Referral Form
This screening record and referral form is a template that pharmacists may wish to adapt and use when recording
screening services. The form allows the details of the service provided to be documented and contains a tear-off referral
form for consumers to take to another health care provider if required.
Screening record form Date
Name Date of birth
Address
Email Phone
Medication regimen (Include all prescription and non-prescription items –
if more space is required, please attach on another sheet of paper)
Directions for use (If more space is required, please attach on another
sheet of paper)
1.
2.
3.
4.
Test(s) (e.g. blood glucose, blood pressure, cholesterol)
Test equipment details
Date Test results Need for referral
Yes No
Yes No
Yes No
Yes No
Screening outcomes
Referred to Date
Address
Email Phone
Pharmacist name Pharmacist signature

Appendices
Referral form Date
Consumer name Phone
Address
Email
Referred to Phone
Address
Test(s) conducted
Test (s)results
Reason for referral
Pharmacy name Phone
Address
Email

Appendices
Appendix 11: Template Consumer Care Plan
Below is a template consumer care plan for pharmacists to document the treatment aims for consumers receiving disease
state management services. The care plan allows the details of each consultation and the goals for the consumer’s
treatment to be documented. A copy of the second page of the care plan should be given to the consumer so they have a
record of their treatment goals and date of next consultation.
Consumer care plan Date
First name Family name Date of birth
Address
Phone Email address
Concession card number Expires
Repatriation health card number Expires
(Please circle colour) Gold / White / Orange
Medicare number (the last digit corresponds to the number on the left of the name) Expires
Safety net number Expires
Emergency contact details
Carer contact details (if applicable)
Height Weight Waist circumference Smoking (Please circle) No / Yes
Number/day
GP name Address
Phone Email
Other health care providers
Name Address
Phone Email
Name Address
Phone Email
Medication profile (Include prescription and non-
prescription items and directions for use. If more space
is required, please attach on another sheet of paper)
Reasons for use (If more space is required, please
attach on another sheet of paper)
Adherence check (Refer to Appendix 4: Adherence
Assessment Tool)
1. e.g. Diabex 500 mg 4 n e.g. Type 2 diabetes e.g. Good
2.
3.
4.
5.
6.
Medical history (e.g. medical conditions, physical disabilities – if more space is required, please attach on another
sheet of paper)
Allergies
Lifestyle review/Consumer self-management issues (e.g. exercise, diet, blood glucose measurements)

Appendices
Clinical tests
Results
Date Result Date Result Date Result
e.g. Blood pressure
e.g Blood glucose
e.g. Cholesterol
e.g. Spirometry
e.g. Peak flow
e.g. Weight
Issues identified/changes since last consultation
Treatment options (e.g. pharmacological, non-pharmacological, lifestyle and self-care activities)
1.
2.
3.
4.
5.
6.
Care plan goals (Goals should be specific, measurable, achievable, realistic and timely)
1.
2.
3.
4.
Care plan review (Please circle) Weekly / Monthly / 3-monthly / 6-monthly
Date of next
review
Referral required
(Please circle) No / Yes
Referred to Phone
Address
Consumer name Consumer signature
NOTE: Page 1 of the consumer care plan to be retained by the pharmacist. Give a copy of page 2 of the consumer care
plan to the consumer.

Appendices
Appendix 12: The History of the Professional
Practice Standards
In late 1997, the Australian Association of Consultant Pharmacy (AACP) released their final report on the Framework
for Standards for Quality Pharmacy Services project.1
Consistent with a recommendation arising from this project, the
preferred framework for quality standards identified in the project was endorsed by the Pharmaceutical Society of Australia
(PSA) National Council in November 1997.
The PSA National Policy Committee believed in standards that were objective, authoritative statements based on
guidelines that represented the requirement for a service to meet a desired level of performance. This led to the publication
of the Pharmacy Practice Handbook.2
In 1998, the Pharmacy Guild of Australia launched the Quality Care Pharmacy Program, which contained a set of
retailing standards for community pharmacies.3
The PSA supported the Guild’s efforts by contributing a set of
professional standards to the document3
that were considered directly relevant to the consumer’s ‘shopping experience’
sin community pharmacy.
Separate to these standards, the PSA developed the first edition of the Professional Practice Standards with the AACP
framework and the International Pharmaceutical Federation’s Standards for Quality of Pharmacy Services: Good Pharmacy
Practice guidelines4
in mind. These standards were designed to define and improve service delivery, and to encourage
uniformity of practice performance across different health care settings. The first edition of the Professional Practice
Standards5
was published in October 1999 and consisted of 11 standards.
As the role of pharmacists in health care delivery has expanded, the PSA has sought to add continuous quality
improvement elements and to update the standards as required. In July 2001, the PSA published an interim update
to the standards, followed by an additional eight standards in version 2 of the Professional Practice Standards released
in October 2002.6
A second detailed review of the Professional Practice Standards in 2005 expanded the scope of the standards and
developed the universal Fundamental Pharmacy Practice standard integral to all pharmacy services and all areas of
practice. The Professional Practice Standards, version 3 was developed by the PSA through an extensive consultation
process with key industry stakeholders and experts from across the profession. The Professional Practice Standards,
version 3 was published in January 2006.7
Each review and subsequent edition ensures that the Professional Practice Standards continues to reflect current practice
as pharmacists in Australia face a professional climate of dynamic change.
References
1. Ware G, Stewart K. Framework for standards for quality pharmacy services: final report. Canberra: Australian Association of Consultant Pharmacy,
November 1997.
2. Pharmaceutical Society of Australia. Pharmacy practice handbook. Canberra: PSA, 1998.
3. Pharmacy Guild of Australia. Quality Care Pharmacy Program: Pharmacy Standards. Canberra: PGA, 1998.
4. ‘International Pharmaceutical Federation. Standards for quality of pharmacy services: good pharmacy practice. Revised edn.
The Hague: FIP, 1997. Available at: http://fip.org/good_pharmacy_practice
5. Pharmaceutical Society of Australia. Professional practice standards. Version 1. Canberra: PSA, 1999.

Appendices
Appendix 13: Project Participants
Project team
Audra Millis
Phoebe King
Jillian Malek
Claire Greenway
The Pharmaceutical Society of Australia is grateful for the
contribution of the following individuals and organisations
to the Professional Practice Standards, version 4.
Standards Steering Committee
Warwick Plunkett Pharmaceutical Society of Australia
(Chair)
Bruce Elliot Pharmaceutical Society of Australia
Peter Guthrey Pharmacy Guild of Australia
Rebekah Moles Society of Hospital Pharmacists
of Australia
Paul Gysslink Association of Professional Engineers,
Scientists and Managers, Australia
Sarah Gillespie Australian Association of Consultant
Pharmacy
John Chapman Australian College of Pharmacy
Robert Scanlon Pharmaceutical Defence Limited
Peter Halstead Australian Pharmacy Council
Lindee Russell Consumers Health Forum of Australia
Andrew Brown Committee of Heads of Pharmacy
Schools of Australia and New Zealand
Steve Marty Pharmacy Board of Australia
Hope Alexander
Carolyn Allen
Parisa Aslani
Jenny Bergin
Amanda Bryce
Brian Charlie
Mary Collins
Peter Crothers
Anne Develin
Simone Diamandis
Rachel Dienaar
Greg Duncan
Sue Edwards
Mark Feldschuh
Frank Fisher
Chris Flood
Jenny Giam
Sarah Gillespie
Sajni Gudka
Peter Guthrey
Laetitia Hattingh
Alison Haywood
Peter Holder
Helen Howarth
Karalyn Huxhagen
Grant Kardachi
Michelle Koo
Shane Jackson
Judy Liauw
Nick Logan
Julie Lord
Jane Ludington
Lia Mahony
Alison Marcus
Grant Martin
Andrew Matthews
Peter Mayne
Joanne McMahon
Jane Mitchell
Rebekah Moles
Geraldine Moses
Judy Mullan
Irvine Newton
Geraldine Peterson-Clark
Neil Petrie
Nicholas Reilly
Judy Rice
Debbie Rigby
Alison Roberts
Debra Rowett
Robert Scanlon
Sue Scott
Lynn Short
Natalie Soulsby
Gerard Stevens
Julie Stokes
Natalie Tasker
Lyn Todd
Robin Toohey
Dimitra Tsucalas
Tim van Bronswijk
Rick Van Drimmelen
Fran Vaughan
Dusan Veljkovic
Graeme Vernon
Australian Medical
Association
Heart Foundation
National Prescribing
Service
Therapeutic Goods
Committee
Expert reviewers

Glossary
Glossary
Term Definition
Adverse drug reaction (ADR) Any response to a drug that is noxious and unintended, and that occurs at doses
normally used in man for prophylaxis, for diagnosis or therapy for disease, or for
the modification of physiological function.1
Adverse drug event (ADE) An event where a medicine is implicated as a causal factor. An ADE encompasses
both the harm from the intrinsic nature of the medicine (e.g. an adverse drug
reaction) and the harm that results from medicine errors or system failures
associated with the manufacture, distribution or use of medicines. Drug interactions
are also examples of ADEs.2
Carer A person, either paid or unpaid, who has assumed a primary caring role
for another person in the community or in their own home. This may include
parents, guardians, children, and friends, as well as aboriginal health workers,
nursing assistants, personal care assistants, and home and community
care (HACC) workers.3
Complementary medicines Medicines that are also known as ‘traditional’ or ‘alternative’ medicines. Examples
include vitamins, minerals, nutritional and herbal supplements, aromatherapy, and
homoeopathic products.4
Consumer Any user or potential user of pharmacy services. This may include a carer, agent,
or another individual who would normally assist the user in taking their medicines
and/or using a therapeutic device. Other health care providers (such as medical
practitioners and nurses) may also at times be users of pharmacy services.
Consumer care plan A plan of systematic care outlined for the consumer that is provided by the
pharmacist in collaboration with the consumer and other health care providers.
It includes an accurate and comprehensive assessment of the consumer’s
health status, recommendations for pharmacological and non-pharmacological
interventions, therapeutic goals that have been developed with the consumer,
the provision of education and counselling, and regular follow ups to monitor the
consumer’s progress.
Controlled area An area constructed and operated in a manner where some attempt is made
to control the introduction of potential contamination and the consequences
of accidental release of living organisms. At a minimum, the area should be
maintained at a pressure negative to the immediate external environment and allow
for the efficient removal of small quantities of airborne contaminants.5
Counselling A two-way communication process between the pharmacist and the consumer in
which the pharmacist ascertains the needs of the consumer and provides him or
her with the information required to safely and effectively administer medicines
and/or use therapeutic devices.
Cytotoxic drugs Medicines used primarily in the treatment of cancer. They have deleterious
effects upon cells and many have been found to be mutagenic, teratogenic,
and carcinogenic.
Cytotoxic drug products A specific term used to refer to cytotoxic drug formulations that are derived from
the manipulation of commercially available cytotoxic raw materials
(drug concentrates).
Dose administration aid (DAA) Sealed, tamper-evident devices that allow individual doses to be packaged
according to the prescribed dose schedule.6
Disease prevention Processes designed to not only prevent the occurrence of disease, such as
through risk factor reduction, but also to arrest the progress of a disease and
to reduce its consequences once established.7

Glossary
Term Definition
Disease state management A consumer-centred process that focuses on managing the health of consumers
suffering from chronic conditions, with the objective of reducing risk factors through
monitoring, counselling, education, enhancing consumer self-management, and
the quality use of medicines.
Evidence-based information Information that has been critically evaluated for its validity, importance,
and relevance.
Harm minimisation The primary principle underlying the National Drug Strategy. It refers to policies
and programs that focus on reducing drug-related harm, and aims to improve
health, social, and economic outcomes for both the individual and the community.
Australia’s harm minimisation strategy focuses on both licit and illicit drugs.8
Hazardous materials Products that can cause adverse health effects, such as severe poisoning, asthma,
skin rashes, allergic reactions, allergic sensitisation, cancer, and other long-term
diseases, from exposure to them and also cause physical effects, such as fire,
explosion, release of hazardous gases, and corrosion. Hazardous materials may
include many commonly found industrial, commercial, pharmaceutical, agricultural,
and domestic chemicals.9
Health care providers Practitioners who provide services to individuals or communities to promote,
maintain, monitor, or restore health (such as a general practitioner, dentist,
physiotherapist or case worker).
Health literacy The ability to understand and interpret the meaning of health information in any
format (e.g. written, oral or electronic). Health literacy influences a consumer’s
ability to make sound health decisions in the context of daily life.10
Health promotion The process of enabling people to both increase control over their health and to
improve their health outcomes.7
Medicine A formulated product or drug designed to deliver a therapeutic outcome or affect
health when administered to a person or animal. Medicines include prescription
and non-prescription products as well as complementary medicines.11
Medication A medicine used by a specific consumer according to a particular
dosing regimen.11
Medication action plan (MAP) An ongoing plan for the use and management of medicines that is developed in
collaboration with the consumer and/or their carer. A medication action plan is
intended to support health care professionals and consumers and/or their carers
in developing suitable strategies to manage the consumer’s medications.12
Medication list A current list of all of the consumer’s current medicines. This list should be
available and easily accessible to the consumer and all those involved in the
consumer’s care.12
Medicines Use Review (MUR) A structured program that allows the consumer to have a face-to-face discussion
with their pharmacist about the medicines they are taking, with the aim of:
• helping the consumer to learn more about their medicines, what they are for,
how they affect the body, and how to take them to get the most benefit
• identifying any problems that the consumer is experiencing with their medicines
• improving the effectiveness of the medicines, and ensuring that the most useful
formulation is prescribed
• supporting clinical and cost-effective prescribing, and encouraging the
consumer not to waste, over-order, or stock-pile their medicines.
Medicines information Written and/or oral information or advice about medicines and pharmacotherapy,
in response to a request from other health care providers, consumers, or other
groups or individuals such as media, policy makers, and lawyers. This information
may be consumer-specific or general information promoting the safe and effective
use of medicines.
Medicines information centre A facility specifically designed for, and specialising in, the provision of medicines
information by pharmacists. Examples may include hospital medicines information
centres, the medical information departments of pharmaceutical companies, and
online pharmacy services providing medicines information.

Glossary
Term Definition
Medicines information
pharmacist
A pharmacist who is appropriately trained, and has demonstrated competency and
knowledge in the provision of a medicines information service.
Medication profile A complete and comprehensive summary of the medicines a consumer is currently
taking. The profile includes key details about the consumer, the issuing pharmacy,
and details for each medicine including active ingredient, brand name, strength,
form, dose and directions for use, and other supplementary information (e.g. route
of administration, indication, and special directions).13
Medication review A retrospective critical review of all prescribed, over-the-counter, and
complementary (herbal) medications. The aim is to optimise therapy and minimise
medication-related problems by assessing any need for changes in medications
and ensuring the consumer’s understanding of the medication regimen.14
Monitoring Refers to the regular measurement and assessment of specific clinical and social
parameters to assist consumers undergoing treatment for, or at risk of, specific
health conditions.
Non-prescription medicines All medicines available for purchase by the public that do not require a prescription.
Non-prescription medicines include, but are not limited to, Pharmacist Only
Medicines (S3), Pharmacy Medicines (S2), unscheduled medicines, complementary
medicines, and nutritional supplements.
Pharmacy practice Pharmacy practice refers to any role, whether remunerated or not, in which the
individual uses their skills and knowledge as a pharmacist in their profession.
Pharmacy practice is not restricted to the provision of direct clinical care. It also
includes working in a direct non-clinical relationship with clients; working in
management, administration, education, research, advisory, regulatory, or policy
development roles; and any other roles that have an impact on the safe, effective
delivery of services in the profession, and/or use the pharmacist’s professional skills.15
Pharmacist Only Medicines
(S3)
Substances and preparations for therapeutic use that:
• are substantially safe in use, but require professional advice or counselling by
a pharmacist
• the use of which requires a pharmacist’s advice, management, or monitoring
• are for ailments or symptoms that:
can be identified by the consumer and verified by a pharmacist
do not require medical diagnosis or only require initial medical diagnosis,
and do not require close medical management.16
Pharmacy Medicines (S2) Substances and preparations for therapeutic use that:
• are substantially safe in use, but where advice or counselling is available
if necessary
• are for minor ailments or symptoms that:
can be easily recognised by the consumer
do not require medical diagnosis or management.16
Primary health care Essential health care made accessible at a cost the country and
community can afford, with methods that are practical, scientifically sound,
and socially acceptable.16
Public health The science and art of promoting health, preventing disease, and prolonging life
through the organised efforts of society.7
Quality assurance (QA)
program
A program of evaluation intended to ensure systems are working well, identify
faults, suggest remedial action, and evaluate new systems. An effective QA
program is an essential part of a pharmaceutical service. It should be included in
every contract and be appropriate to the level of need.
(QUM)
Refers to the selection of wise management options, the choice of suitable
medicines if a medicine is considered necessary, and the safe and effective use of
medicines. The definition of QUM applies equally to decisions about medicine use
by individuals and decisions that affect the health of the population.17
Residential care facility (RCF) An institution that provides accommodation and health care to its residents. Types
of residential care facility include aged care homes, retirement facilities, hostels, and
supported residential services (previously known as special accommodation homes).

Glossary
Professional Practice Standards | Version 4 | 2010 | © Pharmaceutical Society of Australia102
Term Definition
Risk assessment A systematic process of organising information to support a risk decision being
made within a risk management process. Risk assessment consists of the
identification of hazards, and the analysis and evaluation of risks associated with
exposure to those hazards.18
Screening A public health service in which members of a defined population, who may not
know they are at risk of a disease or its complications, undergo tests and/or
are asked questions to identify individuals who may have the disease and who
therefore require further more specific investigations. Such individuals are then
referred to health care professionals for diagnosis.19
Pharmacy services Professional services where pharmacists provide therapeutic goods, information, and
advice about health and therapeutic goods, and any other aspect of consumer care.
Terminal sterilisation Terminal sterilisation involves filling primary packaging containers with formulation,
followed by thermal, ionizing, or chemical modes of sterilization.20
Therapeutic device Any instrument, apparatus, appliance, material, or other article intended to be used
for the diagnosis, prevention, monitoring, treatment, or alleviation of disease or
injury. Common therapeutic devices include nebulisers, spacers, bandages, blood
glucose meters, blood pressure monitors, and pregnancy testing kits.
Therapeutic goods Medicines and therapeutic devices.
Unscheduled medicines Medicines which are exempt from scheduling under the provisions of the Standard
for the Uniform Scheduling of Drugs and Poisons. Examples of unscheduled
medicines include small packs of analgesics and most antacid and laxative
products. The majority of complementary medicines can also be regarded as
unscheduled medicines.
References
1. Therapeutic Goods Administration. Adverse drug reactions:
frequently asked questions. Available at:
www.tga.gov.au/adr/adrfaq.htm#whatisadr
2. Australian Council for Safety and Quality in Health Care. First
national report on patient safety. Canberra: ACSQHC, 2001.
3. Adapted from: Eagar K, Owen A, Williams K et al; Centre for Health
Service Development, University of Wollongong. Effective caring:
a synthesis of the international evidence on carer needs and
interventions. Volume one: the report. Wollongong: University of
Wollongong, 2007. Available at: www.health.gov.au/internet/main/
publishing.nsf/Content/ageing-publicat-effective-caring-v1.htm
4. Therapeutic Goods Administration. Regulation of complementary
medicines. Available at: www.tga.gov.au/cm/cm.htm
5. Pharmaceutical Inspection Convention; Pharmaceutical Inspection
Co-operation Scheme. Glossary. In: Guide to good manufacturing
practice for medicinal products: annexes. PE 009-9 (Annexes).
September 2009: p.133. Available at:
6. Pharmaceutical Society of Australia. Dose administration aids
service. Guidelines and standards for pharmacists. Canberra: PSA,
July 2007. Available at: www.psa.org.au/site.php?id=2065
7. World Health Organization. Health promotion glossary. WHO/HPR/
HEP/98.1. Geneva: WHO, 1998. Available at:
www.who.int/hpr/NPH/docs/hp_glossary_en.pdf
8. Ministerial Council on Drug Strategy. The national drug strategy:
an integrated framework 2004–2009. Canberra: Commonwealth
of Australia, 2004. Available at: www.health.gov.au/internet/
drugstrategy/publishing.nsf/Content/framework0409
9. Workplace Health and Safety Queensland. Understanding hazardous
materials. Available at: www.deir.qld.gov.au/workplace/subjects/
hazardousmaterials/definition/example/index.htm
10. Adams RJ, Stocks NP, Wilson DH et al. Health literacy – a new
concept for general practice? Aust Fam Physician 2009;38:144–7.
11. Pharmaceutical Society of Australia. Competency standards for
pharmacists in Australia 2003. Canberra: PSA, 2003. Available at:
www.psa.org.au/site.php?id=643
12. Australian Pharmaceutical Advisory Council. Guiding principles
to achieve continuity in medication management. Canberra:
internet/main/publishing.nsf/Content/nmp-guiding
13. Pharmaceutical Society of Australia. Medication profiling service.
Guidelines and standards for pharmacists. Canberra: PSA, 2007.
14. National Prescribing Service. Medication review. Prescribing
Practice Review 2000; no. 7. Available at:
www.nps.org.au/__data/assets/pdf_file/0019/16921/ppr07.pdf
15. Pharmacy Board of Australia. Continuing professional development
registration standard. July 2010. Available at:
16. Therapeutic Goods Administration. Interim guidelines for the
National Drugs and Poisons Schedule Committee. November 2009.
Available at: www.tga.gov.au/ndpsc/ndpscg.pdf
17. Australian Government Department of Health and Ageing.
National Medicines Policy: Quality Use of Medicines (QUM).
Available at: www.health.gov.au/internet/main/Publishing.nsf/
Content/nmp-quality.htm
18. Pharmaceutical Inspection Convention; Pharmaceutical Inspection
Co-operation Scheme. Annexe 20: Quality Risk Management.
In: Guide to good manufacturing practice for medicinal products:
annexes. PE 009-9 (Annexes). September 2009: p. 119.
Available at: www.picscheme.org/publication.php?id=4
19. UK National Screening Committee. UK Screening Portal.
What is screening? Available at: www.screening.nhs.uk/screening
20. Tirumalai R, Porter D. Terminal sterilization and potential for
parametric release. American Pharmaceutical Review.
Available at: http://americanpharmaceuticalreview.com/ViewArticle.
aspx?ContentID=278

The Professional Practice Standards version 4 has been endorsed by the following organisations at the time of publication.
A A C P
AUSTRALIAN ASSOCIATION
OF CONSULTANT PHARMACY
© Pharmaceutical Society of Australia 2010
The material in this publication has been provided by the
Pharmaceutical Society of Australia (PSA). The PSA retains copyright
in the publication as a whole and in all material in the publication that
is authored by or on behalf of the PSA.
Apart from any use permitted under the Copyright Act 1968, you
must not make any other use of this material unless you have written
permission to do so. Requests and enquiries regarding permission to
use PSA material should be addressed to:
Publications Manager
PO Box 42
The review of the Professional Practice Standards is funded by
the Australian Government Department of Health and Ageing and
developed by the PSA with support from the Pharmacy Guild of
Australia as part of the Fourth Community Pharmacy Agreement.
Disclaimer
These standards have been designed for use by individual
pharmacists to assess their own professional practice. They are
intended to serve as guidance for desired standards of practice.
However, it is the sole responsibility of the individual pharmacist
to determine, in all circumstances, whether a higher standard is
required. It is equally their responsibility to meet that standard.
The PSA has made every effort to ensure that, at the date of
publication, the document is free from errors and that the advice
and information drawn upon have been provided in good faith.
However, the information contained in this publication is dynamic
in nature due to ongoing research and change in government
regulation and pharmacy practice. Neither the PSA nor any other
person associated with the preparation of this document accepts
liability for any loss that a user of this document may suffer as
a result of reliance on the document and, in particular, for:
• use of the document for a purpose for which it was not intended
• any errors or omissions in the document
• any inaccuracy in the information or data on which the document
is based or which are contained in the document OR
• any interpretations or opinions stated in, or which may be inferred
from, the document.
Notification of any inaccuracy or ambiguity found in this document
should be made without delay in order that the issue may be
investigated and appropriate action taken. Please forward your
notification to:
Policy and Practice Group
PO Box 42
ISBN: 987-0-646-53402-2
Title: Professional Practice Standards – Version 4 – June 2010
Edition: 4th
Date of Publication: June 2010
Publisher: Pharmaceutical Society of Australia

Professional practice-standards-v4

More Related Content

What's hot (20)

Viewers also liked (7)

Similar to Professional practice-standards-v4 (20)

More from Boris cvijic (20)

Recently uploaded (20)

Professional practice-standards-v4